Pt. 4

(g) This section applies to all claims in which a Notice of Disagreement is filed on or after June 1, 2001.

(Authority: 38 U.S.C. 5109A and 7105(d))

[66 FR 21874, May 2, 2001, as amended at 67 FR 46868, July 17, 2002]

PART 4—SCHEDULE FOR RATING DISABILITIES

Subpart A—General Policy in Rating

Sec.

- 4.1 Essentials of evaluative rating.
- 4.2 Interpretation of examination reports.
- Resolution of reasonable doubt 43
- Evaluation of evidence. 4.6
- Higher of two evaluations. 47
- 4.9 Congenital or developmental defects.
- 4.10 Functional impairment.
- 4.13 Effect of change of diagnosis.
- 4.14 Avoidance of pyramiding.
- Total disability ratings. 4.15
- 4.16 Total disability ratings for compensation based on unemployability of the individual.
- 4.17 Total disability ratings for pension based on unemployability and age of the individual.
- 4.17a Misconduct etiology.
- 4.18 Unemployability.
- 4.19 Age in service-connected claims.
- 4.20 Analogous ratings.
- Application of rating schedule. 4.21
- Rating of disabilities aggravated by ac-4.22 tive service.
- 4.23 Attitude of rating officers.
- 4.24 Correspondence.
- 4.25 Combined ratings table.
- 4.26 Bilateral factor.
- Use of diagnostic code numbers. 4.27
- 4.28 Prestabilization rating from date of discharge from service.
- 4.29 Ratings for service-connected disabilities requiring hospital treatment or observation.
- 4.30 Convalescent ratings.
- 4.31 Zero percent evaluations.

Subpart B—Disability Ratings

THE MUSCULOSKELETAL SYSTEM

- 4.40 Functional loss.
- 4.41 History of injury.
- 4.42 Complete medical examination of injury cases. 4.43 Osteomyelitis.
- 4.44 The bones.4.45 The joints.
- 4.46 Accurate measurement.
- 4.47-4.54 [Reserved]
- 4.55 Principles of combined ratings for muscle injuries.
- 4.56 Evaluation of muscle disabilities.

38 CFR Ch. I (7-1-05 Edition)

- Static foot deformities 4 57
- Arthritis due to strain. 4.58
- 4.59 Painful motion.
- 4.60 [Reserved]
- 4.61 Examination.
- 4.62Circulatory disturbances.
- Loss of use of hand or foot. 4.63 Loss of use of both buttocks. 4.64
- 4.65 [Reserved]
- 4.66 Sacroiliac joint.
- 4.67 Pelvic bones.
- Amputation rule. 4.68
- 4.69 Dominant hand.
- Inadequate examinations. 4.70
- 4.71 Measurement of ankylosis and joint motion.
- 4.71a Schedule of ratings-musculoskeletal system.
- 4.72 [Reserved]
- 4.73 Schedule of ratings-muscle injuries.
 - THE ORGANS OF SPECIAL SENSE
- 4.75 Examination of visual acuity.
- 4.76 Examination of field vision.
- 4.76a Computation of average concentric contraction of visual fields.
- 4.77 Examination of muscle function.
- 4.78 Computing aggravation.
- 4.79 Loss of use of one eye, having only light perception.
- 4.80 Rating of one eye.
- 4.81-4.82 [Reserved]
- 4.83 Ratings at scheduled steps and distances.
- 4.83a Impairment of central visual acuity.
- 4.84 Differences between distant and near visual acuity.
- 4.84a Schedule of ratings-eye.

IMPAIRMENT OF AUDITORY ACUITY

- Evaluation of hearing impairment. 4.85 4.86 Exceptional patterns of hearing impair-
- ment. 4.87 Schedule of ratings—ear.
- 4.87a Schedule of ratings-other sense organs.
- INFECTIOUS DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES
- 4.88 [Reserved]
- 4.88a Chronic fatigue syndrome.
- 4.88b Schedule of ratings—infectious dis-eases, immune disorders and nutritional deficiencies.
- 4.88c Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19. 1968.
- 4.89 Ratings for inactive nonpulmonary tuberculosis in effect on August 19, 1968.

THE RESPIRATORY SYSTEM

- 4.96 Special provisions regarding evaluation of respiratory conditions.
- 4.97 Schedule of ratings-respiratory system.

THE CARDIOVASCULAR SYSTEM

- 4.100-4.103 [Reserved]
- 4.104 Schedule of ratings—cardiovascular system.

THE DIGESTIVE SYSTEM

- 4.110 Ulcers.
- 4.111 Postgastrectomy syndromes.
- 4.112 Weight loss.
- 4.113 Coexisting abdominal conditions.
- 4.114 Schedule of ratings-digestive system.

THE GENITOURINARY SYSTEM

- 4.115 Nephritis.
- 4.115a Ratings of the genitourinary system—dysfunctions.
- 4.115b Ratings of the genitourinary system—diagnoses.

GYNECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST

4.116 Schedule of ratings—gynecological conditions and disorders of the breast.

THE HEMIC AND LYMPHATIC SYSTEMS

4.117 Schedule of ratings—hemic and lymphatic systems.

THE SKIN

4.118 Schedule of ratings—skin.

THE ENDOCRINE SYSTEM

4.119 Schedule of ratings—endocrine system.

NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

- 4.120 Evaluations by comparison.
- 4.121 Identification of epilepsy.
- 4.122 Psychomotor epilepsy.
- 4.123 Neuritis, cranial or peripheral.
- 4.124 Neuralgia, cranial or peripheral.
- 4.124a Schedule of ratings—neurological conditions and convulsive disorders.

MENTAL DISORDERS

- 4.125 Diagnosis of mental disorders.
- 4.126 Evaluation of disability from mental disorders.
- 4.127 Mental retardation and personality disorders.
- 4.128 Convalescence ratings following extended hospitalization.
- 4.129 Mental disorders due to traumatic stress.
- 4.130 Schedule of ratings—mental disorders.
 - DENTAL AND ORAL CONDITIONS
- 4.149 [Reserved]
- 4.150 Schedule of ratings—dental and oral conditions.
- APPENDIX A TO PART 4—TABLE OF AMEND-MENTS AND EFFECTIVE DATES SINCE 1946

- Appendix B to Part 4—Numerical Index of Disabilities
- APPENDIX C TO PART 4—ALPHABETICAL INDEX OF DISABILITIES

AUTHORITY: 38 U.S.C. 1155, unless otherwise noted.

SOURCE: 29 FR 6718, May 22, 1964, unless otherwise noted.

Subpart A—General Policy in Rating

§4.1 Essentials of evaluative rating.

This rating schedule is primarily a guide in the evaluation of disability resulting from all types of diseases and injuries encountered as a result of or incident to military service. The percentage ratings represent as far as can practicably be determined the average impairment in earning capacity resulting from such diseases and injuries and their residual conditions in civil occupations. Generally, the degrees of disability specified are considered adequate to compensate for considerable loss of working time from exacerbations or illnesses proportionate to the severity of the several grades of disability. For the application of this schedule, accurate and fully descriptive medical examinations are required, with emphasis upon the limitation of activity imposed by the disabling condition. Over a period of many years, a veteran's disability claim may require reratings in accordance with changes in laws, medical knowledge and his or her physical or mental condition. It is thus essential, both in the examination and in the evaluation of disability, that each disability be viewed in relation to its history.

[41 FR 11292, Mar. 18, 1976]

§4.2 Interpretation of examination reports.

Different examiners, at different times, will not describe the same disability in the same language. Features of the disability which must have persisted unchanged may be overlooked or a change for the better or worse may not be accurately appreciated or described. It is the responsibility of the rating specialist to interpret reports of examination in the light of the whole

§4.2

38 CFR Ch. I (7–1–05 Edition)

recorded history, reconciling the various reports into a consistent picture so that the current rating may accurately reflect the elements of disability present. Each disability must be considered from the point of view of the veteran working or seeking work. If a diagnosis is not supported by the findings on the examination report or if the report does not contain sufficient detail, it is incumbent upon the rating board to return the report as inadequate for evaluation purposes.

[41 FR 11292, Mar. 18, 1976]

§4.3

§4.3 Resolution of reasonable doubt.

It is the defined and consistently applied policy of the Department of Veterans Affairs to administer the law under a broad interpretation, consistent, however, with the facts shown in every case. When after careful consideration of all procurable and assembled data, a reasonable doubt arises regarding the degree of disability such doubt will be resolved in favor of the claimant. See §3.102 of this chapter.

[40 FR 42535, Sept. 15, 1975]

§4.6 Evaluation of evidence.

The element of the weight to be accorded the character of the veteran's service is but one factor entering into the considerations of the rating boards in arriving at determinations of the evaluation of disability. Every element in any way affecting the probative value to be assigned to the evidence in each individual claim must be thoroughly and conscientiously studied by each member of the rating board in the light of the established policies of the Department of Veterans Affairs to the end that decisions will be equitable and just as contemplated by the requirements of the law.

§4.7 Higher of two evaluations.

Where there is a question as to which of two evaluations shall be applied, the higher evaluation will be assigned if the disability picture more nearly approximates the criteria required for that rating. Otherwise, the lower rating will be assigned.

§4.9 Congenital or developmental defects.

Mere congenital or developmental defects, absent, displaced or supernumerary parts, refractive error of the eye, personality disorder and mental deficiency are not diseases or injuries in the meaning of applicable legislation for disability compensation purposes.

[41 FR 11292, Mar. 18, 1976]

§4.10 Functional impairment.

The basis of disability evaluations is the ability of the body as a whole, or of the psyche, or of a system or organ of the body to function under the ordinary conditions of daily life including employment. Whether the upper or lower extremities, the back or abdominal wall, the eyes or ears, or the cardiovascular, digestive, or other system, or psyche are affected, evaluations are based upon lack of usefulness, of these parts or systems, especially in self-support. This imposes upon the medical examiner the responsibility of furnishing, in addition to the etiological, anatomical, pathological, laboratory and prognostic data required for ordinary medical classification, full description of the effects of disability upon the person's ordinary activity. In this connection, it will be remembered that a person may be too disabled to engage in employment although he or she is up and about and fairly comfortable at home or upon limited activity.

[41 FR 11292, Mar. 18, 1976]

§4.13 Effect of change of diagnosis.

The repercussion upon a current rating of service connection when change is made of a previously assigned diagnosis or etiology must be kept in mind. The aim should be the reconciliation and continuance of the diagnosis or etiology upon which service connection for the disability had been granted. The relevant principle enunciated in §4.125, entitled "Diagnosis of mental disorders," should have careful attention in this connection. When any change in evaluation is to be made, the rating agency should assure itself that there has been an actual change in the conditions, for better or worse, and not

merely a difference in thoroughness of the examination or in use of descriptive terms. This will not, of course, preclude the correction of erroneous ratings, nor will it preclude assignment of a rating in conformity with §4.7.

 $[29\ {\rm FR}\ 6718,\ {\rm May}\ 22,\ 1964,\ as\ amended\ at\ 61\ {\rm FR}\ 52700,\ {\rm Oct.}\ 8,\ 1996]$

§4.14 Avoidance of pyramiding.

The evaluation of the same disability under various diagnoses is to be avoided. Disability from injuries to the muscles, nerves, and joints of an extremity may overlap to a great extent, so that special rules are included in the appropriate bodily system for their evaluation. Dyspnea, tachycardia, nervousness, fatigability, etc., may result from many causes; some may be service connected, others, not. Both the use of manifestations not resulting from service-connected disease or injury in establishing the service-connected evaluation, and the evaluation of the same manifestation under different diagnoses are to be avoided.

§4.15 Total disability ratings.

The ability to overcome the handicap of disability varies widely among individuals. The rating, however, is based primarily upon the average impairment in earning capacity, that is, upon the economic or industrial handicap which must be overcome and not from individual success in overcoming it. However, full consideration must be given to unusual physical or mental effects in individual cases, to peculiar effects of occupational activities, to defects in physical or mental endowment preventing the usual amount of success in overcoming the handicap of disability and to the effect of combinations of disability. Total disability will be considered to exist when there is present any impairment of mind or body which is sufficient to render it impossible for the average person to follow a substantially gainful occupation; Provided, That permanent total disability shall be taken to exist when the impairment is reasonably certain to continue throughout the life of the disabled person. The following will be considered to be permanent total disability: the permanent loss of the use of both hands, or of both feet, or of one

hand and one foot, or of the sight of both eyes, or becoming permanently helpless or permanently bedridden. Other total disability ratings are scheduled in the various bodily systems of this schedule.

§4.16 Total disability ratings for compensation based on unemployability of the individual.

(a) Total disability ratings for compensation may be assigned, where the schedular rating is less than total, when the disabled person is, in the judgment of the rating agency, unable to secure or follow a substantially gainful occupation as a result of service-connected disabilities: Provided That, if there is only one such disability, this disability shall be ratable at 60 percent or more, and that, if there are two or more disabilities, there shall be at least one disability ratable at 40 percent or more, and sufficient additional disability to bring the combined rating to 70 percent or more. For the above purpose of one 60 percent disability, or one 40 percent disability in combination, the following will be considered as one disability: (1) Disabilities of one or both upper extremities, or of one or both lower extremities, including the bilateral factor, if applicable, (2) disabilities resulting from common etiology or a single accident, (3) disabilities affecting a single body system, e.g. orthopedic, digestive, rescardiovascular-renal, piratory, neuropsychiatric, (4) multiple injuries incurred in action, or (5) multiple disabilities incurred as a prisoner of war. It is provided further that the existence or degree of nonservice-connected disabilities previous or unemployability status will be disregarded where the percentages referred to in this paragraph for the service-connected disability or disabilities are met and in the judgment of the rating agency such service-connected disabilities render the veteran unemployable. Marginal employment shall not be considered substantially gainful employment. For purposes of this section, marginal employment generally shall be deemed to exist when a veteran's earned annual income does not exceed the amount established by the U.S. Department of Commerce, Bureau of the

38 CFR Ch. I (7–1–05 Edition)

Census, as the poverty threshold for one person. Marginal employment may also be held to exist, on a facts found basis (includes but is not limited to employment in a protected environment such as a family business or sheltered workshop), when earned annual income exceeds the poverty threshold. Consideration shall be given in all claims to the nature of the employment and the reason for termination.

(Authority: 38 U.S.C. 501)

§4.17

(b) It is the established policy of the Department of Veterans Affairs that all veterans who are unable to secure and follow a substantially gainful occupation by reason of service-connected disabilities shall be rated totally disabled. Therefore, rating boards should submit to the Director, Compensation and Pension Service, for extra-schedular consideration all cases of veterans who are unemployable by reason of service-connected disabilities, but who fail to meet the percentage standards set forth in paragraph (a) of this section. The rating board will include a full statement as to the veteran's service-connected disabilities, employment history, educational and vocational attainment and all other factors having a bearing on the issue.

[40 FR 42535, Sept. 15, 1975, as amended at 54 FR 4281, Jan. 30, 1989; 55 FR 31580, Aug. 3, 1990; 58 FR 39664, July 26, 1993; 61 FR 52700, Oct. 8, 1996]

§4.17 Total disability ratings for pension based on unemployability and age of the individual.

All veterans who are basically eligible and who are unable to secure and follow a substantially gainful occupation by reason of disabilities which are likely to be permanent shall be rated as permanently and totally disabled. For the purpose of pension, the permanence of the percentage requirements of §4.16 is a requisite. When the percentage requirements are met, and the disabilities involved are of a permanent nature, a rating of permanent and total disability will be assigned if the veteran is found to be unable to secure and follow substantially gainful employment by reason of such disability. Prior employment or unemployment status is immaterial if in the judgment

of the rating board the veteran's disabilities render him or her unemployable. In making such determinations, the following guidelines will be used:

(a) Marginal employment, for example, as a self-employed farmer or other person, while employed in his or her own business, or at odd jobs or while employed at less than half the usual remuneration will not be considered incompatible with a determination of unemployability, if the restriction, as to securing or retaining better employment, is due to disability.

(b) Claims of all veterans who fail to meet the percentage standards but who meet the basic entitlement criteria and are unemployable, will be referred by the rating board to the Adjudication Officer under §3.321(b)(2) of this chapter.

(Authority: 38 U.S.C. 1155; 38 U.S.C. 3102)

[43 FR 45348, Oct. 2, 1978, as amended at 56 FR 57985, Nov. 15, 1991]

§4.17a Misconduct etiology.

A permanent and total disability rating under the provisions of §§4.15, 4.16 and 4.17 will not be precluded by reason of the coexistence of misconduct disability when:

(a) A veteran, regardless of employment status, also has innocently acquired 100 percent disability, or

(b) Where unemployable, the veteran has other disabilities innocently acquired which meet the percentage requirements of §§4.16 and 4.17 and would render, in the judgment of the rating agency, the average person unable to secure or follow a substantially gainful occupation.

[40 FR 42536, Sept. 15, 1975, as amended at 43 FR 45349, Oct. 2, 1978]

§4.18 Unemployability.

A veteran may be considered as unemployable upon termination of employment which was provided on account of disability, or in which special consideration was given on account of the same, when it is satisfactorily shown that he or she is unable to secure further employment. With amputations, sequelae of fractures and other residuals of traumatism shown to be of

static character, a showing of continuous unemployability from date of incurrence, or the date the condition reached the stabilized level, is a general requirement in order to establish the fact that present unemployability is the result of the disability. However, consideration is to be given to the circumstances of employment in individual claims, and, if the employment was only occasional, intermittent, tryout or unsuccessful, or eventually terminated on account of the disability, present unemployability may be attributed to the static disability. Where unemployability for pension previously has been established on the basis of combined service-connected and nonservice-connected disabilities and the service-connected disability or disabilities have increased in severity, §4.16 is for consideration.

[40 FR 42536, Sept. 15, 1975, as amended at 43 FR 45349, Oct. 2, 1978]

§4.19 Age in service-connected claims.

Age may not be considered as a factor in evaluating service-connected disability; and unemployability, in service-connected claims, associated with advancing age or intercurrent disability, may not be used as a basis for a total disability rating. Age, as such, is a factor only in evaluations of disability not resulting from service, i.e., for the purposes of pension.

 $[29\ {\rm FR}\ 6718,\ {\rm May}\ 22,\ 1964,\ as\ amended\ at\ 43\ {\rm FR}\ 45349,\ {\rm Oct.}\ 2,\ 1978]$

§4.20 Analogous ratings.

When an unlisted condition is encountered it will be permissible to rate under a closely related disease or injury in which not only the functions affected, but the anatomical localization and symptomatology are closely analogous. Conjectural analogies will be avoided, as will the use of analogous ratings for conditions of doubtful diagnosis, or for those not fully supported by clinical and laboratory findings. Nor will ratings assigned to organic diseases and injuries be assigned by analogy to conditions of functional origin.

§4.21 Application of rating schedule.

In view of the number of atypical instances it is not expected, especially with the more fully described grades of disabilities, that all cases will show all the findings specified. Findings sufficiently characteristic to identify the disease and the disability therefrom, and above all, coordination of rating with impairment of function will, however, be expected in all instances.

[41 FR 11293, Mar. 18, 1976]

§4.22 Rating of disabilities aggravated by active service.

In cases involving aggravation by active service, the rating will reflect only the degree of disability over and above the degree existing at the time of entrance into the active service, whether the particular condition was noted at the time of entrance into the active service, or it is determined upon the evidence of record to have existed at that time. It is necessary therefore, in all cases of this character to deduct from the present degree of disability the degree, if ascertainable, of the disability existing at the time of entrance into active service, in terms of the rating schedule, except that if the disability is total (100 percent) no deduction will be made. The resulting difference will be recorded on the rating sheet. If the degree of disability at the time of entrance into the service is not ascertainable in terms of the schedule. no deduction will be made.

§4.23 Attitude of rating officers.

It is to be remembered that the majority of applicants are disabled persons who are seeking benefits of law to which they believe themselves entitled. In the exercise of his or her functions, rating officers must not allow their personal feelings to intrude; an antagonistic, critical, or even abusive attitude on the part of a claimant should not in any instance influence the officers in the handling of the case. Fairness and courtesy must at all times be shown to applicants by all employees whose duties bring them in contact, directly or indirectly, with the Department's claimants.

[41 FR 11292, Mar. 18, 1976]

§4.24 Correspondence.

All correspondence relative to the interpretation of the schedule for rating

disabilities, requests for advisory opinions, questions regarding lack of clarity or application to individual cases involving unusual difficulties, will be addressed to the Director, Compensa-tion and Pension Service. A clear statement will be made of the point or points upon which information is desired, and the complete case file will be simultaneously forwarded to Central Office. Rating agencies will assure themselves that the recent report of physical examination presents an adequate picture of the claimant's condition. Claims in regard to which the schedule evaluations are considered inadequate or excessive, and errors in the schedule will be similarly brought to attention.

[41 FR 11292, Mar. 18, 1976]

§4.25 Combined ratings table.

Table I, Combined Ratings Table, results from the consideration of the efficiency of the individual as affected first by the most disabling condition, then by the less disabling condition, then by other less disabling conditions, if any, in the order of severity. Thus, a person having a 60 percent disability is considered 40 percent efficient. Proceeding from this 40 percent efficiency, the effect of a further 30 percent disability is to leave only 70 percent of the efficiency remaining after consideration of the first disability, or 28 percent efficiency altogether. The indi-vidual is thus 72 percent disabled, as shown in table I opposite 60 percent and under 30 percent.

(a) To use table I, the disabilities will first be arranged in the exact order of their severity, beginning with the greatest disability and then combined with use of table I as hereinafter indicated. For example, if there are two disabilities, the degree of one disability will be read in the left column and the degree of the other in the top row, whichever is appropriate. The figures appearing in the space where the column and row intersect will represent the combined value of the two. This combined value will then be converted to the nearest number divisible by 10,

38 CFR Ch. I (7–1–05 Edition)

and combined values ending in 5 will be adjusted upward. Thus, with a 50 percent disability and a 30 percent disability, the combined value will be found to be 65 percent, but the 65 percent must be converted to 70 percent to represent the final degree of disability. Similarly, with a disability of 40 percent, and another disability of 20 percent, the combined value is found to be 52 percent, but the 52 percent must be converted to the nearest degree divisible by 10, which is 50 percent. If there are more than two disabilities, the disabilities will also be arranged in the exact order of their severity and the combined value for the first two will be found as previously described for two disabilities. The combined value, exactly as found in table I, will be combined with the degree of the third disability (in order of severity). The combined value for the three disabilities will be found in the space where the column and row intersect, and if there are only three disabilities will be converted to the nearest degree divisible by 10, adjusting final 5's upward. Thus, if there are three disabilities ratable at 60 percent, 40 percent, and 20 percent, respectively, the combined value for the first two will be found opposite 60 and under 40 and is 76 percent. This 76 will be combined with 20 and the combined value for the three is 81 percent. This combined value will be converted to the nearest degree divisible by 10 which is 80 percent. The same procedure will be employed when there are four or more disabilities. (See table I).

(b) Except as otherwise provided in this schedule, the disabilities arising from a single disease entity, e.g., arthritis, multiple sclerosis, cerebrovascular accident, etc., are to be rated separately as are all other disabiling conditions, if any. All disabilities are then to be combined as described in paragraph (a) of this section. The conversion to the nearest degree divisible by 10 will be done only once per rating decision, will follow the combining of all disabilities, and will be the last procedure in determining the combined degree of disability.

§4.25

TABLE I—COMBINED RATINGS TABLE [10 combined with 10 is 19]

	l	10 combi	neu with	10 is 19	J					
		10	20	30	40	50	60	70	80	90
19		27	35	43	51	60	68	76	84	92
		28	36	44	52	60	68	76	84	92
21		29	37	45	53	61	68	76	84	92
		30	38	45	53	61	69	77	84	92
		31	38	46	54	62	69	77	85	92
		32 33	39 40	47 48	54 55	62 63	70 70	77 78	85 85	92 93
26		33	40	48	56	63	70	78	85	93
		34	42	49	56	64	71	78	85	93
		35	42	50	57	64	71	78	86	93
		36	43	50	57	65	72	79	86	93
		37	44	51	58	65	72	79	86	93
		38	45	52	59	66	72	79	86	93
		39	46	52 53	59	66	73 73	80	86 87	93
		40 41	46 47	53 54	60 60	67 67	73	80 80	87	93 93
		42	48	55	61	68	74	81	87	94
		42	49	55	62	68	74	81	87	94
		43	50	56	62	69	75	81	87	94
		44	50	57	63	69	75	81	88	94
39		45	51	57	63	70	76	82	88	94
		46	52	58	64	70	76	82	88	94
		47 48	53 54	59 59	65 65	71 71	76 77	82 83	88 88	94 94
		40	54	59 60	66	72	77	83	89	94
		50	55	61	66	72	78	83	89	94
		51	56	62	67	73	78	84	89	95
46		51	57	62	68	73	78	84	89	95
		52	58	63	68	74	79	84	89	95
		53	58	64	69	74	79	84	90	95
		54	59	64 65	69 70	75	80	85	90	95
		55 56	60 61	65 66	70 71	75 76	80 80	85 85	90 90	95 95
		57	62	66	71	76	81	86	90	95
		58	62	67	72	77	81	86	91	95
54		59	63	68	72	77	82	86	91	95
55		60	64	69	73	78	82	87	91	96
56		60	65	69	74	78	82	87	91	96
		61 62	66	70 71	74 75	79 79	83 83	87 87	91 92	96
		62 63	66 67	71	75 75	80	83 84	87	92 92	96 96
		64	68	72	76	80	84	88	92	96
61		65	69	73	77	81	84	88	92	96
		66	70	73	77	81	85	89	92	96
		67	70	74	78	82	85	89	93	96
		68	71	75	78	82	86	89	93	96
		69 69	72	76	79	83 83	86	90 90	93 93	97
		69 70	73 74	76 77	80 80	83 84	86 87	90 90	93	97 97
		70	74	78	80	84 84	87 87	90	93 94	97
		72	75	78	81	85	88	91	94	97
70		73	76	79	82	85	88	91	94	97
		74	77	80	83	86	88	91	94	97
		75	78	80	83	86	89	92	94	97
		76	78	81	84	87	89	92	95	97
		77 78	79 80	82 83	84 85	87 88	90 90	92 93	95 95	97 98
		78 78	80 81	83	85 86	88 88	90 90	93	95 95	98 98
		70	82	84	86	89	90 91	93	95	98
		80	82	85	87	89	91	93	96	98
79		81	83	85	87	90	92	94	96	98
		82	84	86	88	90	92	94	96	98
		83	85	87	89	91	92	94	96	98
		84	86	87	89	91	93	95	96	98
		85	86	88	90	92	93 94	95	97	98
		86 87	87 88	89 90	90 91	92 93	94 94	95 96	97 97	98 99
		87 87	88 89	90 90	91	93	94 94	96 96	97 97	99 99
		88	90	90 91	92 92	93 94	94 95	96	97 97	99
		89	90	92	93	94	95	96	98	99
		90	91	92	93	95	96	87	38	99

38 CFR Ch. I (7-1-05 Edition)

TABLE I—COMBINED RATINGS TABLE—Continued

	10	20	30	40	50	60	70	80	90
90	91 92 93 94 95	92 93 94 94 95	93 94 94 95 96	94 95 95 96 96	95 96 97 97	96 96 97 97 98	97 97 98 98 98	98 98 98 99 99	99 99 99 99 99

(Authority: 38 U.S.C. 1155)

[41 FR 11293, Mar. 18, 1976, as amended at 54 FR 27161, June 28, 1989; 54 FR 36029, Aug. 31, 1989]

§4.26 Bilateral factor.

When a partial disability results from disease or injury of both arms, or of both legs, or of paired skeletal muscles, the ratings for the disabilities of the right and left sides will be combined as usual, and 10 percent of this value will be added (i.e., not combined) before proceeding with further combinations, or converting to degree of disability. The bilateral factor will be applied to such bilateral disabilities before other combinations are carried out and the rating for such disabilities including the bilateral factor in this section will be treated as 1 disability for the purpose of arranging in order of severity and for all further combinations. For example, with disabilities evaluated at 60 percent, 20 percent, 10 percent and 10 percent (the two 10's representing bilateral disabilities), the order of severity would be 60, 21 and 20. The 60 and 21 combine to 68 percent and the 68 and 20 to 74 percent, converted to 70 percent as the final degree of disability.

(a) The use of the terms "arms" and "legs" is not intended to distinguish between the arm, forearm and hand, or the thigh, leg, and foot, but relates to the upper extremities and lower extremities as a whole. Thus with a compensable disability of the right thigh, for example, amputation, and one of the left foot, for example, pes planus, the bilateral factor applies, and similarly whenever there are compensable disabilities affecting use of paired extremities regardless of location or specified type of impairment.

(b) The correct procedure when applying the bilateral factor to disabilities affecting both upper extremities and both lower extremities is to combine the ratings of the disabilities affecting the 4 extremities in the order of their individual severity and apply the bilateral factor by adding, not combining, 10 percent of the combined value thus attained.

(c) The bilateral factor is not applicable unless there is partial disability of compensable degree in each of 2 paired extremities, or paired skeletal muscles.

§4.27 Use of diagnostic code numbers.

The diagnostic code numbers appearing opposite the listed ratable disabilities are arbitrary numbers for the purpose of showing the basis of the evaluation assigned and for statistical analysis in the Department of Veterans Affairs, and as will be observed, extend from 5000 to a possible 9999. Great care will be exercised in the selection of the applicable code number and in its citation on the rating sheet. No other numbers than these listed or hereafter furnished are to be employed for rating purposes, with an exception as described in this section, as to unlisted conditions. When an unlisted disease, injury, or residual condition is encountered, requiring rating by analogy, the diagnostic code number will be "builtup'' as follows: The first 2 digits will be selected from that part of the schedule most closely identifying the part, or system, of the body involved; the last 2 digits will be "99" for all unlisted conditions. This procedure will facilitate a close check of new and unlisted conditions, rated by analogy. In the selection of code numbers, injuries will generally be represented by the number assigned to the residual condition on the basis of which the rating is determined. With diseases, preference is to be given

to the number assigned to the disease itself; if the rating is determined on the basis of residual conditions, the number appropriate to the residual condition will be added, preceded by a hyphen. Thus, rheumatoid (atrophic) arthritis rated as ankylosis of the lumbar spine should be coded "5002-5289." In this way, the exact source of each rating can be easily identified. In the citation of disabilities on rating sheets, the diagnostic terminology will be that of the medical examiner, with no attempt to translate the terms into schedule nomenclature. Residuals of diseases or therapeutic procedures will not be cited without reference to the basic disease.

[41 FR 11293, Mar. 18, 1976]

§4.28 Prestabilization rating from date of discharge from service.

The following ratings may be assigned, in lieu of ratings prescribed elsewhere, under the conditions stated for disability from any disease or injury. The prestabilization rating is not to be assigned in any case in which a total rating is immediately assignable under the regular provisions of the schedule or on the basis of individual unemployability. The prestabilization 50-percent rating is not to be used in any case in which a rating of 50 percent or more is immediately assignable under the regular provisions.

	Rating
Unstabilized condition with severe disability— Substantially gainful employment is not fea- sible or advisable Unhealed or incompletely healed wounds or in-	100
juries— Material impairment of employability likely	50

NOTE (1): Department of Veterans Affairs examination is not required prior to assignment of prestabilization ratings; however, the fact that examination was accomplished will not preclude assignment of these benefits. Prestabilization ratings are for assignment in the immediate postdischarge period. They will continue for a 12-month period following discharge from service. However, prestabilization ratings may be changed to a regular schedular total rating or one authorizing a greater benefit at any time. In each prestabilization rating an examination will be requested to be accomplished not earlier than 6 months nor more than 12 months following discharge. In those prestabilization ratings in which following examination reduction in evaluation is found to be warranted, the higher evaluation will be continued to the end of the 12th month following discharge or to the end of the period provided under §3.105(e) of this chapter, whichever is later. Special monthly compensation should be assigned concurrently in these cases whenever records are adequate to establish entitlement.

NOTE (2): Diagnosis of disease, injury, or residuals will be cited, with diagnostic code number assigned from this rating schedule for conditions listed therein.

[35 FR 11906, July 24, 1970]

§4.29 Ratings for service-connected disabilities requiring hospital treatment or observation.

A total disability rating (100 percent) will be assigned without regard to other provisions of the rating schedule when it is established that a service-connected disability has required hospital treatment in a Department of Veterans Affairs or an approved hospital for a period in excess of 21 days or *hospital observation at Department of Veterans Affairs expense* for a service-connected disability for a period in excess of 21 days.

(a) Subject to the provisions of paragraphs (d), (e), and (f) of this section this increased rating will be effective the first day of continuous hospitalization and will be terminated effective the last day of the month of hospital discharge (regular discharge or release to non-bed care) or effective the last day of the month of termination of treatment or observation for the service-connected disability. A temporary release which is approved by an attending Department of Veterans Affairs physician as part of the treatment plan will not be considered an absence.

(1) An authorized absence in excess of 4 days which begins during the first 21 days of hospitalization will be regarded as the equivalent of hospital discharge effective the first day of such authorized absence. An authorized absence of 4 days or less which results in a total of more than 8 days of authorized absence during the first 21 days of hospitalization will be regarded as the equivalent of hospital discharge effective the ninth day of authorized absence.

(2) Following a period of hospitalization in excess of 21 days, an authorized absence in excess of 14 days or a third

38 CFR Ch. I (7–1–05 Edition)

consecutive authorized absence of 14 days will be regarded as the equivalent of hospital discharge and will interrupt hospitalization effective on the last day of the month in which either the authorized absence in excess of 14 days or the third 14 day period begins, except where there is a finding that convalescence is required as provided by paragraph (e) or (f) of this section. The termination of these total ratings will not be subject to §3.105(e) of this chapter.

§4.30

(b) Notwithstanding that hospital admission was for disability not connected with service, if during such hospitalization, hospital treatment for a service-connected disability is instituted and continued for a period in excess of 21 days, the increase to a total rating will be granted from the first day of such treatment. If service connection for the disability under treatment is granted after hospital admission, the rating will be from the first day of hospitalization if otherwise in order.

(c) The assignment of a total disability rating on the basis of hospital treatment or observation will not preclude the assignment of a total disability rating otherwise in order under other provisions of the rating schedule, and consideration will be given to the propriety of such a rating in all instances and to the propriety of its continuance after discharge. Particular attention, with a view to proper rating under the rating schedule, is to be given to the claims of veterans discharged from hospital, regardless of length of hospitalization, with indications on the final summary of expected confinement to bed or house, or to inability to work with requirement of frequent care of physician or nurse at home.

(d) On these total ratings Department of Veterans Affairs regulations governing effective dates for increased benefits will control.

(e) The total hospital rating if convalescence is required may be continued for periods of 1, 2, or 3 months in addition to the period provided in paragraph (a) of this section.

(f) Extension of periods of 1, 2 or 3 months beyond the initial 3 months

may be made upon approval of the Adjudication Officer.

(g) Meritorious claims of veterans who are discharged from the hospital with less than the required number of days but need post-hospital care and a prolonged period of convalescence will be referred to the Director, Compensation and Pension Service, under §3.321(b)(1) of this chapter.

[29 FR 6718, May 22, 1964, as amended at 41 FR 11294, Mar. 18, 1976; 41 FR 34256, Aug. 13, 1976; 54 FR 4281, Jan. 30, 1989; 54 FR 34981, Aug. 23, 1989]

§4.30 Convalescent ratings.

A total disability rating (100 percent) will be assigned without regard to other provisions of the rating schedule when it is established by report at hospital discharge (regular discharge or release to non-bed care) or outpatient release that entitlement is warranted under paragraph (a) (1), (2) or (3) of this section effective the date of hospital admission or outpatient treatment and continuing for a period of 1, 2, or 3 months from the first day of the month following such hospital discharge or outpatient release. The termination of these total ratings will not be subject to §3.105(e) of this chapter. Such total rating will be followed by appropriate schedular evaluations. When the evidence is inadequate to assign a schedular evaluation, a physical examination will be scheduled and considered prior to the termination of a total rating under this section.

(a) Total ratings will be assigned under this section if treatment of a service-connected disability resulted in:

(1) Surgery necessitating at least one month of convalescence (Effective as to outpatient surgery March 1, 1989.)

(2) Surgery with severe postoperative residuals such as incompletely healed surgical wounds, stumps of recent amputations, therapeutic immobilization of one major joint or more, application of a body cast, or the necessity for house confinement, or the necessity for continued use of a wheelchair or crutches (regular weight-bearing prohibited). (Effective as to outpatient surgery March 1, 1989.)

(3) Immobilization by cast, without surgery, of one major joint or more.

(Effective as to outpatient treatment March 10, 1976.)

A reduction in the total rating will not be subject to §3.105(e) of this chapter. The total rating will be followed by an open rating reflecting the appropriate schedular evaluation; where the evidence is inadequate to assign the schedular evaluation, a physcial examination will be scheduled prior to the end of the total rating period.

(b) A total rating under this section will require full justification on the rating sheet and may be extended as follows:

(1) Extensions of 1, 2 or 3 months beyond the initial 3 months may be made under paragraph (a) (1), (2) or (3) of this section.

(2) Extensions of 1 or more months up to 6 months beyond the initial 6 months period may be made under paragraph (a) (2) or (3) of this section upon approval of the Adjudication Officer.

 $[41\ {\rm FR}\ 34256,\ {\rm Aug.}\ 13,\ 1976,\ as\ amended\ at\ 54\ {\rm FR}\ 4281,\ {\rm Jan.}\ 30,\ 1989]$

§4.31 Zero percent evaluations.

In every instance where the schedule does not provide a zero percent evaluation for a diagnostic code, a zero percent evaluation shall be assigned when the requirements for a compensable evaluation are not met.

[58 FR 52018, Oct. 6, 1993]

Subpart B—Disability Ratings

THE MUSCULOSKELETAL SYSTEM

§4.40 Functional loss.

Disability of the musculoskeletal system is primarily the inability, due to damage or infection in parts of the system, to perform the normal working movements of the body with normal excursion, strength, speed, coordination and endurance. It is essential that the examination on which ratings are based adequately portray the anatomical damage, and the functional loss, with respect to all these elements. The functional loss may be due to absence of part, or all, of the necessary bones, joints and muscles, or associated structures, or to deformity, adhesions, defective innervation, or other pathology, or it may be due to pain, supported by adequate pathology and evidenced by the visible behavior of the claimant undertaking the motion. Weakness is as important as limitation of motion, and a part which becomes painful on use must be regarded as seriously disabled. A little used part of the musculoskeletal system may be expected to show evidence of disuse, either through atrophy, the condition of the skin, absence of normal callosity or the like.

§4.41 History of injury.

In considering the residuals of injury, it is essential to trace the medical-industrial history of the disabled person from the original injury, considering the nature of the injury and the attendant circumstances, and the requirements for, and the effect of, treatment over past periods, and the course of the recovery to date. The duration of the initial, and any subsequent, period of total incapacity, especially periods reflecting delayed union, inflammation, swelling, drainage, or operative intervention, should be given close attention. This consideration, or the absence of clear cut evidence of injury, may result in classifying the disability as not of traumatic origin, either reflecting congenital or developmental etiology, or the effects of healed disease.

§4.42 Complete medical examination of injury cases.

The importance of complete medical examination of injury cases at the time of first medical examination by the Department of Veterans Affairs cannot be overemphasized. When possible, this should include complete neurological and psychiatric examination, and other special examinations indicated by the physical condition, in addition to the required general and orthopedic or surgical examinations. When complete examinations are not conducted covering all systems of the body affected by disease or injury, it is impossible to visualize the nature and extent of the service connected disability. Incomplete examination is a common cause of incorrect diagnosis, especially in the neurological and psychiatric fields, and frequently leaves the Department of

§4.42

38 CFR Ch. I (7–1–05 Edition)

Veterans Affairs in doubt as to the presence or absence of disabling conditions at the time of the examination.

§4.43 Osteomyelitis.

Chronic, or recurring, suppurative osteomyelitis, once clinically identified, including chronic inflammation of bone marrow, cortex, or periosteum, should be considered as a continuously disabling process, whether or not an actively discharging sinus or other obvious evidence of infection is manifest from time to time, and unless the focus is entirely removed by amputation will entitle to a permanent rating to be combined with other ratings for residual conditions, however, not exceeding amputation ratings at the site of election.

§4.44 The bones.

The osseous abnormalities incident to trauma or disease, such as malunion with deformity throwing abnormal stress upon, and causing malalignment of joint surfaces, should be depicted from study and observation of all available data, beginning with inception of injury or disease, its nature, degree of prostration, treatment and duration of convalescence, and progress of recovery with development of permanent residuals. With shortening of a long bone, some degree of angulation is to be expected; the extent and direction should be brought out by X-ray and observation. The direction of angulation and extent of deformity should be carefully related to strain on the neighboring joints, especially those connected with weight-bearing.

§4.45 The joints.

As regards the joints the factors of disability reside in reductions of their normal excursion of movements in different planes. Inquiry will be directed to these considerations:

(a) Less movement than normal (due to ankylosis, limitation or blocking, adhesions, tendon-tie-up, contracted scars, etc.).

(b) More movement than normal (from flail joint, resections, nonunion of fracture, relaxation of ligaments, etc.).

(c) Weakened movement (due to muscle injury, disease or injury of peripheral nerves, divided or lengthened tendons, etc.).

(d) Excess fatigability.

(e) Incoordination, impaired ability to execute skilled movements smoothly.

(f) Pain on movement, swelling, deformity or atrophy of disuse. Instability of station, disturbance of locomotion, interference with sitting, standing and weight-bearing are related considerations. For the purpose of rating disability from arthritis, the shoulder, elbow, wrist, hip, knee, and ankle are considered major joints; multiple involvements of the interphalangeal, metacarpal and carpal joints of the upper extremities, the interphalangeal, metatarsal and tarsal joints of the lower extremities, the cervical vertebrae, the dorsal vertebrae, and the lumbar vertebrae, are considered groups of minor joints, ratable on a with major joints. parity The lumbosacral articulation and both sacroiliac joints are considered to be a group of minor joints, ratable on disturbance of lumbar spine functions.

§4.46 Accurate measurement.

Accurate measurement of the length of stumps, excursion of joints, dimensions and location of scars with respect to landmarks, should be insisted on. The use of a goniometer in the measurement of limitation of motion is indispensable in examinations conducted within the Department of Veterans Affairs. Muscle atrophy must also be accurately measured and reported.

[41 FR 11294, Mar. 18, 1976]

§§4.47-4.54 [Reserved]

§4.55 Principles of combined ratings for muscle injuries.

(a) A muscle injury rating will not be combined with a peripheral nerve paralysis rating of the same body part, unless the injuries affect entirely different functions.

(b) For rating purposes, the skeletal muscles of the body are divided into 23 muscle groups in 5 anatomical regions: 6 muscle groups for the shoulder girdle and arm (diagnostic codes 5301 through 5306); 3 muscle groups for the forearm and hand (diagnostic codes 5307 through 5309); 3 muscle groups for the

§4.43

foot and leg (diagnostic codes 5310 through 5312); 6 muscle groups for the pelvic girdle and thigh (diagnostic codes 5313 through 5318); and 5 muscle groups for the torso and neck (diagnostic codes 5319 through 5323).

(c) There will be no rating assigned for muscle groups which act upon an ankylosed joint, with the following exceptions:

(1) In the case of an ankylosed knee, if muscle group XIII is disabled, it will be rated, but at the next lower level than that which would otherwise be assigned.

(2) In the case of an ankylosed shoulder, if muscle groups I and II are severely disabled, the evaluation of the shoulder joint under diagnostic code 5200 will be elevated to the level for unfavorable ankylosis, if not already assigned, but the muscle groups themselves will not be rated.

(d) The combined evaluation of muscle groups acting upon a single unankylosed joint must be lower than the evaluation for unfavorable ankylosis of that joint, except in the case of muscle groups I and II acting upon the shoulder.

(e) For compensable muscle group injuries which are in the same anatomical region but do not act on the same joint, the evaluation for the most severely injured muscle group will be increased by one level and used as the combined evaluation for the affected muscle groups.

(f) For muscle group injuries in different anatomical regions which do not act upon ankylosed joints, each muscle group injury shall be separately rated and the ratings combined under the provisions of §4.25.

(Authority: 38 U.S.C. 1155)

[62 FR 30237, June 3, 1997]

§4.56 Evaluation of muscle disabilities.

(a) An open comminuted fracture with muscle or tendon damage will be rated as a severe injury of the muscle group involved unless, for locations such as in the wrist or over the tibia, evidence establishes that the muscle damage is minimal.

(b) A through-and-through injury with muscle damage shall be evaluated

as no less than a moderate injury for each group of muscles damaged.

(c) For VA rating purposes, the cardinal signs and symptoms of muscle disability are loss of power, weakness, lowered threshold of fatigue, fatiguepain, impairment of coordination and uncertainty of movement.

(d) Under diagnostic codes 5301 through 5323, disabilities resulting from muscle injuries shall be classified as slight, moderate, moderately severe or severe as follows:

(1) *Slight disability of muscles*—(i) *Type of injury.* Simple wound of muscle without debridement or infection.

(ii) *History and complaint.* Service department record of superficial wound with brief treatment and return to duty. Healing with good functional results. No cardinal signs or symptoms of muscle disability as defined in paragraph (c) of this section.

(iii) *Objective findings.* Minimal scar. No evidence of fascial defect, atrophy, or impaired tonus. No impairment of function or metallic fragments retained in muscle tissue.

(2) Moderate disability of muscles—(i) *Type of injury.* Through and through or deep penetrating wound of short track from a single bullet, small shell or shrapnel fragment, without explosive effect of high velocity missile, residuals of debridement, or prolonged infection.

(ii) *History and complaint.* Service department record or other evidence of in-service treatment for the wound. Record of consistent complaint of one or more of the cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section, particularly lowered threshold of fatigue after average use, affecting the particular functions controlled by the injured muscles.

(iii) *Objective findings*. Entrance and (if present) exit scars, small or linear, indicating short track of missile through muscle tissue. Some loss of deep fascia or muscle substance or impairment of muscle tonus and loss of power or lowered threshold of fatigue when compared to the sound side.

(3) *Moderately severe disability of muscles*—(i) *Type of injury.* Through and through or deep penetrating wound by small high velocity missile or large

38 CFR Ch. I (7–1–05 Edition)

low-velocity missile, with debridement, prolonged infection, or sloughing of soft parts, and intermuscular scarring.

(ii) *History and complaint.* Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section and, if present, evidence of inability to keep up with work requirements.

(iii) *Objective findings.* Entrance and (if present) exit scars indicating track of missile through one or more muscle groups. Indications on palpation of loss of deep fascia, muscle substance, or normal firm resistance of muscles compared with sound side. Tests of strength and endurance compared with sound side demonstrate positive evidence of impairment.

(4) Severe disability of muscles—(i) Type of injury. Through and through or deep penetrating wound due to high-velocity missile, or large or multiple low velocity missiles, or with shattering bone fracture or open comminuted fracture with extensive debridement, prolonged infection, or sloughing of soft parts, intermuscular binding and scarring.

(ii) *History and complaint.* Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section, worse than those shown for moderately severe muscle injuries, and, if present, evidence of inability to keep up with work requirements.

(iii) Objective findings. Ragged, depressed and adherent scars indicating wide damage to muscle groups in missile track. Palpation shows loss of deep fascia or muscle substance, or soft flabby muscles in wound area. Muscles swell and harden abnormally in contraction. Tests of strength, endurance, or coordinated movements compared with the corresponding muscles of the uninjured side indicate severe impairment of function. If present, the following are also signs of severe muscle disability:

(A) X-ray evidence of minute multiple scattered foreign bodies indicating intermuscular trauma and explosive effect of the missile.

(B) Adhesion of scar to one of the long bones, scapula, pelvic bones, sacrum or vertebrae, with epithelial sealing over the bone rather than true skin covering in an area where bone is normally protected by muscle.

(C) Diminished muscle excitability to pulsed electrical current in electrodiagnostic tests.

(D) Visible or measurable atrophy.

(E) Adaptive contraction of an opposing group of muscles.

(F) Atrophy of muscle groups not in the track of the missile, particularly of the trapezius and serratus in wounds of the shoulder girdle.

(G) Induration or atrophy of an entire muscle following simple piercing by a projectile.

(Authority: 38 U.S.C. 1155

[62 FR 30238, June 3, 1997]

§4.57 Static foot deformities.

It is essential to make an initial distinction between bilateral flatfoot as a congenital or as an acquired condition. The congenital condition, with depression of the arch, but no evidence of abnormal callosities, areas of pressure, strain or demonstrable tenderness, is a congenital abnormality which is not compensable or pensionable. In the acquired condition, it is to be remembered that depression of the longitudinal arch, or the degree of depression, is not the essential feature. The attention should be given to anatomical changes, as compared to normal, in the relationship of the foot and leg, particularly to the inward rotation of the superior portion of the os calcis, medial deviation of the insertion of the Achilles tendon, the medial tilting of the upper border of the astragalus. This is an unfavorable mechanical relationship of the parts. A plumb line dropped from the middle of the patella falls inside of the normal point. The forepart of the foot is abducted, and the foot everted. The plantar surface of the foot is painful and shows demonstrable tenderness, and manipulation of the foot produces spasm of the Achilles tendon, peroneal spasm due to adhesion about the peroneal sheaths, and other evidence of pain and limited

§4.57

motion. The symptoms should be apparent without regard to exercise. In severe cases there is gaping of bones on the inner border of the foot, and rigid valgus position with loss of the power of inversion and adduction. Exercise with undeveloped or unbalanced musculature, producing chronic irritation, can be an aggravating factor. In the absence of trauma or other definite evidence of aggravation, service connection is not in order for pes cavus which is a typically congenital or juvenile disease.

§4.58 Arthritis due to strain.

With service incurred lower extremity amputation or shortening, a disabling arthritis, developing in the same extremity, or in both lower extremities, with indications of earlier, or more severe, arthritis in the injured extremity, including also arthritis of the lumbosacral joints and lumbar spine, if associated with the leg amputation or shortening, will be considered as service incurred, provided, however, that arthritis affecting joints not directly subject to strain as a result of the service incurred amputation will not be granted service connection. This will generally require separate evaluation of the arthritis in the joints directly subject to strain. Amputation, or injury to an upper extremity, is not considered as a causative factor with subsequently developing arthritis, except in joints subject to direct strain or actually injured.

§4.59 Painful motion.

With any form of arthritis, painful motion is an important factor of disability, the facial expression, wincing, etc., on pressure or manipulation, should be carefully noted and definitely related to affected joints. Muscle spasm will greatly assist the identification. Sciatic neuritis is not uncommonly caused by arthritis of the spine. The intent of the schedule is to recognize painful motion with joint or periarticular pathology as productive of disability. It is the intention to recognize actually painful, unstable, or malaligned joints, due to healed injury, as entitled to at least the minimum compensable rating for the joint. Crepitation either in the soft tissues such as the tendons or ligaments, or crepitation within the joint structures should be noted carefully as points of contact which are diseased. Flexion elicits such manifestations. The joints involved should be tested for pain on both active and passive motion, in weight-bearing and nonweight-bearing and, if possible, with the range of the opposite undamaged joint.

§4.60 [Reserved]

§4.61 Examination.

With any form of arthritis (except traumatic arthritis) it is essential that the examination for rating purposes cover all major joints, with especial reference to Heberden's or Haygarth's nodes.

§4.62 Circulatory disturbances.

The circulatory disturbances, especially of the lower extremity following injury in the popliteal space, must not be overlooked, and require rating generally as phlebitis.

§4.63 Loss of use of hand or foot.

Loss of use of a hand or a foot, for the purpose of special monthly compensation, will be held to exist when no effective function remains other than that which would be equally well served by an amputation stump at the site of election below elbow or knee with use of a suitable prosthetic appliance. The determination will be made on the basis of the actual remaining function of the hand or foot, whether the acts of grasping, manipulation, etc., in the case of the hand, or of balance and propulsion, etc., in the case of the foot, could be accomplished equally well by an amputation stump with prosthesis.

(a) Extremely unfavorable complete ankylosis of the knee, or complete ankylosis of 2 major joints of an extremity, or shortening of the lower extremity of $3\frac{1}{2}$ inches (8.9 cms.) or more, will be taken as loss of use of the hand or foot involved.

(b) Complete paralysis of the external popliteal nerve (common peroneal) and consequent, footdrop, accompanied by characteristic organic changes including trophic and circulatory disturbances and other concomitants confirmatory of complete paralysis of this nerve, will be taken as loss of use of the foot.

 $[29\ {\rm FR}\ 6718,\ {\rm May}\ 22,\ 1964,\ {\rm as}\ {\rm amended}\ {\rm at}\ 43\ {\rm FR}\ 45349,\ {\rm Oct.}\ 2,\ 1978]$

§4.64 Loss of use of both buttocks.

Loss of use of both buttocks shall be deemed to exist when there is severe damage to muscle Group XVII, bilateral (diagnostic code number 5317) and additional disability rendering it impossible for the disabled person, without assistance, to rise from a seated position and from a stooped position (fingers to toes position) and to maintain postural stability (the pelvis upon head of femur). The assistance may be rendered by the person's own hands or arms, and, in the matter of postural stability, by a special appliance.

§4.65 [Reserved]

§4.66 Sacroiliac joint.

The common cause of disability in this region is arthritis, to be identified in the usual manner. The lumbosacral and sacroiliac joints should be considered as one anatomical segment for rating purposes. X-ray changes from arthritis in this location are decrease or obliteration of the joint space, with the appearance of increased bone density of the sacrum and ilium and sharpening of the margins of the joint. Disability is manifest from erector spinae spasm (not accounted for by other pathology), tenderness on deep palpation and percussion over these joints, loss of normal quickness of motion and resiliency, and postural defects often accompanied by limitation of flexion and extension of the hip. Traumatism is a rare cause of disability in this connection, except when superimposed upon congenital defect or upon an existent arthritis; to permit assumption of pure traumatic origin, objective evidence of damage to the joint, and history of trauma sufficiently severe to injure this extremely strong and practically immovable joint is required. There should be careful consideration of lumbosacral sprain, and the various symptoms of pain and paralysis attrib38 CFR Ch. I (7–1–05 Edition)

utable to disease affecting the lumbar vertebrae and the intervertebral disc.

§4.67 Pelvic bones.

The variability of residuals following these fractures necessitates rating on specific residuals, faulty posture, limitation of motion, muscle injury, painful motion of the lumbar spine, manifest by muscle spasm, mild to moderate sciatic neuritis, peripheral nerve injury, or limitation of hip motion.

§4.68 Amputation rule.

The combined rating for disabilities of an extremity shall not exceed the rating for the amputation at the elective level, were amputation to be performed. For example, the combined evaluations for disabilities below the knee shall not exceed the 40 percent evaluation, diagnostic code 5165. This 40 percent rating may be further combined with evaluation for disabilities above the knee but not to exceed the above the knee amputation elective level. Painful neuroma of a stump after amputation shall be assigned the evaluation for the elective site of reamputation.

§4.69 Dominant hand.

Handedness for the purpose of a dominant rating will be determined by the evidence of record, or by testing on VA examination. Only one hand shall be considered dominant. The injured hand, or the most severely injured hand, of an ambidextrous individual will be considered the dominant hand for rating purposes.

(Authority: 38 U.S.C. 1155)

[62 FR 30239, June 3, 1997]

§4.70 Inadequate examinations.


If the report of examination is inadequate as a basis for the required consideration of service connection and evaluation, the rating agency may request a supplementary report from the examiner giving further details as to the limitations of the disabled person's ordinary activity imposed by the disease, injury, or residual condition, the prognosis for return to, or continuance of, useful work. When the best interests of the service will be advanced by personal conference with the examiner,

such conference may be arranged through channels.

§4.71 Measurement of ankylosis and joint motion.

Plates I and II provide a standardized description of ankylosis and joint motion measurement. The anatomical position is considered as 0° , with two major exceptions: (a) Shoulder rotation—arm abducted to 90° , elbow flexed to 90° with the position of the forearm reflecting the midpoint 0° between internal and external rotation of the

shoulder; and (b) supination and pronation—the arm next to the body, elbow flexed to 90° , and the forearm in midposition 0° between supination and pronation. Motion of the thumb and fingers should be described by appropriate reference to the joints (See Plate III) whose movement is limited, with a statement as to how near, in centimeters, the tip of the thumb can approximate the fingers can approximate the proximal transverse crease of palm.






PLATE I

§4.71

§4.71a

Rat-




PLATE II

[29 FR 6718, May 22, 1964, as amended at 43 FR 45349, Oct. 2, 1978; 67 FR 48785, July 26, 2002]

§4.71a Schedule of ratings—musculoskeletal system.

ACUTE, SUBACUTE, OR CHRONIC DISEASES

	Rat- ing
 5000 Osteomyelitis, acute, subacute, or chronic: Of the pelvis, vertebrae, or extending into major joints, or with multiple localization or with long history of intractability and debility, anemia, amyloid liver changes, or other continuous 	
constitutional symptoms	100
Frequent episodes, with constitutional symptoms With definite involucrum or sequestrum, with or	60
without discharging sinus	30
tive infection within the past 5 years Inactive, following repeated episodes, without	20
evidence of active infection in past 5 years	10

ACUTE, SUBACUTE, OR CHRONIC DISEASES— Continued

	ing
NOTE (1): A rating of 10 percent, as an exception to the amputation rule, is to be assigned in any case of active osteomyelitis where the amputation rating for the affected part is no percent. This 10 percent rating and the other partial ratings of 30 percent or less are to be combined with ratings for ankylosis, limited motion, nonunion or malunion, shortening, etc., subject, of course, to the amputation rule. The 60 percent rating, as it is based on con- stitutional symptoms, is not subject to the am- putation rule. A rating for osteomyelitis will not be applied following cure by removal or radical resection of the affected bone.	

§4.71a

ACUTE, SUBACUTE, OR CHRONIC DISEASES—Continued

38 CFR Ch. I (7-1-05 Edition)

ACUTE, SUBACUTE, OR CHRONIC DISEASES—Continued

Continued		Continued	
	Rat- ing		Rat- ing
 NOTE (2): The 20 percent rating on the basis of activity within the past 5 years is not assignable following the initial infection of active osteomyelitis with no subsequent reactivation. The prerequisite for this historical rating is an established recurrent osteomyelitis. To qualify for the 10 percent rating, 2 or more episodes following the initial infection are required. This 20 percent rating or the 10 percent rating, when applicable, will be assigned once only to cover disability at all sites of previously active infection with a future ending date in the case of the 20 percent rating. 5001 Bones and joints, tuberculosis of, active or inactive: Active	ing 100	 With X-ray evidence of involvement of 2 or more major joints or 2 or more minor joint groups, with occasional incapacitating exacerbations With X-ray evidence of involvement of 2 or more major joints or 2 or more minor joint groups NOTE (1): The 20 pct and 10 pct ratings based on X-ray findings, above, will not be combined with ratings based on limitation of motion. NOTE (2): The 20 pct and 10 pct ratings based on X-ray findings, above, will not be utilized in rating conditions listed under diagnostic codes 5013 to 5024, inclusive. S006 Arthritis, gonorrheal. S005 Arthritis, typhoid. S007 Arthritis, streptococcic. S009 Arthritis, other types (specify). With the types of arthritis, diagnostic codes 504 through 5009, rate the disability as rheumatoid arthritis. S010 Arthritis, due to trauma, substantiated by X-ray findings: Rate as arthritis, degenerative. 	
 battors routed over prolonged periods Symptom combinations productive of definite impairment of health objectively supported by examination findings or incapacitating exacerbations occurring 3 or more times a year One or two exacerbations a year in a well-established diagnosis 	60 40 20	 5011 Bones, caisson disease of: Rate as arthritis, cord involvement, or deafness, depending on the severity of disabling manifestations. 5012 Bones, new growths of, malignant NOTE: The 100 percent rating will be continued for 1 year following the cessation of surgical, X-ray, antineoplastic chemotherapy or other 	100
 For chronic residuals: For residuals such as limitation of motion or ankylosis, favorable or unfavorable, rate under the appropriate diagnostic codes for the specific joints involved. Where, however, the limitation of motion of the specific joint or joints involved is noncompensable under the codes a rating of 10 percent is for application for each such major joint or group of minor joints affected by limitation of motion, to be combined, not added under diagnostic code 5002. Limitation of motion to be combined, not added under diagnostic code 5002. Limitation of motion must be objectively confirmed by findings such as swelling, muscle spasm, or satisfactory evidence of painful motion. NOTE: The ratings for the active process will not be combined with the residual ratings for limitation of motion or ankylosis. Assign the higher evaluation. 5003 Arthritis, degenerative (hypertrophic or osteoarthritis): Degenerative arthritis established by X-ray findings will be rated on the basis of limitation of motion under the appropriate diagnostic codes for the specific joint or joints involved (DC 		therapeutic procedure. At this point, if there has been no local recurrence or metastases, the rating will be made on residuals. 5013 Osteoporosis, with joint manifestations. 5014 Osteomalacia. 5015 Bones, new growths of, benign. 5016 Osteitis deformans. 5017 Gout. 5018 Hydrarthrosis, intermittent. 5019 Bursitis. 5020 Synovitis. 5022 Myositis. 5022 Myositis. 5023 Myositis ossificans. 5024 Tenosynovitis. 5023 Myositis ossificans. 5024 Tenosynovitis. 5023 The diseases under diagnostic codes 5013 through 5024 will be rated on limitation of mo- tion of affected parts, as arthritis, degenera- tive, except gout which will be rated under di- agnostic code 5002. 5025 Fibromyalgia (fibrositis, primary fibromyalgia syndrome) With widespread musculoskeletal pain and ten- der points, with or without associated fatigue, sleep disturbance, stiffness, paresthesias.	
5200 etc.). When however, the limitation of motion of the specific joint or joints involved is noncompensable under the appropriate diag- nostic codes, a rating of 10 pct is for applica- tion for each such major joint or group of minor joints affected by limitation of motion, to be combined, not added under diagnostic code 5003. Limitation of motion must be ob- jectively confirmed by findings such as swell- ing, muscle spasm, or satisfactory evidence of painful motion. In the absence of limitation of motion, rate as below:		 sleep disturbance, stiffness, parestnesias, headache, irritable bowel symptoms, depression, anxiety, or Raynaud's-like symptoms: That are constant, or nearly so, and refractory to therapy That are episodic, with exacerbations often precipitated by environmental or emotional stress or by overexention, but that are present more than one-third of the time That require continuous medication for control 	40 20 10

ACUTE, SUBACUTE, OR CHRONIC DISEASES— Continued

§4.71a

PROSTHETIC IMPLANTS—Continued

			Bat	ina
	Rat- ing		Major	Minor
oth the	-	Following implantation of prosthesis		
		with painful motion or weakness		
				190
ck) and				
				70
Bat	ina			50
Tiat				30
Major	Minor	5055 Knee replacement (prosthesis).		
		Prosthetic replacement of knee joint:		
		For 1 year following implantation of		
				100
100	100			
100	100			60
60	50			
		5262.		
				30
		5056 Ankle replacement (prosthesis).		
30	20	Prosthetic replacement of ankle joint:		
				100
100	100			40
50	40			
		5270 or 5271.		
		Minimum rating		20
		NOTE (1): The 100 pct rating for 1 year		
30	20			
100	100	rating period the earliest date perma-		
		nent use of crutches is established.		
40	30	COMBINATIONS OF DISABILITIES		
		5104 Anatomical loss of one hand and loss		
				1100
				100
20	20			1100
		5106 Anatomical loss of both hands		1100
		5107 Anatomical loss of both feet		1100
		5108 Anatomical loss of one hand and one		
		foot		1100
				1100
				1100
				110
1		100l	1	¹ 100
	Major 100 60 30 100 50 30 100 40	ing poth the is both affects ince, an- ck) and ing Rating Minor Major Minor 100 100 60 50 30 20 100 100 50 40 30 20 100 100 50 40 30 20 100 100 50 40 30 20 100 100 30 30	ing poth the is both affects infe, an- ck) and Following implantation of prosthesis with painful motion or weakness such as to require the use of crutches Maior Markedly severe residual weak- ness, pain or limitation of pros- thesis Major Minor Major Minor 5055 Knee replacement of knee joint: For 1 year following implantation of prosthesis 100 100 <td>ing Major both the is both affects ine, an- ck) and Following implantation of prosthesis with painful motion or weakeness such as to require the use of crutches Markedly severe residual weak- ness, pain or limitation of pros- thesis Markedly severe residuals weak- ness, pain or limitation of motion Major Minor 5055 Stops pain or limitation of motion for motion motion Major Minor 5055 Stops pain or limitation of motion for year following implantation of prosthesis 100 100 For 1 year following implantation of prosthesis 60 50 of motion rate by analogy to di- agnostic codes 5256, 5261, or 5262. 30 20 Sos Ankle replacement (prosthesis). Prosthetic replacement (prosthesis). 90 20 Sos Ankle replacement (prosthesis). Prosthetic replacement of ankle joint: For 1 year following implantation of prosthesis 30 20 Sos Ankle replacement (prosthesis). Prosthetic replacement of ankle joint: For 1 year following inplantation of motion rate by analogy to 5270 or 5271. Minimum rating 30 20 Of motion rate by analogy to 5270 or 5271. Minimum rating assignable during the 100 pct rating period the earliest date perma- nent use of crutches is established. 40 30 COMBINAT</td>	ing Major both the is both affects ine, an- ck) and Following implantation of prosthesis with painful motion or weakeness such as to require the use of crutches Markedly severe residual weak- ness, pain or limitation of pros- thesis Markedly severe residuals weak- ness, pain or limitation of motion Major Minor 5055 Stops pain or limitation of motion for motion motion Major Minor 5055 Stops pain or limitation of motion for year following implantation of prosthesis 100 100 For 1 year following implantation of prosthesis 60 50 of motion rate by analogy to di- agnostic codes 5256, 5261, or 5262. 30 20 Sos Ankle replacement (prosthesis). Prosthetic replacement (prosthesis). 90 20 Sos Ankle replacement (prosthesis). Prosthetic replacement of ankle joint: For 1 year following implantation of prosthesis 30 20 Sos Ankle replacement (prosthesis). Prosthetic replacement of ankle joint: For 1 year following inplantation of motion rate by analogy to 5270 or 5271. Minimum rating 30 20 Of motion rate by analogy to 5270 or 5271. Minimum rating assignable during the 100 pct rating period the earliest date perma- nent use of crutches is established. 40 30 COMBINAT

§4.71a

38 CFR Ch. I (7-1-05 Edition)

TABLE II—RATINGS FOR MULTIPLE LOSSES OF EXTREMITIES WITH DICTATOR'S RATING CODE AND 38
CFR CITATION

			Impairment of o	other extremity		
Impairment of one extremity	Anatomical loss or loss of use below elbow	Anatomical loss or loss of use below knee	Anatomical loss or loss of use above elbow (preventing use of prosthesis)	Anatomical loss or loss of use above knee (preventing use of prosthesis)	Anatomical loss near shoulder (preventing use of prosthesis)	Anatomical loss near hip (pre- venting use of prosthesis)
Anatomical loss or loss of use below elbow. Anatomical loss or loss of use below knee.	M Codes M-1 a, b, or c, 38 CFR 3.350 (c)(1)(i).	L Codes L-1 d, e, f, or g, 38 CFR 3.350(b). L Codes L-1 a, b, or c, 38 CFR 3.350(b).	M ¹ / ₂ Code M–5, 38 CFR 3.350 (f)(1)(x). L ¹ / ₂ Code L–2 b, 38 CFR 3.350 (f)(1)(iii).	L ¹ / ₂ Code L-2 c, 38 CFR 3.350 (f)(1)(vi). L ¹ / ₂ Code L-2 a, 38 CFR 3.350 (f)(1)(i).	N Code N-3, 38 CFR 3.350 (f)(1)(xi). M Code M-3 b, 38 CFR 3.350 (f)(1)(iv).	M Code M-3 c, 38 CFR 3.350 (f)(1)(viii) M Code M-3 a, 38 CFR 3.350 (f)(1)(ii)
Anatomical loss or loss of use above elbow (preventing use of prosthesis).			N Code N–1, 38 CFR 3.350 (d)(1).	M Code M–2 a, 38 CFR 3.350 (c)(1)(iii).	N ¹ / ₂ Code N–4, 38 CFR 3.350 (f)(1)(ix).	M ¹ ⁄2 Code M–4 c, 38 CFR 3.350 (f)(1)(xi)
Anatomical loss or loss of use above knee (preventing use of prosthesis).				M Code M–2 a, 38 CFR 3.350 (c)(1)(ii).	M ¹ / ₂ Code M–4 b, 38 CFR 3.350 (f)(1)(vii).	M ¹ / ₂ Code M–4 a, 38 CFR 3.350 (f)(1)(v)
Anatomical loss near shoulder (preventing use					O Code O–1, 38 CFR 3.350 (e)(1)(i).	N Code N–2 b, 38 CFR 3.350 (d)(3)
of prosthesis). Anatomical loss near hip (pre- venting use of prosthesis).						N Code N–2 a, 38 CFR 3.350 (d)(2)

NOTE.—Need for aid attendance or permanently bedridden qualifies for subpar. L. Code L–1 h, i (38 CFR 3.350(b)). Paraplegia with loss of use of both lower extremities and loss of anal and bladder sphincter control qualifies for subpar. O. Code O–2 (38 CFR 3.350(e)(2)). Where there are additional disabilities rated 50% or 100%, or anatomical or loss of use of a third extremity see 38 CFR 3.350(f) (3), (4) or (5).

(Authority: 38 U.S.C. 1115)

AMPUTATIONS: UPPER EXTREMITY—Continued

AMPUTATIONS: UPPER EXTREMITY

		Rat	ng
		Major	Minor
Arm, a	amputation of:		
	articulation	1 90	1 90
5121 Abo	ove insertion of deltoid	1 90	¹ 80
5122 Bel	ow insertion of deltoid	¹ 80	170
Forea	rm, amputation of:		
5123 Abo	ove insertion of pronator teres	¹ 80	¹ 70
5124 Bel	ow insertion of pronator teres	¹ 70	¹ 60
5125 Hai	nd, loss of use of	¹ 70	¹ 60
	MULTIPLE FINGER AMPUTATIONS		
5126 Fiv	e digits of one hand, amputation		
of	-	¹ 70	¹ 60
Four o	ligits of one hand, amputation of:		
5127 Thu	Imb, index, long and ring	¹ 70	¹ 60
	umb, index, long and little	¹ 70	¹ 60
5129 Thu	umb, index, ring and little	¹ 70	¹ 60
	umb, long, ring and little	¹ 70	¹ 60
	ex, long, ring and little	60	50
	digits of one hand, amputation of:		
	imb, index and long	60	50
	mb, index and ring	60	50
	imb, index and little	60	50
	imb, long and ring	60	50
5136 Thu	umb, long and little	60	50

		Rat	ing
		Major	Minor
5137	Thumb, ring and little	60	50
5138	Index, long and ring	50	40
5139	Index, long and little	50	40
5140	Index, ring and little	50	40
5141	Long, ring and little	40	30
T	wo digits of one hand, amputation of:		
5142	Thumb and index	50	40
5143	Thumb and long	50	40
5144	Thumb and ring	50	40
5145	Thumb and little	50	40
5146	Index and long	40	30
5147	Index and ring	40	30
5148	Index and little	40	30
5149	Long and ring	30	20
5150	Long and little	30	20
5151	Ring and little	30	20
,	 a) The ratings for multiple finger amputations apply to amputations at the proximal interphalangeal joints or through proximal phalanges. b) Amputation through middle phalanges will be rated as prescribed for unfavorable ankylosis of the fingers. 		

AMPUTATIONS: UPPER EXTREMITY—Continued

§4.71a

AMPUTATIONS: UPPER EXTREMITY—Continued


	Rat	ing		Rati	ing
	Major	Minor		Major	Min
(c) Amputations at distal joints, or through distal phalanges, other than			With metacarpal resection At metacarpophalangeal joint or through	40	
negligible losses, will be rated as pre-			proximal phalanx	30	
scribed for favorable ankylosis of the fingers			At distal joint or through distal phalanx 5153 Index finger, amputation of	20	
(d) Amputation or resection of meta- carpal bones (more than one-half the bone lost) in multiple fingers injuries will require a rating of 10 percent			With metacarpal resection (more than one-half the bone lost)	30	
added to (not combined with) the rat-			thereto	20	
ings, multiple finger amputations, sub- ject to the amputation rule applied to			Through middle phalanx or at distal joint 5154 Long finger, amputation of:	10	
the forearm. (e) Combinations of finger amputations at various levels, or finger amputa-			With metacarpal resection (more than one-half the bone lost) Without metacarpal resection, at proxi-	20	
tions with ankylosis or limitation of motion of the fingers will be rated on the basis of the grade of disability;			mal interphalangeal joint or proximal thereto	10	
i.e., amputation, unfavorable anky- losis, most representative of the lev- els or combinations. With an even			With interactarian resection (infore than one-half the bone lost)	20	
number of fingers involved, and adja- cent grades of disability, select the higher of the two grades.			5156 Little finger, amputation of: With metacarpal resection (more than	10	
(f) Loss of use of the hand will be held to exist when no effective function re- mains other than that which would be			With interactarian resection (infore than one-half the bone lost)	20	
equally well served by an amputation stump with a suitable prosthetic applicance.			NOTE: The single finger amputation rat- ings are the only applicable ratings	10	
SINGLE FINGER AMPUTATIONS			for amputations of whole or part of single fingers.		

5152 Thumb, amputation of:

¹ Entitled to special monthly compensation.

§4.71a

38 CFR Ch. I (7-1-05 Edition)



SINGLE FINGER AMPUTATIONS

PLATE III

AMPUTATIONS: LOWER EXTREMITY

	Rat- ing
Thigh, amputation of:	
5160 Disarticulation, with loss of extrinsic pelvic gir-	
dle muscles	² 90
5161 Upper third, one-third of the distance from	
perineum to knee joint measured from perineum	² 80
5162 Middle or lower thirds	² 60
Leg, amputation of:	
5163 With defective stump, thigh amputation rec-	
ommended	² 60
5164 Amputation not improvable by prosthesis con-	
trolled by natural knee action	² 60
5165 At a lower level, permitting prosthesis	² 40
5166 Forefoot, amputation proximal to metatarsal	
bones (more than one-half of metatarsal loss)	² 40
5167 Foot, loss of use of	² 40

§4.71a

AMPUTATIONS: LOWER EXTREMITY—Continued

	Rat- ing
5170 Toes, all, amputation of, without metatarsal	00
loss 5171 Toe, great, amputation of:	30
With removal of metatarsal head	30
Without metatarsal involvement	10
5172 Toes, other than great, amputation of, with re- moval of metatarsal head:	
One or two	20
Without metatarsal involvement	0
5173 Toes, three or four, amputation of, without metatarsal involvement:	
Including great toe	20
Not including great toe	10

² Also entitled to special monthly compensation.

§4.71a

38 CFR Ch. I (7-1-05 Edition)




PLATE IV

THE SHOULDER AND ARM

	Rating	
	Major	Minor
5200 Scapulohumeral articulation, anky- losis of:		
NOTE: The scapula and humerus move as one piece.		
Unfavorable, abduction limited to 25° from side	50	40
Intermediate between favorable and un- favorable	40	30
Favorable, abduction to 60°, can reach mouth and head	30	20
To 25° from side Midway between side and shoulder	40	30
level	30	20
At shoulder level	20	20
5202 Humerus, other impairment of:		
Loss of head of (flail shoulder)	80	70
Nonunion of (false flail joint) Fibrous union of	60 50	50 40
Recurrent dislocation of at	50	40
scapulohumeral joint.		
With frequent episodes and guard-		
ing of all arm movements	30	20
With infrequent episodes, and		20
guarding of movement only at		
shoulder level	20	20
Malunion of:		
Marked deformity	30	20
Moderate deformity	20	20
5203 Clavicle or scapula, impairment of:		
Dislocation of	20	20
Nonunion of:		
With loose movement	20	20
Without loose movement	10	10
Malunion of	10	10
Or rate on impairment of function of contiguous joint.		

THE ELBOW AND FOREARM

	Rati	ing
	Major	Minor
5205 Elbow, ankylosis of:		
Unfavorable, at an angle of less than		
50° or with complete loss of		
supination or pronation	60	50
Intermediate, at an angle of more than		
90°, or between 70° and 50°	50	40
Favorable, at an angle between 90° and		
70°	40	30
5206 Forearm, limitation of flexion of:		
Flexion limited to 45°	50	40
Flexion limited to 55°	40	30
Flexion limited to 70°	30	20
Flexion limited to 90°	20	20
Flexion limited to 100°	10	10
Flexion limited to 110°	0	(
5207 Forearm, limitation of extension of:		
Extension limited to 110°	50	4
Extension limited to 100°	40	30
Extension limited to 90°	30	2
Extension limited to 75°	20	2
Extension limited to 60°	10	10
Extension limited to 45°	10	10
5208 Forearm, flexion limited to 100° and		
extension to 45°	20	20
5209 Elbow, other impairment of Flail joint	60	50

§4.71a

THE ELBOW AND FOREARM—Continued

	Rat	ing
	Major	Minor
Joint fracture, with marked cubitus varus or cubitus valgus deformity or with ununited fracture of head of ra- dius	20	20
5210 Radius and ulna, nonunion of, with	20	20
flail false joint 5211 Ulna, impairment of: Nonunion in upper half, with false movement: With loss of bone substance (1 inch	50	40
(2.5 cms.) or more) and marked deformity	40	30
Without loss of bone substance or deformity	30	20
Nonunion in lower half	20	20
Malunion of, with bad alignment 5212 Radius, impairment of: Nonunion in lower half, with false move- ment:	10	10
With loss of bone substance (1 inch (2.5 cms.) or more) and marked deformity	40	30
Without loss of bone substance or deformity	30	20
Nonunion in upper half Malunion of, with bad alignment 5213 Supination and pronation, impairment of:	20 10	20 20 10
Loss of (bone fusion):		
The hand fixed in supination or hyperpronation The hand fixed in full pronation	40 30	30 20
The hand fixed near the middle of the arc or moderate pronation	20	20
Limitation of pronation:	20	20
Motion lost beyond middle of arc Motion lost beyond last quarter of arc, the hand does not approach	30	20
full pronation Limitation of supination:	20	20
To 30° or less NOTE: In all the forearm and wrist inju- ries, codes 5205 through 5213, mul- tiple impaired finger movements due to tendon tie-up, muscle or nerve in- jury, are to be separately rated and combined not to exceed rating for loss of use of hand.	10	10

THE WRIST

	Rating	
	Major	Minor
 5214 Wrist, ankylosis of: Unfavorable, in any degree of palmar flexion, or with ulnar or radial devi- ation and the second second second second Any other position, except favorable Favorable in 20° to 30° dorsiflexion NOTE: Extremely unfavorable ankylosis will be rated as loss of use of hands under diagnostic code 5125. 5215 Wrist, limitation of motion of: 	50 40 30	40 30 20
Dorsiflexion less than 15°	10	10
Palmar flexion limited in line with fore- arm	10	10

§4.71a

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND

38 CFR Ch. I (7-1-05 Edition)

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

	Rating				ing
	Major	Minor		Major	Mino
1) For the index long ring and little fingers			(iv) If only the metacarpophalangeal		
1) For the index, long, ring, and little fingers (digits II, III, IV, and V), zero degrees of			or proximal interphalangeal joint		
flexion represents the fingers fully ex-			is ankylosed, and there is a gap		
tended, making a straight line with the rest			of two inches (5.1 cm.) or less		
of the hand. The position of function of the			between the fingertip(s) and the		
hand is with the wrist dorsiflexed 20 to 30			proximal transverse crease of the		
degrees, the metacarpophalangeal and			palm, with the finger(s) flexed to		
proximal interphalangeal joints flexed to			the extent possible, evaluate as		
30 degrees, and the thumb (digit I) ab-			favorable ankylosis		
ducted and rotated so that the thumb pad			(4) Evaluation of ankylosis of the thumb:		
faces the finger pads. Only joints in these			(i) If both the carpometacarpal and		
positions are considered to be in favorable			interphalangeal joints are		
position. For digits II through V, the			ankylosed, and either is in exten-		
metacarpophalangeal joint has a range of			sion or full flexion, or there is ro-		
			tation or angulation of a bone,		
zero to 90 degrees of flexion, the proximal			evaluate as amputation at		
interphalangeal joint has a range of zero			metacarpophalangeal joint or		
to 100 degrees of flexion, and the distal			through proximal phalanx		
(terminal) interphalangeal joint has a			(ii) If both the carpometacarpal and		
range of zero to 70 or 80 degrees of flex-			interphalangeal joints are		
ion			ankylosed, evaluate as unfavor-		
2) When two or more digits of the same			able ankylosis, even if each joint		
hand are affected by any combination of			is individually fixed in a favorable		
amputation, ankylosis, or limitation of mo-			position		
tion that is not otherwise specified in the			(iii) If only the carpometacarpal or		
rating schedule, the evaluation level as-			interphalangeal joint is		
signed will be that which best represents			ankylosed, and there is a gap of		
the overall disability (i.e., amputation, un-			more than two inches (5.1 cm.)		
favorable or favorable ankylosis, or limita-			between the thumb pad and the		
tion of motion), assigning the higher level					
of evaluation when the level of disability is			fingers, with the thumb attempt-		
equally balanced between one level and			ing to oppose the fingers, evalu-		
the next higher level			ate as unfavorable ankylosis		
3) Evaluation of ankylosis of the index,			(iv) If only the carpometacarpal or		
long, ring, and little fingers:			interphalangeal joint is		
(i) If both the metacarpophalangeal			ankylosed, and there is a gap of		
and proximal interphalangeal			two inches (5.1 cm.) or less be-		
joints of a digit are ankylosed,			tween the thumb pad and the fin-		
and either is in extension or full			gers, with the thumb attempting		
			to oppose the fingers, evaluate		
flexion, or there is rotation or an-			as favorable ankylosis		
gulation of a bone, evaluate as			(5) If there is limitation of motion of two or		
amputation without metacarpal			more digits, evaluate each digit separately		
resection, at proximal inter-			and combine the evaluations		
phalangeal joint or proximal			I Multiple Digite: Unfeverable Ank	wlesis	
thereto(ii) If both the metacarpophalangeal			I. Multiple Digits: Unfavorable Ank	yiosis	
and proximal interphalangeal			5216 Five digits of one hand, unfavorable		
joints of a digit are ankylosed,			ankylosis of	60	5
evaluate as unfavorable anky-			Note: Also consider whether evaluation as		
losis, even if each joint is individ-			amputation is warranted.		
ually fixed in a favorable position.			5217 Four digits of one hand, unfavorable		
(iii) If only the metacarpophalangeal			ankylosis of:		
or proximal interphalangeal joint			Thumb and any three fingers	60	!
is ankylosed, and there is a gap			Index, long, ring, and little fingers	50	4
of more than two inches (5.1			Note: Also consider whether evaluation as		
cm.) between the fingertip(s) and			amputation is warranted.		
the proximal transverse crease of			5218 Three digits of one hand, unfavorable		
the palm, with the finger(s) flexed			ankylosis of:		
			Thumb and any two fingers	50	
to the extent possible, evaluate			Index, long, and ring; index, long,		
as unfavorable ankylosis			and little; or index, ring, and little		
			fingers	40	
			Long, ring, and little fingers	30	
			Note: Also consider whether evaluation as		.
			amputation is warranted.		
			5219 Two digits of one hand, unfavorable ankylosis of:		

§4.71a

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

	Rat	ing
	Major	Minor
Index and long; index and ring; or index and little fingers Long and ring; long and little; or	30	20
ring and little fingers Note: Also consider whether evaluation as amputation is warranted.	20	20
II. Multiple Digits: Favorable Anky	ylosis	
5220 Five digits of one hand, favorable an- kylosis of	50	40
Thumb and any three fingers	50	40
Index, long, ring, and little fingers 5222 Three digits of one hand, favorable an- kylosis of:	40	30
Thumb and any two fingers Index, long, and ring; index, long, and little; or index, ring, and little	40	30
fingers	30	20
Long, ring and little fingers 5223 Two digits of one hand, favorable an- kylosis of:	20	20
Thumb and any finger Index and long; index and ring; or	30	20
index and little fingers Long and ring; long and little; or	20	20
ring and little fingers	10	10
III. Ankylosis of Individual Dig	its	
5224 Thumb, ankylosis of:		
Unfavorable	20	20
Favorable	10	10

5224 Thumb, ankylosis of: Unfavorable Favorable	20	
Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
5225 Index finger, ankylosis of:		
Unfavorable or favorable	10	
5226 Long finger, ankylosis of:		
Unfavorable or favorable	10	
Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
5227 Ring or little finger, ankylosis of:		
Unfavorable or favorable	0	

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—CONTINUED

		Rating	
		Major	Mino
amp addi sulti	Also consider whether evaluation as outation is warranted and whether an itional evaluation is warranted for re- ng limitation of motion of other digits iterference with overall function of the d.		
	IV. Limitation of Motion of Individua	al Digits	
5228	Thumb, limitation of motion: With a gap of more than two inches (5.1 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers	20	20
	With a gap of one to two inches (2.5 to 5.1 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose	10	1(
5229	the fingers With a gap of less than one inch (2.5 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers Index or long finger, limitation of mo-	0	
tion:	With a gap of one inch (2.5 cm.) or more between the fingertip and the proximal transverse crease of the palm, with the finger flexed to the extent possible, or; with ex- tension limited by more than 30 degrees	10	1(
5230	and the proximal transverse crease of the palm, with the fin- ger flexed to the extent possible, and; extension is limited by no more than 30 degrees	0	(
tion:	Any limitation of motion	0	(

THE SPINE

	Rat- ing
General Rating Formula for Diseases and Injuries of the Spine	
(For diagnostic codes 5235 to 5243 unless 5243 is evaluated under the Formula for Rating Intervertebral Disc Syndrome Based on Incapaci- tating Episodes):	
With or without symptoms such as pain (whther or not it radiates), stiffness, or aching in the area of the spine affected by residuals of injury or disease	
Unfavorable ankylosis of the entire spine	100
Unfavorable ankylosis of the entire thoracolumbar spine	50

10

§4.71a

THE SPINE—Continued

38 CFR Ch. I (7-1-05 Edition)

THE SPINE—Continued


		THE SPINE—Continued	
	Rat- ing		Rat- ing
 Unfavorable ankylosis of the entire cervical spine; or, forward flexion of the thoracolumbar spine 30 degrees or less; or, favorable ankylosis of the entire thoracolumbar spine in thoracolumbar spine		 Note (2): (See also Plate V.) For VA compensation purposes, normal forward flexion of the cervical spine is zero to 45 degrees, extension is zero to 45 degrees, left and right lateral rotation are zero to 80 degrees. Normal forward flexion of the thoracolumbar spine is zero to 90 degrees, extension is zero to 30 degrees, extension is zero to 30 degrees, extension are zero to 30 degrees, extension are zero to 30 degrees, extension, are zero to 30 degrees. The combined range of motion refers to the sum of the range of forward flexion, extension, left and right lateral flexion, and left and right rotation. The normal combined range of motion of the cervical spine is 340 degrees. The normal ranges of motion for each component of spinal motion provided in this note are the maximum that can be used for calculation of the combined range of motion. Note (3): In exceptional cases, an examiner may state that because of age, body habitus, neurologic disease, or other factors not the result of disease or injury of the spine, the range of motion of the spine in a particular individual, even though it does not conform to the normal range of motion stated in Note (2). Provided that the examiner supplies an explanation, the examiner's assessment that the range of motion is normal for that individual will be accepted. Note (4): Round each range of motion measurement to the nearest fixed degrees. Note (5): For VA compensation purposes, unfavorable ankylosis results in one or more of the following: difficulty walking because of a spinal segment in neutral position (zero degrees) always represents favorable ankylosis. Note (6): Separately evaluate disability of the thoracolumbar and or ervical spine tracture or disocation or disocation; or neurologic symptoms due to pressure of the costal margin on the abdomer; dyspnea or dysphagia; atlantoaxial or cervical spine segments, except when there is unfavorable ankylosis of both segments, which will be rated as a single di	

THE SPINE—Continued

THE SPINE—Continued

	Rat- ing		Rat- ing
Formula for Rating Intervertebral Disc Syndrome Based on Incapacitating Episodes With incapacitating episodes having a total duration of at least 6 weeks during the past 12 months With incapacitating episodes having a total duration of at least 4 weeks but less than 6 weeks during the past 12 months With incapacitating episodes having a total duration of at least 2 weeks but less than 4 weeks during the past 12 months With incapacitating episodes having a total duration of at least 2 weeks but less than 4 weeks during the past 12 months With incapacitating episodes having a total duration of at least one week but less than 2 weeks during the past 12 months	60 40 20 10	 Note (1): For purposes of evaluations under diagnostic code 5243, an incapacitating episode is a period of acute signs and symptoms due to intervertebral disc syndrome that requires bed rest prescribed by a physician and treatment by a physician. Note (2): If intervertebral disc syndrome is present in more than one spinal segment, provided that the effects in each spinal segment are clearly distinct, evaluate each segment on the basis of incapacitating episodes or under the General Rating Formula for Diseases and Injuries of the Spine, whichever method results in a higher evaluation for that segment. 	

§4.71a



§4.71a

38 CFR Ch. I (7-1-05 Edition)




PLATE V RANGE OF MOTION OF CERVICAL AND THORACOLUMBAR SPINE

THE HIP AND THIGH

	Rat- ing
5250 Hip, ankylosis of: Unfavorable, extremely unfavorable ankylosis, the foot not reaching ground, crutches neces-	
sitated	390
Intermediate	70
Favorable, in flexion at an angle between 20°	
and 40°, and slight adduction or abduction 5251 Thigh, limitation of extension of:	60
Extension limited to 5°	10
5252 Thigh, limitation of flexion of:	
Flexion limited to 10°	40
Flexion limited to 20°	30
Flexion limited to 30°	20
Flexion limited to 45°	10
5253 Thigh, impairment of:	
Limitation of abduction of, motion lost beyond	
10°	20
Limitation of adduction of, cannot cross legs	10
Limitation of rotation of, cannot toe-out more	
than 15°, affected leg	10
5254 Hip, flail joint	80
5255 Femur, impairment of:	
Fracture of shaft or anatomical neck of:	
With nonunion, with loose motion (spiral or	
oblique fracture)	80
With nonunion, without loose motion,	
weightbearing preserved with aid of brace	60
Fracture of surgical neck of, with false joint	60
Malunion of:	
With marked knee or hip disability	30
With moderate knee or hip disability	20
With slight knee or hip disability	10

THE KNEE AND LEG-Continued

	Rat- ing
With moderate knee or ankle disability	20
With slight knee or ankle disability	10
5263 Genu recurvatum (acquired, traumatic, with weakness and insecurity in weight-bearing objec-	
tively demonstrated)	10

THE ANKLE

	Rat- ing
5270 Ankle, ankylosis of:	
In plantar flexion at more than 40°, or in	
dorsiflexion at more than 10° or with abduc-	
tion, adduction, inversion or eversion deformity	40
In plantar flexion, between 30° and 40°, or in	
dorsiflexion, between 0° and 10°	30
In plantar flexion, less than 30°	20
5271 Ankle, limited motion of:	
Marked	20
Moderate	10
5272 Subastragalar or tarsal joint, ankylosis of:	
In poor weight-bearing position	20
In good weight-bearing position	10
5273 Os calcis or astragalus, malunion of:	
Marked deformity	20
Moderate deformity	10
5274 Astragalectomy	20

³Entitled to special monthly compensation.

THE KNEE AND LEG

	Rat- ing
5256 Knee, ankylosis of:	
Extremely unfavorable, in flexion at an angle of	
45° or more	60
In flexion between 20° and 45°	50
In flexion between 10° and 20°	40
Favorable angle in full extension, or in slight	
flexion between 0° and 10°	30
5257 Knee, other impairment of:	
Recurrent subluxation or lateral instability:	
Severe	30
Moderate	20
Slight	10
5258 Cartilage, semilunar, dislocated, with frequent	
episodes of "locking," pain, and effusion into the	00
joint	20
5259 Cartilage, semilunar, removal of, symptomatic 5260 Leg, limitation of flexion of:	10
Flexion limited to 15°	30
Flexion limited to 30°	20
Flexion limited to 45°	10
Flexion limited to 60°	0
5261 Leg, limitation of extension of:	0
Extension limited to 45°	50
Extension limited to 30°	40
Extension limited to 20°	30
Extension limited to 15°	20
Extension limited to 10°	10
Extension limited to 5°	0
5262 Tibia and fibula, impairment of:	
Nonunion of, with loose motion, requiring brace	40
Malunion of:	
With marked knee or ankle disability	30

SHORTENING OF THE LOWER EXTREMITY

	Rat- ing
 5275 Bones, of the lower extremity, shortening of: Over 4 inches (10.2 cms.) 3½ to 4 inches (8.9 cms. to 10.2 cms.) 3 to 3½ inches (7.6 cms. to 8.9 cms.) 2½ to 3 inches (6.4 cms. to 7.6 cms.) 2½ to 2 inches (6.4 cms. to 7.6 cms.) 1¼ to 2 inches (3.2 cms. to 5.1 cms.) NOTE: Measure both lower extremities from anterior superior spine of the ilium to the internal malleolus of the tibia. Not to be combined with other ratings for fracture or faulty union in the same extremity. 	³ 60 ³ 50 40 30 20 10

³Also entitled to special monthly compensation.

THE FOOT

	Rat- ing
 5276 Flatfoot, acquired: Pronounced; marked pronation, extreme tenderness of plantar surfaces of the feet, marked inward displacement and severe spasm of the tendo achillis on manipulation, not improved by orthopedic shoes or appliances. Bilateral Unilateral Severe; objective evidence of marked deformity (pronation, abduction, etc.), pain on manipulation and use accentuated, indication of swelling on use, characteristic callosities: 	50 30
Bilateral Unilateral	30 20

§4.71a

§4.72

THE FOOT—Continued

	Rat- ing
 Moderate; weight-bearing line over or medial to great toe, inward bowing of the tendo achillis, pain on manipulation and use of the feet, bilateral or unilateral Mild; symptoms relieved by built-up shoe or arch support 5277 Weak foot, bilateral: A symptomatic condition secondary to many constitutional conditions, characterized by atrophy of the musculature, disturbed circulation, and weakness: 	10 0
Rate the underlying condition, minimum rat- ing	10
Marked contraction of plantar fascia with dropped forefoot, all toes hammer toes, very painful callosities, marked varus deformity: Bilateral Unilateral All toes tending to dorsiflexion, limitation of dorsiflexion at ankle to right angle, shortened plantar fascia, and marked tenderness under metatarsal heads:	50 30
Bilateral Unilateral Great toe dorsiflexed, some limitation of dorsiflexion at ankle, definite tenderness under	30 20
metatarsal heads: Bilateral Unilateral Slight	10 10 0
5279 Metatarsalgia, anterior (Morton's disease), unilateral, or bilateral	10
 5280 Hallux valgus, unilateral: Operated with resection of metatarsal head Severe, if equivalent to amputation of great toe 5281 Hallux rigidus, unilateral, severe: Rate as hallux valgus, severe. Note: Not to be combined with claw foot ratings. 	10 10
5282 Hammer toe: All toes, unilateral without claw foot Single toes	10 0
nonunion of: Severe	30 20 10
5284 Foot injuries, other: 5284 Foot injuries, other: Severe	30 20 10

THE SKULL

		Rat- ing
5296 bles	Skull, loss of part of, both inner and outer ta-	
	s. /ith brain hernia	80
Ń	/ithout brain hernia:	
	Area larger than size of a 50-cent piece or	
	1.140 in ² (7.355 cm ²)	50
	Area intermediate	30
	Area smaller than the size of a 25-cent	
	piece or 0.716 in 2 (4.619 cm 2)	10

38 CFR Ch. I (7-1-05 Edition)

THE SKULL—Continued

	Rat- ing
NOTE: Rate separately for intracranial com- plications.	

THE RIBS

	Rat- ing
5297 Ribs, removal of:	
More than six	50
Five or six	40
Three or four	30
Тwo	20
One or resection of two or more ribs without re-	
generation	10
NOTE (1): The rating for rib resection or removal is not to be applied with ratings for purrulent pleurisy, lobectomy, pneumonectomy or inju- ries of pleural cavity.	
NOTE (2): However, rib resection will be consid- ered as rib removal in thoracoplasty performed for collapse therapy or to accomplish oblitera- tion of space and will be combined with the rating for lung collapse, or with the rating for lobectomy, pneumonectomy or the graduated ratings for pulmonary tuberculosis.	

THE COCCYX

	Rat- ing
5298 Coccyx, removal of:	
Partial or complete, with painful residuals	10
Without painful residuals	0

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 40 FR 42536, Sept. 15, 1975; 41 FR 11294, Mar. 18, 1976; 43 FR 45350, Oct. 2, 1978; 51 FR 6411, Feb. 24, 1986; 61 FR 20439, May 7, 1996; 67 FR 48785, July 26, 2002; 68 FR 51456, Aug. 27, 2003; 69 FR 32450, June 10, 2004]

§4.72 [Reserved]

§4.73 Schedule of ratings—muscle injuries.

NOTE: When evaluating any claim involving muscle injuries resulting in loss of use of any extremity or loss of use of both buttocks (diagnostic code 5317, Muscle Group XVII), refer to \$3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation.

THE SHOULDER GIRDLE AND ARM

THE FOREARM AND HAND

	Rating			Rati	ng	
	Domi- nant	Non- domi- nant		Domi- nant	Non- domi- nant	
 5301 Group I. Function: Upward rotation of scapula; elevation of arm above shoulder level. Extrinsic muscles of shoulder girdle: (1) Trapezius; (2) levator scapulae; (3) serratus magnus. Severe	40 30 10 0	30 20 10 0	5307 Group VII. Function: Flexion of wrist and fingers. Muscles arising from internal condyle of humerus: Flexors of the carpus and long flexors of fingers and thumb; pronator. Severe Moderately Severe Slight S308 Group VIII. Function: Extension of wrist, fingers, and thumb; abduction of thumb. Muscles arising mainly from exter- nal condyle of humerus: Extensors of car- pus, fingers, and thumb; supinator. Severe Moderately Severe Moderately Severe	40 30 10 0 30 20	30 20 10 20 20	
latissimus dorsi and teres major (teres major, atthough technically an intrinsic muscle, is included with latissimus dorsi); (3) pectoralis minor; (4) rhomboid. Severe	40 30 20 0 40 30 20 0	30 20 0 30 20 20 20 20 20 0	Moderate Slight	10 0	11	
5304 Group IV. Function: Stabilization of shoulder against injury in strong move- ments, holding head of humerus in socket; abduction; outward rotation and inward ro- tation of arm. Intrinsic muscles of shoulder girdle: (1) Supraspinatus; (2) Infraspinatus			THE FOOT AND LEG		Rat- ing	
and teres minor; (3) subscapularis; (4) coracobrachialis. Severe	30 20 10 0 40 30 10 0	20 20 10 0 30 20 10 0	5310 Group X. Function: Movements of t and toes; propulsion thrust in walking. I muscles of the foot: Plantar: (1) Flexor di brevis; (2) abductor hallucis; (3) abductor minimi; (4) quadratus plantae; (5) lumbrica flexor hallucis brevis; (7) adductor hallucis; or digiti minimi brevis; (9) dorsal and interossei. Other important plantar structures tar aponeurosis, long plantar calcaneonavicular ligament, tendons of p tibial, peroneus longus, and long flexors of and little toes. Severe Moderately Severe Moderate	Intrinsic gitorum or digiti les; (6) (8) flex- plantar s: Plan- and osterior of great	30 20 11	
Sight States of the second state of the second states of the second stat	40 30 10 0	30 20 10 0	Slight Dorsal: (1) Extensor hallucis brevis; (2) e digitorum brevis. Other important dorsal stru cruciate, crural, deltoid, and other ligamen dons of long extensors of toes and perone cles. Severe Moderately Severe Moderately Severe	ensor hallucis brevis; (2) extensor is. Other important dorsal structures: I, deltoid, and other ligaments; ten- extensors of toes and peronei mus- tely Severe		

§4.73

§4.73

THE FOOT AND LEG—Continued

	Rat- ing
 NOTE: Minimum rating for through-and-through wounds of the foot—10. 5311 Group XI. <i>Function:</i> Propulsion, plantar flexion of foot (1); stabilization of arch (2, 3); flexion of toes (4, 5); Flexion of knee (6). <i>Posterior and lateral crural muscles, and muscles of the calf:</i> (1) Triceps surae (gastrocnemius and soleus); (2) tibialis posterior; (3) peroneus longus; (4) peroneus brevis; (5) flexor hallucis longus; (6) flexor digitorum longus; (7) popliteus; (8) plantaris. Severe	30 20 10 0
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

THE PELVIC GIRDLE AND THIGH

	Rat- ing
5313 Group XIII. Function: Extension of hip and flexion of knee; outward and inward rotation of flexed knee; acting with rectus femoris and sarto- rius (see XIV, 1, 2) synchronizing simultaneous flexion of hip and knee and extension of hip and knee by belt-over-pulley action at knee joint. Pos- terior thigh group, Hamstring complex of 2-joint muscles: (1) Biceps femoris; (2) semimembranosus; (3) semitendinosus. Severe Moderately Severe Moderate Slight	40 30 10
5314 Group XIV. Function: Extension of knee (2, 3, 4, 5); simultaneous flexion of hip and flexion of knee (1); tension of fascia lata and iliotibial (Maissiat's) band, acting with XVII (1) in postural support of body (6); acting with hamstrings in synchronizing hip and knee (1, 2). Anterior thigh group: (1) Sartorius; (2) rectus femoris; (3) vastus externus; (4) vastus intermedius; (5) vastus intermus; (6) tensor vaginae femoris.	0
Severe	40 30 10 0
Severe Moderately Severe Moderate Slight	30 20 10 0
pectineus. Severe Moderately Severe Moderate Slight	40 30 10 0

38 CFR Ch. I (7-1-05 Edition)

THE PELVIC GIRDLE AND THIGH—Continued

	Rat- ing
 5317 Group XVII. <i>Function:</i> Extension of hip (1); abduction of thigh; elevation of opposite side of pelvis (2, 3); tension of fascia lata and iliotibial (Maissiat's) band, acting with XIV (6) in postural support of body steadying pelvis upon head of femur and condyles of femur on tibia (1). <i>Pelvic girdle group 2:</i> (1) Gluteus maximus; (2) gluteus medius; (3) gluteus minimus. Severe	*50 40 20 0
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

*If bilateral, see §3.350(a)(3) of this chapter to determine whether the veteran may be entitled to special monthly compensation.

THE TORSO AND NECK

Rat-

	ing
5319 Group XIX. <i>Function:</i> Support and compres- sion of abdominal wall and lower thorax; flexion and lateral motions of spine; synergists in strong downward movements of arm (1). <i>Muscles of the</i> <i>abdominal wall:</i> (1) Rectus abdominis; (2) external oblique; (3) internal oblique; (4) transversalis; (5) quadratus lumborum. Severe Moderately Severe	50
Moderately Severe	10
5320 Group XX. Function: Postural support of body; extension and lateral movements of spine. Spinal muscles: Sacrospinalis (erector spinae and its pro- longations in thoracic and cervical regions). Cervical and thoracic region:.	
Severe	40
Moderately Severe	20
Moderate	1
Slight Lumbar region:.	
Severe	6
Moderately Severe	4
Moderate	2
Slight	
5321 Group XXI. <i>Function:</i> Respiration. <i>Muscles of respiration:</i> Thoracic muscle group.	
Severe or Moderately Severe	2
Moderate	1
Slight	
5322 Group XXII. Function: Rotary and forward movements of the head; respiration; deglutition.	
Muscles of the front of the neck: (Lateral, supra-,	
and infrahyoid group.) (1) Trapezius I (clavicular in- sertion); (2) sternocleidomastoid; (3) the "hyoid"	
muscles; (4) sternothyroid; (5) digastric.	
Severe	3
Moderately Severe	2
Moderate	1

THE TORSO AND NECK-Continued

	Rat- ing
5323 Group XXIII. Function: Movements of the head; fixation of shoulder movements. Muscles of the side and back of the neck: Suboccipital; lateral vertebral and anterior vertebral muscles. Severe Moderately Severe Moderate Slight	30 20 10

MISCELLANEOUS

	Rat-
	ing
 5324 Diaphragm, rupture of, with herniation. Rate under diagnostic code 7346. 5325 Muscle injury, facial muscles. Evaluate functional impairment as seventh (facial) cranial nerve neuropathy (diagnostic code 8207), disfiguring scar (diagnostic code 7800), etc. Minimum, if interfering to any extent with mastication—10. 5326 Muscle hernia, extensive. Without other injury to the muscle—10. 5327 Muscle, neoplasm of, malignant (excluding soft tissue sarcoma)—100. 	
NOTE: A rating of 100 percent shall continue beyond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examina- tion. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residual impairment of function.	
 5328 Muscle, neoplasm of, benign, postoperative. Rate on impairment of function, i.e., limitation of motion, or scars, diagnostic code 7805, etc. 5329 Sarcoma, soft itssue (of muscle, fat, or fibrous connective tissue)—100. NOTE: A rating of 100 percent shall continue beyond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examina- tion. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis. 	

(Authority: 38 U.S.C. 1155)

rate on residual impairment of function.

[62 FR 30239, June 3, 1997]

THE ORGANS OF SPECIAL SENSE

§4.75 Examination of visual acuity.

Ratings on account of visual impairments considered for service connection are, when practicable, to be based only on examination by specialists. Such special examinations should include uncorrected and corrected cen-

§4.76a

tral visual acuity for distance and near, with record of the refraction. Snellen's test type or its equivalent will be used. Mydriatics should be routine, except when contraindicated. Funduscopic and ophthalmological findings must be recorded. The best distant vision obtainable after best correction by glasses will be the basis except in cases of of rating, keratoconus in which contact lenses are medically required. Also, if there exists a difference of more than 4 oters of spherical correction been the two eyes, the best possible al acuity of the poorer eye without sses, or with a lens of not more than iopters difference from that used n the better eye will be taken as the al acuity of the poorer eye. When n a difference exists, close attention be given to the likelihood of conital origin in mere refractive error.

'R 42537, Sept. 15, 1975]

6 Examination of field vision.

easurement of the visual field will made when there is disease of the c nerve or when otherwise indied. The usual perimetric methods be employed, using a standard peeter and 3 mm. white test object. east 16 meridians 221/2 degrees apart be charted for each eye. (See Fig-1. For the 8 principal meridians, see e III.) The charts will be made a t of the report of examination. Not than 2 recordings, and when pose, 3 will be made. The minimum it for this function is established as oncentric central contraction of the al field to 5°. This type of contracn of the visual field reduces the visefficiency to zero. Where available the examination for form field should be supplemented, when indicated, by the use of tangent screen or campimeter. This last test is especially valuable in detection of scotoma.

[43 FR 45352, Oct. 2, 1978]

§4.76a Computation of average concentric contraction of visual fields.

The extent of contraction of visual field in each eye is determined by recording the extent of the remaining visual fields in each of the eight 45 degree principal meridians. The number


§4.76a

of degrees lost is determined at each meridian by subtracting the remaining degrees from the normal visual fields given in table III. The degrees lost are then added together to determine total degrees lost. This is subtracted from 500. The difference represents the total remaining degrees of visual field. The difference divided by eight represents the average contraction for rating purposes.

38 CFR Ch. I (7-1-05 Edition)

TABLE III—NORMAL VISUAL FIELD EXTENT AT 8 PRINCIPAL MERIDIANS

Meridian	Normal de- grees
Temporally	85
Down temporally	85
Down	65
Down nasally	50
Nasally	60
Up nasally	55
Up	45
Up temporally	55
Total	500



§4.76a

TS-19

52a

Example of computation of concentric contraction under the schedule with abnormal findings taken from Figure 1.

Loss	Degrees
Temporally	55
Down temporally	55
Down	45

§4.77

Loss	Degrees
Down nasally Nasally Up nasally Up Up Up temporally	30 40 35 25 35
Total loss	320

Remaining field 500° minus 320° = 180°. 180° \div 8 = 221/2° average concentric contraction.

[43 FR 45352, Oct. 2, 1978]

§4.77 Examination of muscle function.

The measurement of muscle function will be undertaken only when the history and findings reflect disease or injury of the extrinsic muscles of the eye, or of the motor nerves supplying these muscles. The measurement will

38 CFR Ch. I (7-1-05 Edition)

be performed using a Goldmann Perimeter Chart as in Figure 2 below. The chart identifies four major quadrants, (upward, downward, and two lateral) plus a central field (20° or less). The examiner will chart the areas in which diplopia exists, and such plotted chart will be made a part of the examination report. Muscle function is considered normal (20/40) when diplopia does not 40° in the lateral or exist within downward quadrants, or within 30° in the upward quadrant. Impairment of muscle function is to be supported in each instance by record of actual appropriate pathology. Diplopia which is only occasional or correctable is not considered a disability.




Figure 2. Goldmann Perimeter Chart

[53 FR 30262, Aug. 11, 1988]

§4.78 Computing aggravation.

In determining the effect of aggravation of visual disability, even though the visual impairment of only one eye is service connected, evaluate the vision of both eyes, before and after suffering the aggravation, and subtract the former evaluation from the latter except when the bilateral vision amounts to total disability. In the event of subsequent increase in the disability of either eye, due to intercurrent disease or injury not associated with the service, the condition of the eves before suffering the subsequent increase will be taken as the basis of compensation subject to the provisions of §3.383(a) of this chapter.

[29 FR 6718, May 22, 1964, as amended at 43 FR 45354, Oct. 2, 1978]

§4.79 Loss of use of one eye, having only light perception.

Loss of use or blindness of one eye, having only light perception, will be held to exist when there is inability to recognize test letters at 1 foot (.30m.) and when further examination of the eyes reveals that perception of objects, hand movements or counting fingers cannot be accomplished at 3 feet (.91m.), lesser extents of visions, particularly perception of objects, hand movements, or counting fingers at distances less than 3 feet (.91 m.), being considered of negligible utility. With visual acuity 5/200 (1.5/60) or less or the visual field reduced to 5° concentric contraction, in either event in both eyes, the question of entitlement on account of regular aid and attendance will be determined on the facts in the individual case.

[43 FR 45354, Oct. 2, 1978]

§4.80 Rating of one eye.

Combined ratings for disabilities of the same eye should not exceed the amount for total loss of vision of that eye unless there is an enucleation or a serious cosmetic defect added to the total loss of vision. §§4.81-4.82 [Reserved]

§4.83 Ratings at scheduled steps and distances.

In applying the ratings for impairment of visual acuity, a person not having the ability to read at any one of the scheduled steps or distances, but reading at the next scheduled step or distance, is to be rated as reading at this latter step or distance. That is, a person who can read at 20/100 (6/30) but who cannot at 20/70 (6/21), should be rated as seeing at 20/100 (6/30).

[41 FR 34257, Aug. 13, 1976, as amended at 43 FR 45354, Oct. 2, 1978]

§4.83a Impairment of central visual acuity.

The percentage evaluation will be found from table V by intersecting the horizontal row appropriate for the Snellen index for one eye and the vertical column appropriate to the Snellen index of the other eye. For example, if one eye has a Snellen index of 5/200 (1.5/60) and the other eye has a Snellen index of 20/70 (6/21), the percentage evaluation is found in the third horizontal row from the bottom and the fourth vertical column from the left. The evaluation is 50 percent and the diagnostic code 6073.

 $[41\ {\rm FR}\ 11297,\ Mar.\ 18,\ 1976,\ as\ amended\ at\ 43\ {\rm FR}\ 45354,\ {\rm Oct.}\ 2,\ 1978]$

§4.84 Differences between distant and near visual acuity.

Where there is a substantial difference between the near and distant corrected vision, the case should be referred to the Director, Compensation and Pension Service.

[40 FR 42537, Sept. 15, 1975]

§4.84a Schedule of ratings—eye.

DISEASES OF THE EYE

		Rat- ing
6000	Uveitis	
6001	Keratitis	
6002	Scleritis	
6003	Iritis	
6004	Cyclitis	
6005	Choroiditis	
6006	Retinitis	
6007	Hemorrhage, intra-ocular, recent	
6008	Retina, detachment of	
6009	Eye, injury of, unhealed:	

§4.84a

DISEASES OF THE EYE-Continued

38 CFR Ch. I (7-1-05 Edition)

DISEASES OF THE EYE-Continued

	Rat- ing		Rat- ing
The above disabilities, in chronic form, are to be		Unilateral	10
rated from 10 percent to 100 percent for im-		6026 Neuritis, optic:	
pairment of visual acuity or field loss, pain,		Rate underlying disease, and combine impair-	
rest-requirements, or episodic incapacity, com-		ment of visual acuity or field loss.	
bining an additional rating of 10 percent during		6027 Cataract, traumatic:	
continuance of active pathology. Minimum rat-		Preoperative.	
ing during active pathology	10		
6010 Eye, tuberculosis of, active or inactive:		Rate on impairment of vision.	
Active	100	Postoperative.	
Inactive: See §§ 4.88b and 4.89.		Rate on impairment of vision and aphakia.	
6011 Retina, localized scars, atrophy, or irregular-		6028 Cataract, senile, and others:	
ities of, centrally located, with irregular, duplicated enlarged or diminished image:		Preoperative.	
Unilateral or bilateral	10	Rate on impairment of vision.	
6012 Glaucoma, congestive or inflammatory:	10	Postoperative.	
Frequent attacks of considerable duration; during		Rate on impairment of vision and aphakia.	
continuance of actual total disability	100	6029 Aphakia:	
Or, rate as iritis, diagnostic Code 6003.		Bilateral or unilateral	30
6013 Glaucoma, simple, primary, noncongestive:		NOTE: The 30 percent rating prescribed for	
Rate on impairment of visual acuity or field loss.		aphakia is a minimum rating to be applied to	
Minimum rating	10	the unilateral or bilateral condition and is not	
6014 New growths, malignant (eyeball only):		to be combined with any other rating for im-	
Pending completion of operation or other indi-	400	paired vision. When only one eye is aphakic,	
cated treatment	100	the eye having poorer corrected visual acuity	
Healed; rate on residuals. 6015 New growths, benign (eyeball and adnexa,		will be rated on the basis of its acuity without correction. When both eyes are aphakic, both	
other than superficial)		will be rated on corrected vision. The cor-	
Rate on impaired vision, minimum	10	rected vision of one or both aphakic eyes will	
Healed; rate on residuals.	10	be taken one step worse than the ascertained	
6016 Nystagmus, central	10	value, however, not better than 20/70 (6/21).	
6017 Conjunctivitis, trachomatous, chronic:		Combined ratings for disabilities of the same	
Active; rate for impairment of visual acuity; min-		eye should not exceed the amount for total	
imum rating while there is active pathology	30	loss of vision of that eye unless there is an	
Healed; rate on residuals, if no residuals	0	enucleation or a serious cosmetic defect	
6018 Conjunctivitis, other, chronic:		added to the total loss of vision.	
Active, with objective symptoms	10	6030 Accommodation, paralysis of	20
Healed; rate on residuals, if no residuals	0	6031 Dacryocystitis	
Pupil wholly obscured.		Rate as epiphora.	
Rate equivalent to 5/200 (1.5/60).		6032 Eyelids, loss of portion of:	
Pupile one-half or more obscured.		Rate as disfigurement. (See diseases of the	
Rate equivalent to 20/100 (6/30).		skin.)	
With less interference with vision.		6033 Lens, crystalline, dislocation of:	
Rate as disfigurement.		Rate as aphakia.	
6020 Ectropion:		6034 Pterygium:	
Bilateral	20	Rate for loss of vision, if any.	
Unilateral 6021 Entropion:	10	6035 Keratoconus: To be evaluated on impairment	
Bilateral	20	of corrected visual acuity using contact lenses.	
Unilateral	10	NOTE: When contact lenses are medically re-	
6022 Lagophthalmos:		quired for keratoconus, either unilateral or bi- lateral, the minimum rating will be 30 percent.	
Bilateral	20	ateral, the minimum fatting will be 50 percent.	
Unilateral	10		
6023 Eyebrows, loss of, complete, unilateral or bi-			
lateral	10		
6024 Eyelashes, loss of, complete, unilateral or bi-			
lateral	10		
6025 Epiphora (lacrymal duct, interference with, from any cause):			
Bilateral	20		
Diratoral	20		

		nore at ear SC	B-1 38	(1)(iii)		B-1 38		(1)(iii)	B-1 38		(1)(iii)
		60% or more at least one ear SC	O Code OB-1 38	CFH 3.350(e)(1)(iii)		O Code OB-1 38	CFR	3.350(e)(1)(iii)	O Code OB-1 38	CFR	3.350(e)(1)(iii)
	ing loss	40% at least one ear SC	Add a full step	Code PB-3 38 CFR	3.350(f)(2)(vi).	O Code OB-2 38	CFR	3.350(e)(1)(iv).	Add full step Code O Code OB-2 38	CFR	3.350(e)(1)(iv).
	Plus service-connected Hearing loss	30% at least one ear SC	Add a full step	Code PB-3 38 CFR	3.350(f)(2)(vi).	Add a full step	Code PB-3 38	CFR 3.350(f)(2)(iv)	Add full step Code	PB-3 38 CFR	3.350(f)(2)(vi).
	Plus ser	10% or 20% at least one ear SC	No additional	SMC.		Add 1/2 step Code	PB-2 38 CFR	3.350(f)(2)(v).	Add 1/2 step Code	PB-2 38 CFR	3.350(f)(2)(v).
CITATIONS		Total deafness one ear	Add 1/2 step Code	PB-1 38 CFH 3.350(f)(2)(iv).		O Code OB-2 38	CFR	3.350(e)(1)(iv).	O Code OB-2 38	CFR	3.350(e)(1)(iv).
		No light percep- tion or anatomical loss	M Code MB-2 a	or d 38 CFH 3.350(f)(2)(ii).		M+1/2 Code MB-3 0 Code OB-2 38	a or b 38 CFR	3.350(f)(iii).	N Code NB-1 a-b 0 Code OB-2 38	or c 38 CFR	3.350(d)(4).
	Vision other eye	Light perception only	Ľ.	38 CFH 3.350(f)(2)(i).		M Code MB-1 a	38 CFR	3.350(c)(1)((iv).			
		5/200 (1.5/60) or less	Ľ	CFH 3.350(b)(2).							
		Vision one eye	5/200 (1.5/60) or	less.		Light perception	only.		No light perception	or anatomical	loss.

¹ With need for aid and attendance qualifies for Subpar. m. code MB–1, b; 38 CFR 3.350(c)(1)(v). NOTE. (1) Any of the additional SMC payable under Dictator's Codes PB–1, PB–2, or PB–3 is not to exceed the rate payable under Subpar. O. (2) If in addition to any of the above the veteran has the service-connected loss or loss of use of an extremity, additional SMC is payable, not to exceed the rate payable under Subpar. O. See Dictator's Codes PB–4, PB–5, PB–6, and 38 CFR 3.350(f)(2)(vii) (A), (B), (C).

Department of Veterans Affairs

§4.84a

§4.84a

(Authority: 38 U.S.C. 1115)

IMPAIRMENT OF CENTRAL VISUAL ACUITY

38 CFR Ch. I (7-1-05 Edition)

IMPAIRMENT OF CENTRAL VISUAL ACUITY-Continued

IMPAIRMENT OF CENTRAL VISUAL AC	UIIY		<u> </u>
	Rat-		Rat- ing
	ing	6076 In the other eye 20/100 (6/30)	60
6061 Anatomical loss both eyes	⁵ 100	6076 In the other eye 20/70 (6/21)	50
6062 Blindness in both eyes having only light pe	er-	6076 In the other eye 20/50 (6/15)	40
ception		6077 In the other eye 20/40 (6/12)	30
Anatomical loss of 1 eye:		Vision in 1 eye 15/200 (4.5/60):	00
6063 In the other eye 5/200 (1.5/60)	5100	6075 In the other eye 15/200 (4.5/60)	80
6064 In the other eye 10/200 (3/60)		6075 In the other eye 20/200 (6/60)	70
6064 In the other eye 15/200 (4.5/60)	⁶ 80	6076 In the other eye 20/100 (6/30)	60
6064 In the other eye 20/200 (6/60)		6076 In the other eye 20/70 (6/21)	40
6065 In the other eye 20/100 (6/30)	⁶ 60	6076 In the other eye 20/50 (6/15)	30
6065 In the other eye 20/70 (6/21)	⁶ 60	6077 In the other eye 20/40 (6/12)	20
6065 In the other eye 20/50 (6/15)	6 50	Vision in 1 eye 20/200 (6/60):	20
6066 In the other eye 20/40 (6/12)	⁶ 40	6075 In the other eye 20/200 (6/60)	70
Blindness in 1 eye, having only light perception	.:	6076 In the other eye 20/100 (6/30)	60
6067 In the other eye 5/200 (1.5/60)	5100	6076 In the other eye 20/70 (6/21)	40
6068 In the other eye 10/200 (3/60)		6076 In the other eye 20/50 (6/15)	30
6068 In the other eye 15/200 (4.5/60)		6077 In the other eye 20/40 (6/12)	20
6068 In the other eye 20/200 (6/60)		Vision in 1 eye 20/100 (6/30):	20
6069 In the other eye 20/100 (6/30)		6078 In the other eye 20/100 (6/30)	50
6069 In the other eye 20/70 (6/21)		6078 In the other eye 20/70 (6/21)	30
6069 In the other eye 20/50 (6/15)		6078 In the other eye 20/50 (6/15)	20
6070 In the other eye 20/40 (6/12)	5 30	6079 In the other eye 20/40 (6/12)	10
Vision in 1 eye 5/200 (1.5/60):		Vision in 1 eye 20/70 (6/21):	10
6071 In the other eye 5/200 (1.5/60)		6078 In the other eye 20/70 (6/21)	30
6072 In the other eye 10/200 (3/60)		6078 In the other eye 20/50 (6/15)	20
6072 In the other eye 15/200 (4.5/60)		6079 In the other eye 20/40 (6/12)	10
6072 In the other eye 20/200 (6/60)		Vision in 1 eye 20/50 (6/15):	10
6073 In the other eye 20/100 (6/30)		6078 In the other eye 20/50 (6/15)	10
6073 In the other eye 20/70 (6/21)		6079 In the other eye 20/40 (6/12)	10
6073 In the other eye 20/50 (6/15)		Vision in 1 eye 20/40 (6/12):	
6074 In the other eye 20/40 (6/12)	30	In the other eye 20/40 (6/12)	0
Vision in 1 eye 10/200 (3/60):			
6075 In the other eye 10/200 (3/60)		⁵ Also entitled to special monthly compensation.	
6075 In the other eye 15/200 (4.5/60)		⁶ Add 10% if artificial eye cannot be worn; also en	titled to
6075 In the other eye 20/200 (6/60)	70	special monthly compensation.	

TABLE V-RATINGS FOR CENTRAL VISUAL ACUITY IMPAIRMENT

[With Diagnostic Code]

		Vision in other eye												
Vision in one eye	20/40 (6/ 12)	20/50 (6/ 15)	20/70 (6/ 21)	20/100 (6/30)	20/200 (6/60)	15/200 (4.5/60)	10/200 (3/60)	5/200 (1.5/60)	Light percep- tion only/ana- tomical loss					
20/40 (6/12)	0													
20/50 (6/15)	10 (6079)	10 (6078)												
20/70 (6/21)	10 (6079)	20 (6078)	30 (6078)											
20/100 (6/30)	10 (6079)	20 (6078)	30 (6078)	50 (6078)										
20/200 (6/60)	20 (6077)	30 (6076)	40 (6076)	60 (6076)	70 (6075)									
15/200 (4.5/60)	20 (6077)	30 (6076)	40 (6076)	60 (6076)	70 (6075)	80 (6075)								
10/200 (3/60)	30 (6077)	40 (6076)	50 (6076)	60 (6076)	70 (6075)	80 (6075)	90 (6075)							
5/200 (1.5/60)	30 (6074)	40 (6073)	50 (6073)	60 (6073)	70 (6072)	80 (6072)	90 (6072)	⁵ 100 (6071)						

§4.84a

TABLE V-RATINGS FOR CENTRAL VISUAL ACUITY IMPAIRMENT-Continued [With Diagnostic Code]

		Vision in other eye											
Vision in one eye	20/40 (6/ 12)	20/50 (6/ 15)	20/70 (6/ 21)	20/100 (6/30)	20/200 (6/60)	15/200 (4.5/60)	10/200 (3/60)	5/200 (1.5/60)	Light percep- tion only/ana- tomical loss				
Light per- ception only	⁵ 30 (6070)	⁵ 40 (6069)	⁵ 50 (6069)	⁵ 60 (6069)	⁵ 70 (6068)	⁵ 80 (6068)	⁵ 90 (6068)	⁵ 100 (6067)	⁵ 100 (6062)				
Anatomical loss of one eye	⁶ 40 (6066)	⁶ 50 (6065)	⁶ 60 (6065)	⁶ 60 (6065)	⁶ 70 (6064)	⁶ 80 (6064)	⁶ 90 (6064)	⁵ 100 (6063)	⁵ 100 (6061)				

⁵ Also entitled to special monthly compensation.
 ⁶Add 10 percent if artificial eye cannot be worn; also entitled to special monthly compensation.

RATINGS FOR IMPAIRMENT OF FIELD VISION

RATINGS FOR IMPAIRMENT OF FIELD VISION-Continued

	Rat- ing
6080 Field vision, impairment of:	
Homonymous hemianopsia	30
Field, visual, loss of temporal half:	
Bilateral	30
Unilateral	10
Or rate as 20/70 (6/21).	
Field, visual, loss of nasal half:	
Bilateral	20
Unilateral	10
Or rate as 20/50 (6/15).	
Field, visual, concentric contraction of:	
To 5°:	
Bilateral	100
Unilateral	30
Or rate as 5/200 (1.5/60).	
To 15° but not to 5°:	
Bilateral	70
Unilateral	20
Or rate as 20/200 (6/60).	
To 30° but not to 15°:	
Bilateral	50
Unilateral	10
Or rate as 20/100 (6/30).	
To 45° but not to 30°:	
Bilateral	30
Unilateral	10
Or rate as 20/70 (6/21):	
To 60° but not to 45°:	
Bilateral	20
Unilateral	10
Or rate as 20/50 (6/15).	
Note (1): Correct diagnosis reflecting disease or injury should be cited	

	Rat- ing
Note (2): Demonstrable pathology commensu- rate with the functional loss will be required. The concentric contraction ratings require con- traction within the stated degrees, temporally; the nasal contraction may be less. The alter- native ratings are to be employed when there is ratable defect of visual acuity, or a different impairment of the visual field in the other eye. Concentric contraction resulting from demon- strable pathology to 5 degrees or less will be considered on a parity with reduction of cen- tral visual acuity to 5/200 (1.5/60) or less for all purposes including entitlement under §3.350(b)(2) of this chapter; not however, for the purpose of §3.350(a) of this chapter. Enti- tlement on account of blindness requiring reg- ular aid and attendance, §3.350(c) of this chapter, will continue to be determined on the facts in the individual case.	
6081 Scotoma, pathological, unilateral: Large or centrally located, minimum NOTE: Rate on loss of central visual acuity or im- pairment of field vision. Do not combine with any other rating for visual impairment.	10

RATINGS FOR IMPAIRMENT OF MUSCLE FUNCTION [6090 Diplopia (double vision)]

Degree of diplopia	Equiva- lent visual acuity
(a) Central 20° (b) 21° to 30°:	5/200
(1) Down	15/200
(2) Lateral	20/100
(3) Up	20/70
(c) 31° to 40°:	
(1) Down	20/200
(2) Lateral	20/70
(3) Up	20/40
Note: (1) Correct diagnosis reflecting disease or injury should be cited	

RATINGS FOR IMPAIRMENT OF MUSCLE

[6090 Diplopia (double vision)]

Degree of diplopia								
 Note: (2) The above ratings will be applied to only one eye. Ratings will not be applied for both diplopia and decreased visual acuity or field of vision in the same eye. When diplopia is present and there is also ratable impairment of visual acuity or field of vision of both eyes the above diplopia ratings will be applied to the poorer eye while the better eye is rated according to the best corrected visual acuity or visual field. Note: (3) When the diplopia field extends beyond more than one quadrant or more than one range of degrees, the evaluation for diplopia will be based on the quadrant and degree range that provide the highest evaluation. Note: (4) When diplopia exists in two individual and separate areas of the same eye, the equivalent visual acuity will be taken one step worse, but no worse than 5/200. 								
 6091 Symblepharon Rate as limited muscle function, diagnostic code 6090 6092 Diplopia, due to limited muscle function Rate as diagnostic code 6090 								

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 40 FR 42537, Sept. 15, 1975; 41 FR 11297, Mar. 18, 1976; 43 FR 45354, Oct. 2, 1978; 51 FR 6411, Feb. 24, 1986; 53 FR 30264, Aug. 11, 1988; 53 FR 50955, Dec. 19, 1988; 57 FR 24364, June 9, 1992]

IMPAIRMENT OF AUDITORY ACUITY

§4.85 Evaluation of hearing impairment.

(a) An examination for hearing impairment for VA purposes must be conducted by a state-licensed audiologist and must include a controlled speech discrimination test (Maryland CNC) and a puretone audiometry test. Examinations will be conducted without the use of hearing aids.
(b) Table VI, "Numeric Designation

(b) Table VI, "Numeric Designation of Hearing Impairment Based on Puretone Threshold Average and Speech Discrimination," is used to determine a Roman numeral designation (I through XI) for hearing impairment based on a combination of the percent of speech discrimination (horizontal

38 CFR Ch. I (7–1–05 Edition)

rows) and the puretone threshold average (vertical columns). The Roman numeral designation is located at the point where the percentage of speech discrimination and puretone threshold average intersect.

(c) Table VIa, "Numeric Designation of Hearing Impairment Based Only on Puretone Threshold Average," is used to determine a Roman numeral designation (I through XI) for hearing impairment based only on the puretone threshold average. Table VIa will be used when the examiner certifies that use of the speech discrimination test is not appropriate because of language difficulties, inconsistent speech discrimination scores, etc., or when indicated under the provisions of §4.86.

(d) "Puretone threshold average," as used in Tables VI and VIa, is the sum of the puretone thresholds at 1000, 2000, 3000 and 4000 Hertz, divided by four. This average is used in all cases (including those in §4.86) to determine the Roman numeral designation for hearing impairment from Table VI or VIa.

(e) Table VII, "Percentage Evaluations for Hearing Impairment," is used to determine the percentage evaluation by combining the Roman numeral designations for hearing impairment of each ear. The horizontal rows represent the ear having the better hearing and the vertical columns the ear having the poorer hearing. The percentage evaluation is located at the point where the row and column intersect.

(f) If impaired hearing is service-connected in only one ear, in order to determine the percentage evaluation from Table VII, the non-service-connected ear will be assigned a Roman Numeral designation for hearing impairment of I, subject to the provisions of § 3.383 of this chapter.

(g) When evaluating any claim for impaired hearing, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation due either to deafness, or to deafness in combination with other specified disabilities.

(h) Numeric tables VI, VIA*, and VII.

§4.85

NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ON PURETONE THRESHOLD AVERAGE AND SPEECH DISCRIMINATION

TABLE VI

% of discrim- ination	0-41	42-49	50-57	58-65	66-73	74-81	82-89	90-97	98+
92-100	I	I	I	II	II	II	III	Ш	IV
84-90	II	11	II	III	III	III	IV	IV	IV
76-82	ш	III	IV	IV	IV	V	V	V	V
68-74	IV	IV	V	V	VI	VI	VII	VII	VII
60-66	v	V	VI	VI	VII	VII	VIII	VIII	VIII
52-58	VI	VI	VII	VII	VIII	VIII	VIII	VIII	IX
44-50	VII	VII	VIII	VIII	VIII	IX	IX	IX	X
36-42	VIII	VIII	VIII	IX	IX	IX	X	X	Х
0-34	IX	X	XI	XI	XI	XI	XI	XI	XI

Puretone Threshold Average

TABLE VIA*

NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ONLY ON PURETONE THRESHOLD AVERAGE

Puretone Threshold Average

0-41	42-48	49-55	56-62	63-69	70-76	77-83	84-90	91-97	98-104	105+
Ι	II	III	IV	V	VI	VII	VIII	IX	Х	XI

* This table is for use only as specified in §§ 4.85 and 4.86.

38 CFR Ch. I (7-1-05 Edition)

TABLE VII

PERCENTAGE EVALUATION FOR HEARING IMPAIRMENT (DIAGNOSTIC CODE 6100)

Poorer Ear

XI	100*										
X	90	80									
IX	80	70	60				-				
VIII	70	60	50	50							
VII	60	60	50	40	40						
VI	50	50	40	40	30	30					
V	40	40	40	30	30	20	20				
IV	30	30	30	20	20	20	10	10	-		
III	20	20	20	20	20	10	10	10	0		
II	10	10	10	10	10	10	10	0.	0	0	
I	10	10	0	0	0	0	0	0	. 0	0	0
	XI	X	IX	VIII	VII	VI	V	IV	III	Π	I
	X IX VIII VII VI IV IV III II	X 90 X 80 VII 70 VII 60 VI 50 V 40 IV 30 III 20 II 10 I 10	X 90 80 X 90 80 IX 80 70 VII 70 60 VII 60 60 VI 50 50 V 40 40 IV 30 30 II 20 20 II 10 10	N 90 80 X 90 80 1 IX 80 70 60 VII 70 60 50 VII 60 60 50 VI 50 50 40 V 40 40 40 IV 30 30 30 III 20 20 20 II 10 10 0	Image: Market	Image: Marking Constraint of the system of the sy	Image: Marking the structure Image: Marking the structure <t< th=""><th>Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemX9080Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemIM8070605050Image: Normal systemImage: Normal systemVII706050404040Image: Normal systemImage: Normal systemVII60605040403030Image: Normal systemVI5050404030302020IV5050404030302020IV30303020202010III20202020202010III10101010101010III101000000</th><th>Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemX9080Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemIX80706050Image: Normal systemImage: Normal systemImage: Normal systemVII70605050Image: Normal systemImage: Normal systemImage: Normal systemVII606050404040Image: Normal systemImage: Normal systemVI50504040303030Image: Normal systemImage: Normal systemVI5050404030302020Image: Normal systemVI5050404030302020Image: Normal systemVI5050404030302020Image: Normal systemVI303030202020101010III202020202020101010III10100000000</th><th>Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemX9080Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemXI8070605050Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemVII706050504040Image: Normal systemImage: Normal systemImage: Normal systemVII60605040403030Image: Normal systemImage: Normal systemImage: Normal systemVII5050404030302020Image: Normal systemImage: Normal systemVI5050404030302020Image: Normal systemImage: Normal systemVI3030302020201010Image: Normal systemIII20202020201010100III10101010101000III1010000000</th><th>IIIIIIIIIIIX9080IIIIIIIIIIIX807060IIIIIIIIVII70605050IIIIIIVII6060504040IIIIIVI505040403030IIIIV404030302020IIIIIV303020201010IIIIII202020201010000II101000000000</th></t<>	Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemX9080Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemIM8070605050Image: Normal systemImage: Normal systemVII706050404040Image: Normal systemImage: Normal systemVII60605040403030Image: Normal systemVI5050404030302020IV5050404030302020IV30303020202010III20202020202010III10101010101010III101000000	Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemX9080Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemIX80706050Image: Normal systemImage: Normal systemImage: Normal systemVII70605050Image: Normal systemImage: Normal systemImage: Normal systemVII606050404040Image: Normal systemImage: Normal systemVI50504040303030Image: Normal systemImage: Normal systemVI5050404030302020Image: Normal systemVI5050404030302020Image: Normal systemVI5050404030302020Image: Normal systemVI303030202020101010III202020202020101010III10100000000	Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemX9080Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemXI8070605050Image: Normal systemImage: Normal systemImage: Normal systemImage: Normal systemVII706050504040Image: Normal systemImage: Normal systemImage: Normal systemVII60605040403030Image: Normal systemImage: Normal systemImage: Normal systemVII5050404030302020Image: Normal systemImage: Normal systemVI5050404030302020Image: Normal systemImage: Normal systemVI3030302020201010Image: Normal systemIII20202020201010100III10101010101000III1010000000	IIIIIIIIIIIX9080IIIIIIIIIIIX807060IIIIIIIIVII70605050IIIIIIVII6060504040IIIIIVI505040403030IIIIV404030302020IIIIIV303020201010IIIIII202020201010000II101000000000

* Review for entitlement to special monthly compensation under §3.350 of this chapter.

[64 FR 25206, May 11, 1999]

§4.86 Exceptional patterns of hearing impairment.

(a) When the puretone threshold at each of the four specified frequencies (1000, 2000, 3000, and 4000 Hertz) is 55 decibels or more, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher numeral. Each ear will be evaluated separately.

(b) When the puretone threshold is 30 decibels or less at 1000 Hertz, and 70 decibels or more at 2000 Hertz, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher numeral. That numeral will then be elevated to the next higher

§4.86

Roman numeral. Each ear will be evaluated separately.

(Authority: 38 U.S.C. 1155)

[64 FR 25209, May 11, 1999]

§4.87 Schedule of ratings—ear.

DISEASES OF THE EAR

	Rat- ing
6200 Chronic suppurative otitis media, mastoiditis, or cholesteatoma (or any combination): During suppuration, or with aural polyps NOTE: Evaluate hearing impairment, and com- plications such as labyrinthitis, tinnitus, facial nerve paralysis, or bone loss of skull, sepa- rately.	10
6201 Chronic nonsuppurative otitis media with effu- sion (serous otitis media): Rate hearing impairment 6202 Otosclerosis: Rate hearing impairment	
6204 Peripheral vestibular disorders: Dizziness and occasional staggering Occasional dizziness NOTE: Objective findings supporting the diag- nosis of vestibular disequilibrium are required before a compensable evaluation can be as- signed under this code. Hearing impairment or suppuration shall be separately rated and combined.	30 10
6205 Meniere's syndrome (endolymphatic hydrops): Hearing impairment with attacks of vertigo and cerebellar gait occurring more than once weekly, with or without tinnitus Hearing impairment with attacks of vertigo and cerebellar gait occurring from one to four	100
 times a month, with or without tinnitus Hearing impairment with vertigo less than once a month, with or without tinnitus NOTE: Evaluate Meniere's syndrome either under these criteria or by separately evaluating vertigo (as a peripheral vestibular disorder), hearing impairment, and tinnitus, whichever method results in a higher overall evaluation. But do not combine an evaluation for hearing impairment, tinnitus, or vertigo with an evaluation 	60 30
tion under diagnostic code 6205. 6207 Loss of auricle: Complete loss of both Complete loss of one Deformity of one, with loss of one-third or more of the substance 6208 Malignant neoplasm of the ear (other than skin only) NOTE: A rating of 100 percent shall continue be- yond the cessation of any surgical, radiation treatment, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appro- priate disability rating shall be determined by mandatory VA examination. Any change in evaluation based on that or any subsequent examination shall be subject to the provisions	50 30 10
of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on re- siduals.	

⁶²⁰⁹ Benign neoplasms of the ear (other than skin only):

DISEASES OF THE EAR-Continued

	Rat- ing
 Swelling, dry and scaly or serous discharge, and itching requiring frequent and prolonged treatment	10 0 10

(Authority: 38 U.S.C. 1155)

 $[64\ {\rm FR}\ 25210,\ {\rm May}\ 11,\ 1999,\ as\ amended\ at\ 68\ {\rm FR}\ 25823,\ {\rm May}\ 14,\ 2003]$

§4.87a Schedule of ratings—other sense organs.

	Rat- ing
 6275 Sense of smell, complete loss 6276 Sense of taste, complete loss NOTE: Evaluation will be assigned under diagnostic codes 6275 or 6276 only if there is an anatomical or pathological basis for the condition. 	10 10

(Authority: 38 U.S.C. 1155) [64 FR 25210, May 11, 1999]

INFECTIOUS DISEASES, IMMUNE DIS-ORDERS AND NUTRITIONAL DEFI-CIENCIES

§4.88 [Reserved]

§4.88a Chronic fatigue syndrome.

(a) For VA purposes, the diagnosis of chronic fatigue syndrome requires:

(1) new onset of debilitating fatigue severe enough to reduce daily activity to less than 50 percent of the usual level for at least six months; and

(2) the exclusion, by history, physical examination, and laboratory tests, of all other clinical conditions that may produce similar symptoms; and

(3) six or more of the following:

(i) acute onset of the condition,

(ii) low grade fever,

(iii) nonexudative pharyngitis,

§4.88a

Rate on impairment of function.

⁶²¹⁰ Chronic otitis externa:

§4.88b

(iv) palpable or tender cervical or axillary lymph nodes,

(v) generalized muscle aches or weakness,

(vi) fatigue lasting 24 hours or longer after exercise,

38 CFR Ch. I (7-1-05 Edition)

(vii) headaches (of a type, severity, or pattern that is different from headaches in the pre-morbid state),(viii) migratory joint pains,(ix) neuropsychologic symptoms,(x) sleep disturbance.

(b) [Reserved]

[59 FR 60902, Nov. 29, 1994]

§4.88b Schedule of ratings—infectious diseases, immune disorders and nutritional deficiencies.

		Rating
6300	Cholera, Asiatic:	
	As active disease, and for 3 months convalescence Thereafter rate residuals such as renal necrosis under the appropriate system	100
6301	Visceral Leishmaniasis:	I
	During treatment for active disease	100
	NOTE: A 100 percent evaluation shall continue beyond the cessation of treatment for active disease. Six discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory tion. Any change in evaluation based upon that or any subsequent examination shall be subject to the §3.105(e) of this chapter. Rate residuals such as liver damage or lymphadenopathy under the appropriate the subject is a subject to the	VA examina- provisions of
3302	Leprosy (Hansen's Disease): As active disease	100
	NOTE: A 100 percent evaluation shall continue beyond the date that an examining physician has determine has become inactive. Six months after the date of inactivity, the appropriate disability rating shall be dimandatory VA examination. Any change in evaluation based upon that or any subsequent examination ject to the provisions of §3.105(e) of this chapter. Rate residuals such as skin lesions or periphera under the appropriate system.	etermined by shall be sub-
6304		
	As active disease	100
	NOTE: The diagnosis of malaria depends on the identification of the malarial parasites in blood smears. I served in an endemic area and presents signs and symptoms compatible with malaria, the diagnosis m on clinical grounds alone. Relapses must be confirmed by the presence of malarial parasites in blood sr Thereafter rate residuals such as liver or spleen damage under the appropriate system	ay be based
6305	Lymphatic Filariasis:	
	As active disease	100
6306		I
	As active disease, and for 3 months convalescence	100
	Thereafter rate residuals such as skin lesions under the appropriate system	
5307	Plague:	100
	As active disease Thereafter rate residuals such as lymphadenopathy under the appropriate system	100
6308		
	As active disease	100
	Thereafter rate residuals such as liver or spleen damage or central nervous system involvement under the	e appropriate
6309	system Rheumatic fever:	I
5000	As active disease	100
	Thereafter rate residuals such as heart damage under the appropriate system	
5310	Syphilis, and other treponemal infections: Rate the complications of nervous system, vascular system, eyes or ears. (See DC 7004, syphilitic heart 8013, cerebrospinal syphilis, DC 8014, meningovascular syphilis, DC 8015, tabes dorsalis, and DC 93 associated with central nervous system syphilis)	
6311	Tuberculosis, miliary:	
	As active disease	100
6212	Inactive: See §§ 4.88c and 4.89. Avitaminosis:	
5010	Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	100
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor	60
	With stomatitis, diarrhea, and symmetrical dermatitis	40
	With stomatitis, or achlorhydria, or diarrhea	20
	Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discomfort, weakness, inability to concentrate and irritability	10
6314	Beriberi:	
	As active disease:	
	As active disease:	

§4.88b

		Rating
	With cardiomegaly, or; with peripheral neuropathy with footdrop or atrophy of thigh or calf muscles With peripheral neuropathy with absent knee or ankle jerks and loss of sensation, or; with symptoms such as weakness, fatigue, anorexia, dizziness, heaviness and stiffness of legs, headache or sleep	60
	disturbance Thereafter rate residuals under the appropriate body system.	30
6315	Pellagra: Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	100
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor With stomatitis, diarrhea, and symmetrical dermatitis	60 40
	With stomatitis, or achlorhydria, or diarrhea	20 10
6316	Brucellosis:	100
6317	As active disease	100
6318	As active disease, and for 3 months convalescence Thereafter rate residuals such as spleen damage or skin conditions under the appropriate system	100
	As active disease Thereafter rate residuals such as arthritis, lung lesions or meningitis under the appropriate system	100
6319	Lyme Disease: As active disease Thereafter rate residuals such as arthritis under the appropriate system	100
6320		100
6350		
	Not to be combined with ratings under DC 7809 Acute, with frequent exacerbations, producing severe impairment of health	100
	Exacerbations lasting a week or more, 2 or 3 times per year Exacerbations once or twice a year or symptomatic during the past 2 years	60 10
	NOTE: Evaluate this condition either by combining the evaluations for residuals under the appropriate sy evaluating DC 6350, whichever method results in a higher evaluation.	stem, or by
6351	HIV-Related Illness: AIDS with recurrent opportunistic infections or with secondary diseases afflicting multiple body systems; HIV-related illness with debility and progressive weight loss, without remission, or few or brief remis-	
	sions Refractory constitutional symptoms, diarrhea, and pathological weight loss, or; minimum rating following development of AIDS-related opportunistic infection or neoplasm	100 60
	Recurrent constitutional symptoms, intermittent diarrhea, and on approved medication(s), or; minimum rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	30
	Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased	10
	T4 cell count	0
	NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protoc credited medical institution. NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms n separately under appropriate codes if higher overall evaluation results, but not in combination with perc	ay be rated
6354	erwise assignable above. Chronic Fatigue Syndrome (CFS):	
	Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a of other signs and symptoms:	combination
	Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care. Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness.	100
	level, or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year	60
	Which are nearly constant and restrict routine daily activities to 50 to 75 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year	40
	Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least two but less than four	10
	weeks total duration per year	20
	duration per year, or; symptoms controlled by continuous medication	10 e it requires

[61 FR 39875, July 31, 1996]

§4.88c

§4.88c Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19, 1968.

	Rat- ing
 For 1 year after date of inactivity, following active tuberculosis Thereafter: Rate residuals under the specific body system or systems affected. Following the total rating for the 1 year period after date of inactivity, the schedular evaluation for residuals of nonpulmonary tuberculosis, i.e., ankylosis, surgical removal of a part, etc., will be assigned under the appropriate diagnostic code for tuberculosis of the body part affected. For example, tuberculosis of the hip joint with residual ankylosis would be coded 5001–5250. Where there are existing residuals of pulmonary and nonpulmonary conditions, the evaluations for residual separate functional impairment may be combined. Where there are existing pulmonary and nonpulmonary conditions, the total rating for the 1 year, after attainment of inactivity, may not be applied to both conditions during the 1-year period. However, the total rating during the 1-year total evaluation, so as to allow any additional benefit provided during such period. 	100

[34 FR 5062, Mar. 11, 1969. Redesignated at 59 FR 60902, Nov. 29, 1994]

§4.89 Ratings for inactive nonpulmonary tuberculosis in effect on August 19, 1968.

Public Law 90-493 repealed section 356 of title 38, United States Code which provided graduated ratings for inactive tuberculosis. The repealed section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90-493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For use in rating cases in which the protective provisions of Pub. L. 90-493 apply, the former evaluations are retained in this section.

	Rat- ing
For 2 years after date of inactivity, following active tuberculosis, which was clinically identified during	
service or subsequently	100
Thereafter, for 4 years, or in any event, to 6 years	
after date of inactivity	50
Thereafter, for 5 years, or to 11 years after date of	
inactivity	30
Thereafter, in the absence of a schedular compen-	
sable permanent residual	0

38 CFR Ch. I (7-1-05 Edition)

ing Following the total rating for the 2-year period after date of inactivity, the schedular evaluation for residuals of nonpulmonary tuberculosis, i.e., anky-losis, surgical removal of a part, etc., if in excess of 50 percent or 30 percent will be assigned under the appropriate diagnostic code for the specific re-sidual preceded by the diagnostic code for tuberculosis of the body part affected. For example, tuberculosis of the hipjoint with residual ankylosis would be coded 5001-5250. The graduated ratings for nonpulmonary tuberculosis will not be combined with residuals of nonpul-monary tuberculosis unless the graduated rating and the rating for residual disability cover separate functional losses, e.g., graduated ratings for tuber-culosis of the kidney and residuals of tuberculosis of the spine. Where there are existing pulmonary and nonpulmonary conditions, the graduated eval-uation for the pulmonary, or for the nonpulmonary, condition will be utilized, combined with evaluations for residuals of the condition not covered by the graduated evaluation utilized, so as to provide the higher evaluation over such period. The ending dates of all graduated ratings of nonpulmonary tuberculosis will be controlled by the date of attainment of inactivity. These ratings are applicable only to veterans with nonpulmonary tuberculosis active on or after Octo-

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 43 FR 45361, Oct. 2, 1978]

ber 10, 1949.

THE RESPIRATORY SYSTEM

§4.96 Special provisions regarding evaluation of respiratory conditions.

(a) Rating coexisting respiratory conditions. Ratings under diagnostic codes 6600 through 6817 and 6822 through 6847 will not be combined with each other. Where there is lung or pleural involvement, ratings under diagnostic codes 6819 and 6820 will not be combined with each other or with diagnostic codes 6600 through 6817 or 6822 through 6847. A single rating will be assigned under the diagnostic code which reflects the predominant disability with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation. However, in cases protected by the provisions of Pub. L. 90-493, the graduated ratings of 50 and 30 percent for inactive tuberculosis will not be elevated.

(b) *Rating "protected" tuberculosis cases.* Public Law 90-493 repealed section 356 of title 38, United States Code which had provided graduated ratings for inactive tuberculosis. The repealed

section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90–493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For application in rating cases in which the protective provisions of Pub. L. 90–493 apply the former evaluations pertaining to pulmonary tuberculosis are retained in §4.97.

(c) *Special monthly compensation.* When evaluating any claim involving

complete organic aphonia, refer to $\S3.350$ of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, there are other conditions in this section which under certain circumstances also establish entitlement to special monthly compensation.

(Authority: 38 U.S.C. 1155)

 $[34\ {\rm FR}\ 5062,\ {\rm Mar.}\ 11,\ 1969,\ as\ amended\ at\ 61\ {\rm FR}\ 46727,\ {\rm Sept.}\ 5,\ 1996]$

§ 4.97	Schedu	le of	ratings-	-respiratory	system.

		Rating
	DISEASES OF THE NOSE AND THROAT	
	Septum, nasal, deviation of: Traumatic only, With 50-percent obstruction of the nasal passage on both sides or complete obstruction on one side Nose, loss of part of, or scars: Exposing both nasal passages	10
	Loss of part of one ala, or other obvious disfigurement	10
	Or evaluate as DC 7800, scars, disfiguring, head, face, or neck.	
6511 6512 6513	Sinusitis, pansinusitis, chronic. Sinusitis, ethmoid, chronic. Sinusitis, frontal, chronic. Sinusitis, maxillary, chronic. Sinusitis, sphenoid, chronic. General Rating Formula for Sinusitis (DC's 6510 through 6514): Following radical surgery with chronic osteomyelitis, or; near constant sinusitis characterized by	
	headaches, pain and tenderness of affected sinus, and purulent discharge or crusting after re- peated surgeries	50
	weeks) antibiotic treatment, or; more than six non-incapacitating episodes per year of sinusitis characterized by headaches, pain, and purulent discharge or crusting One or two incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six	30
	weeks) antibiotic treatment, or; three to six non-incapacitating episodes per year of sinusitis char- acterized by headaches, pain, and purulent discharge or crusting Detected by X-ray only	10
	Note: An incapacitating episode of sinusitis means one that requires bed rest and treatment by a physician.	
	Laryngitis, tuberculous, active or inactive. Rate under §§4.88c or 4.89, whichever is appropriate.	
5516	Laryngitis, chronic: Hoarseness, with thickening or nodules of cords, polyps, submucous infiltration, or pre-malignant changes on biopsy	30
6518	Hoarseness, with inflammation of cords or mucous membrane Laryngectomy, total. Rate the residuals of partial laryngectomy as laryngitis (DC 6516), aphonia (DC 6519), or stenosis of larynx	10 1100
	(DC 6520).	
6519	Aphonia, complete organic: Constant inability to communicate by speech Constant inability to speak above a whisper	¹ 100 60
	Note: Evaluate incomplete aphonia as laryngitis, chronic (DC 6516).	
6520	Larynx, stenosis of, including residuals of laryngeal trauma (unilateral or bilateral): Forced expiratory volume in one second (FEV–1) less than 40 percent of predicted value, with Flow-Volume Loop compatible with upper airway obstruction, or; permanent tracheostomy FEV–1 of 40- to 55-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction FEV–1 of 56- to 70-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction FEV–1 of 71- to 80-percent predicted, with Flow-Volume Loop compatible with upper airway obstruction	100 60 30 10
	Note: Or evaluate as aphonia (DC 6519).	
6521	Pharynx, injuries to:	

§4.97

38 CFR Ch. I (7-1-05 Edition)

		Rating
	Stricture or obstruction of pharynx or nasopharynx, or; absence of soft palate secondary to trauma, chemical burn, or granulomatous disease, or; paralysis of soft palate with swallowing difficulty (nasal regurgitation) and speech impairment	50
6522	Allergic or vasomotor rhinitis:	
	With polyps	30
	Without polyps, but with greater than 50-percent obstruction of nasal passage on both sides or complete ob- struction on one side	10
6523	Bacterial rhinitis:	
	Rhinoscleroma	50
	With permanent hypertrophy of turbinates and with greater than 50-percent obstruction of nasal passage on both sides or complete obstruction on one side	10
6524	Granulomatous rhinitis:	
	Wegener's granulomatosis, lethal midline granuloma	100
	Other types of granulomatous infection	20

DISEASES OF THE TRACHEA AND BRONCHI

6600	Bronchitis, chronic:	
	FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-per- cent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	100 60 30
	predicted	10
6601	Bronchiectasis:	
	With incapacitating episodes of infection of at least six weeks total duration per year	100
	With incapacitating episodes of infection of four to six weeks total duration per year, or; near constant findings of cough with purulent sputum associated with anorexia, weight loss, and frank hemoptysis and requiring antibiotic usage almost continuously	60
	With incapacitating episodes of infection of two to four weeks total duration per year, or; daily productive cough with sputum that is at times purulent or blood-tinged and that requires prolonged (lasting four to six weeks) antibiotic usage more than twice a year	30
	Intermitten productive cough with acute infection requiring a course of antibiotics at least twice a year Or rate according to pulmonary impairment as for chronic bronchitis (DC 6600).	10
	Note: An incapacitating episode is one that requires bedrest and treatment by a physician.	
6602	Asthma, bronchial:	
	FEV-1 less than 40-percent predicted, or; FEV-1/FVC less than 40 percent, or; more than one attack per week with episodes of respiratory failure, or; requires daily use of systemic (oral or parenteral) high dose corticosteroids or immuno-suppressive medications	100
	or parenteral) corticosteroids	60
	FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; daily inhalational or oral bron- chodilator therapy, or; inhalational anti-inflammatory medication	30
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; intermittent inhalational or oral bronchodilator therapy	10
	Note: In the absence of clinical findings of asthma at time of examination, a verified history of asthmatic at- tacks must be of record.	
6603	Emphysema, pulmonary: FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy. FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55-percent, or; DLCO (SB) of 40- to 55-percent	100
	cent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit) FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent	60
	predicted	30
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted	10
6604	Chronic obstructive nulmonary diseases	

6604 Chronic obstructive pulmonary disease:

§4.97

§4.97

FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor	ng
pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo	
of barando barandori, bij bijobabajo of abaro robpinatory fanaro, bij rodanob barpanoni bijgon anorapy.	00
FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-per-	
	60
FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent predicted	30
FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent	
predicted	10

DISEASES OF THE LUNGS AND PLEURA—TUBERCULOSIS Ratings for Pulmonary Tuberculosis Entitled on August 19, 1968

 Tuberculosis, pulmonary, chronic, far advanced, active Tuberculosis, pulmonary, chronic, moderately advanced, active Tuberculosis, pulmonary, chronic, minimal, active Tuberculosis, pulmonary, chronic, active, advancement unspecified Tuberculosis, pulmonary, chronic, far advanced, inactive. Tuberculosis, pulmonary, chronic, in a radvanced, inactive. Tuberculosis, pulmonary, chronic, moderately advanced, inactive. Tuberculosis, pulmonary, chronic, moderately advanced, inactive. Tuberculosis, pulmonary, chronic, moderately advanced, inactive. Tuberculosis, pulmonary, chronic, inactive, advancement unspecified. General Rating Formula for Inactive Pulmonary Tuberculosis: For two years after date of inactivity, following active tuberculosis, which was clinically identified during service or subsequently Thereafter for for years, or in any event, to six years after date of inactivity. Thereafter, for five years, or to eleven years after date of inactivity Ellowing for endepende legione discovery time while the discovery endependence active. 	100 100 100 100 100 50 30
Following far advanced lesions diagnosed at any time while the disease process was active, minimum Following moderately advanced lesions, provided there is continued disability, emphysema, dyspnea on exer- tion, impairment of health, etc	30 20
Note (1): The 100-percent rating under codes 6701 through 6724 is not subject to a requirement of precedent hospital treatment. It will be reduced to 50 percent for failure to submit to examination or to follow prescribed treatment upon report to that effect from the medical authorities. When a veteran is placed on the 100-percent rating for inactive tuberculosis, the medical authorities will be appropriately notified of the fact, and of the necessity, as given in footnote 1 to 38 U.S.C. 1156 (and formerly in 38 U.S.C. 356, which has been repealed by Public Law 90–493), to notify the Adjudication Division in the event of failure to submit to examination or to follow treatment. Note (2): The graduated 50-percent and 30-percent ratings and the permanent 30 percent ratings for inactive pulmonary tuberculosis are not to be combined with ratings for other respiratory disabilities. Following thoracoplasty the rating will be for removal of ribs combined with the rating for collapsed lung. Resection of the ribs incident to thoracoplasty will be rated as removal.	

Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968

6730	Tuberculosis, pulmonary, chronic, active	100
	 Note: Active pulmonary tuberculosis will be considered permanently and totally disabling for non-service-connected pension purposes in the following circumstances: (a) Associated with active tuberculosis involving other than the respiratory system. (b) With severe associated symptoms or with extensive cavity formation. (c) Reactivated cases, generally. (d) With advancement of lesions on successive examinations or while under treatment. (e) Without retrogression of lesions or other evidence of material improvement at the end of six 	
	months hospitalization or without change of diagnosis from "active" at the end of 12 months hos- pitalization. Material improvement means lessening or absence of clinical symptoms, and X-ray findings of a stationary or retrogressive lesion.	
6731	Tuberculosis, pulmonary, chronic, inactive: Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600). Rate thoracoplasty as re- moval of ribs under DC 5297.	
	Note: A mandatory examination will be requested immediately following notification that active tuberculosis evaluated under DC 6730 has become inactive. Any change in evaluation will be carried out under the provisions of §3.105(e).	
6732	Pleurisy, tuberculous, active or inactive: Rate under §§ 4.88c or 4.89, whichever is appropriate.	
-	NONTUBERCULOUS DISEASES	

6817 Pulmonary Vascular Disease: Primary pulmonary hypertension, or; chronic pulmonary thromboembolism with evidence of pulmonary hyper-tension, right ventricular hypertrophy, or cor pulmonale, or; pulmonary hypertension secondary to other ob-structive disease of pulmonary arteries or veins with evidence of right ventricular hypertrophy or cor pulmonale

100

38 CFR Ch. I (7-1-05 Edition)

		Rating
	Chronic pulmonary thromboembolism requiring anticoagulant therapy, or; following inferior vena cava surgery	Thating
	without evidence of pulmonary hypertension or right ventricular dysfunction	60
	Symptomatic, following resolution of acute pulmonary embolism	30
	Asymptomatic, following resolution of pulmonary thromboembolism	0
	Note: Evaluate other residuals following pulmonary embolism under the most appropriate diagnostic code, such as chronic bronchitis (DC 6600) or chronic pleural effusion or fibrosis (DC 6844), but do not combine that evaluation with any of the above evaluations.	
	6819 Neoplasms, malignant, any specified part of respiratory system exclusive of skin growths	100
	Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chem- otherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	100
6820	Neoplasms, benign, any specified part of respiratory system. Evaluate using an appropriate respiratory analogy.	
	Bacterial Infections of the Lung	
6822 6823 6824	Chronic lung abscess. General Rating Formula for Bacterial Infections of the Lung (diagnostic codes 6822 through 6824): Active infection with systemic symptoms such as fever, night sweats, weight loss, or hemoptysis	100
	Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600).	
	Interstitial Lung Disease	
6825		
6826	Desquamative interstitial pneumonitis.	
6827 6828	Pulmonary alveolar proteinosis. Eosinophilic granuloma of lung.	
6829	Drug-induced pulmonary pneumonitis and fibrosis.	
6830	Radiation-induced pulmonary pneumonitis and fibrosis.	
6831	Hypersensitivity pneumonitis (extrinsic allergic alveolitis).	
6832	Pneumoconiosis (silicosis, anthracosis, etc.).	
6833	Asbestosis.	
	General Rating Formula for Interstitial Lung Disease (diagnostic codes 6825 through 6833): Forced Vital Capacity (FVC) less than 50-percent predicted, or; Diffusion Capacity of the Lung for	
	Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or;	
	maximum exercise capacity less than 15 ml/kg/min oxygen consumption with cardiorespiratory limi-	
	tation, or; cor pulmonale or pulmonary hypertension, or; requires outpatient oxygen therapy	100
	FVC of 50- to 64-percent predicted, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum ex-	
	ercise capacity of 15 to 20 ml/kg/min oxygen consumption with cardiorespiratory limitation	60
	FVC of 65- to 74-percent predicted, or; DLCO (SB) of 56- to 65-percent predicted	30
	FVC of 75- to 80-percent predicted, or; DLCO (SB) of 66- to 80-percent predicted	10
-	Mycotic Lung Disease	
6834 6835		
6836		
6837	Cryptococcosis.	
6838	Aspergillosis.	
6839	Mucormycosis.	
	General Rating Formula for Mycotic Lung Disease (diagnostic codes 6834 through 6839):	100
	Chronic pulmonary mycosis with persistent fever, weight loss, night sweats, or massive hemoptysis Chronic pulmonary mycosis requiring suppressive therapy with no more than minimal symptoms	100
	such as occasional minor hemoptysis or productive cough	50
	Chronic pulmonary mycosis with minimal symptoms such as occasional minor hemoptysis or produc-	50
	tive cough	30
	Healed and inactive mycotic lesions, asymptomatic	0
	Note: Coccidioidomycosis has an incubation period up to 21 days, and the disseminated phase is ordinarily manifest within six months of the primary phase. However, there are instances of dissemination delayed up to many years after the initial infection which may have been unrecognized. Accordingly, when service con- nection is under consideration in the absence of record or other evidence of the disease in service, service in southwestern United States where the disease is endemic and absence of prolonged residence in this lo- cality before or after service will be the deciding factor.	
	Restrictive Lung Disease	

§4.97

⁶⁸⁴⁰ Diaphragm paralysis or paresis.6841 Spinal cord injury with respiratory insufficiency.6842 Kyphoscoliosis, pectus excavatum, pectus carinatum.

§4.104

		Rating
6843 6844 6845	J	100 60 30 10
6846	Group XXI (DC 5321), however, will not be separately rated.	
	fever, night sweats, and weight loss despite treatment	100 60 30
6047	Chronic hilar adenopathy or stable lung infiltrates without symptoms or physiologic impairment Or rate active disease or residuals as chronic bronchitis (DC 6600) and extra-pulmonary involvement under specific body system involved.	0
6847	Sleep Apnea Syndromes (Obstructive, Central, Mixed): Chronic respiratory failure with carbon dioxide retention or cor pulmonale, or; requires tracheostomy	100 50 30 0
1 Be	eview for entitlement to special monthly compensation under \$3,350 of this chapter	

 $^{\rm 1}\,{\rm Review}$ for entitlement to special monthly compensation under §3.350 of this chapter.

[61 FR 46728, Sept. 5, 1996]

THE CARDIOVASCULAR SYSTEM

§§ 4.100-4.103 [Reserved]

§4.104 Schedule of ratings—cardiovascular system.

DISEASES OF THE HEART

	Rat- ing
NOTE (1): Evaluate cor pulmonale, which is a form of secondary heart disease, as part of the pulmonary condition that causes it.	

DISEASES OF THE HEART-Continued

Rating

NOTE (2): One MET (metabolic equivalent) is the energy cost of standing quietly at rest and represents an oxygen uptake of 3.5 milliliters per kilogram of body weight per minute. When the level of METs at which dyspnea, fatigue, angina, dizziness, or syncope develops is required for evaluation, and a laboratory determination of METs by exercise testing cannot be done for medical reasons, an estimation by a medical examiner of the level of activity (expressed in METs and supported by specific examples, such as slow stair climbing or shoveling snow) that results in dyspnea, fatigue, angina, dizziness, or syncope may be used.

7000 Valvular heart disease (including rheumatic heart disease):

§4.104

DISEASES OF THE HEART-Continued

38 CFR Ch. I (7-1-05 Edition)

DISEASES OF THE HEART-Continued

		Rat- ing		Rat- ing
	During active infection with valvular heart damage and for three months following		Thereafter, with documented pericarditis re- sulting in: Chronic congestive heart failure, or; work-	
	cessation of therapy for the active infec- tion	100	load of 3 METs or less results in dyspnea,	
	Thereafter, with valvular heart disease (doc-		fatigue, angina, dizziness, or syncope, or;	
	umented by findings on physical examina-		left ventricular dysfunction with an ejection	
	tion and either echocardiogram, Doppler		fraction of less than 30 percent.	1(
	echocardiogram, or cardiac catheteriza-		More than one episode of acute congestive heart failure in the past year, or; workload	
	tion) resulting in: Chronic congestive heart failure, or; work-		of greater than 3 METs but not greater	
	load of 3 METs or less results in dyspnea,		than 5 METs results in dyspnea, fatigue,	
	fatigue, angina, dizziness, or syncope, or;		angina, dizziness, or syncope, or; left ven-	
	left ventricular dysfunction with an ejection		tricular dysfunction with an ejection frac-	
	fraction of less than 30 percent	100	tion of 30 to 50 percent Workload of greater than 5 METs but not	6
	More than one episode of acute congestive heart failure in the past year, or; workload		greater than 7 METs results in dyspnea,	
	of greater than 3 METs but not greater		fatigue, angina, dizziness, or syncope, or;	
	than 5 METs results in dyspnea, fatigue,		evidence of cardiac hypertrophy or dilata-	
	angina, dizziness, or syncope, or; left ven-		tion on electro-cardiogram, echocardio-	
	tricular dysfunction with an ejection frac-	60	gram, or X-ray Workload of greater than 7 METs but not	:
	tion of 30 to 50 percent Workload of greater than 5 METs but not	60	greater than 10 METs results in dyspnea,	
	greater than 7 METs results in dyspnea,		fatigue, angina, dizziness, or syncope, or;	
	fatigue, angina, dizziness, or syncope, or;		continuous medication required	
	evidence of cardiac hypertrophy or dilata-		7003 Pericardial adhesions: Chronic congestive heart failure, or; work-	
	tion on electro-cardiogram, echocardio- gram, or X-ray	30	load of 3 METs or less results in dyspnea,	
	Workload of greater than 7 METs but not	00	fatigue, angina, dizziness, or syncope, or;	
	greater than 10 METs results in dyspnea,		left ventricular dysfunction with an ejection	
	fatigue, angina, dizziness, or syncope, or;		fraction of less than 30 percent	1(
	continuous medication required	10	More than one episode of acute congestive heart failure in the past year, or; workload	
001	Endocarditis:		of greater than 3 METs but not greater	
	For three months following cessation of therapy for active infection with cardiac in-		than 5 METs results in dyspnea, fatigue,	
	volvement	100	angina, dizziness, or syncope, or; left ven-	
	Thereafter, with endocarditis (documented		tricular dysfunction with an ejection frac- tion of 30 to 50 percent	(
	by findings on physical examination and		Workload of greater than 5 METs but not	
	either echocardiogram, Doppler echo-		greater than 7 METs results in dyspnea,	
	cardiogram, or cardiac catheterization) re- sulting in:		fatigue, angina, dizziness, or syncope, or;	
	Chronic congestive heart failure, or; work-		evidence of cardiac hypertrophy or dilata- tion on electro-cardiogram, echocardio-	
	load of 3 METs or less results in dyspnea,		gram, or X-ray	3
	fatigue, angina, dizziness, or syncope, or;		Workload of greater than 7 METs but not	
	left ventricular dysfunction with an ejection fraction of less than 30 percent	100	greater than 10 METs results in dyspnea,	
	More than one episode of acute congestive	100	fatigue, angina, dizziness, or syncope, or;	
	heart failure in the past year, or; workload		continuous medication required 7004 Syphilitic heart disease:	
	of greater than 3 METs but not greater		Chronic congestive heart failure, or; work-	
	than 5 METs results in dyspnea, fatigue,		load of 3 METs or less results in dyspnea,	
	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-		fatigue, angina, dizziness, or syncope, or;	
	tion of 30 to 50 percent	60	left ventricular dysfunction with an ejection fraction of less than 30 percent	1(
	Workload of greater than 5 METs but not		More than one episode of acute congestive	
	greater than 7 METs results in dyspnea,		heart failure in the past year, or; workload	
	fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-		of greater than 3 METs but not greater	
	tion on electrocardiogram, echocardio-		than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven-	
	gram, or X-ray	30	tricular dysfunction with an ejection frac-	
	Workload of greater than 7 METs but not		tion of 30 to 50 percent	6
	greater than 10 METs results in dyspnea,		Workload of greater than 5 METs but not	
	fatigue, angina, dizziness, or syncope, or; continuous medication required	10	greater than 7 METs results in dyspnea,	
002	Pericarditis:	10	fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-	
	For three months following cessation of		tion on electrocardiogram, echocardio-	
	therapy for active infection with cardiac in-		gram, or X-ray	3
	volvement	100	Workload of greater than 7 METs but not	
			greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	
			allule, anuma, uzziness, or syncope, or i	

DISEASES OF THE HEART-Continued

DISEASES OF THE HEART-Continued

DISEASES OF THE HEART—Continued			DISEASES OF THE HEART-Continued	
	Rat- ing			Rat- ing
NOTE: Evaluate syphilitic aortic aneurysms under DC 7110 (aortic aneurysm).			More than one episode of acute congestive heart failure in the past year, or; workload	
7005 Arteriosclerotic heart disease (Coronary artery disease): With documented coronary artery disease resulting in:			of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection			tion of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-	6
fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater	100		tion on electrocardiogram, echocardio- gram, or X-ray Workload of greater than 7 METs but not	31
than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-			greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	1
tion of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-	60	7008	Hyperthyroid heart disease: Include as part of the overall evaluation for hyperthyroidism under DC 7900. How- ever, when atrial fibrillation is present, hy- perthyroidism may be evaluated either under DC 7000 evaluated either	
tion on electrocardiogram, echocardio- gram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dyspnea,	30	7010	under DC 7900 or under DC 7010 (supra- ventricular arrhythmia), whichever results in a higher evaluation. Supraventricular arrhythmias:	
fatigue, angina, dizziness, or syncope, or, continuous medication required NOTE: If nonservice-connected arteriosclerotic heart	10		Paroxysmal atrial fibrillation or other supra- ventricular tachycardia, with more than four episodes per year documented by ECG or Holter monitor	30
disease is superimposed on service-connected val- vular or other non-arteriosclerotic heart disease, request a medical opinion as to which condition is causing the current signs and symptoms.			Permanent atrial fibrillation (lone atrial fibril- lation), or; one to four episodes per year of paroxysmal atrial fibrillation or other su- praventricular tachycardia documented by	
7006 Myocardial infarction: During and for three months following myo- cardial infarction, documented by labora- tory tests Thereafter:	100	7011	ECG or Holter monitor Ventricular arrhythmias (sustained): For indefinite period from date of hospital admission for initial evaluation and med- ical therapy for a sustained ventricular ar-	1(
With history of documented myocardial in- farction, resulting in: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea,			rhythmia, or; for indefinite period from date of hospital admission for ventricular aneurysmectomy, or; with an automatic implantable Cardioverter-Defibrillator (AICD) in place	10
fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload	100		Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	10
of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-			fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater	100
tion of 30 to 50 percent	60		than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	6
tion on electrocardiogram, echocardio- gram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dyspnea,	30		greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio-	
fatigue, angina, dizziness, or syncope, or; continuous medication required	10		gram, or X-ray	30
left ventricular dysfunction with an ejection fraction of less than 30 percent	100			

§4.104

§4.104

DISEASES OF THE HEART-Continued

38 CFR Ch. I (7-1-05 Edition)

DISEASES OF THE HEART-Continued

	Rat- ing		Rat- ing
Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10	Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	1(
NOTE: A rating of 100 percent shall be assigned from the date of hospital admission for initial eval- uation and medical therapy for a sustained ven- tricular arrhythmia or for ventricular aneurysmectomy. Six months following discharge, the appropriate disability rating shall be deter- mined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of 0.4.007(c) this absorbed to the provisions of		 NOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for valve replace- ment. Six months following discharge, the appro- priate disability rating shall be determined by man- datory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. 7017 Coronary bypass surgery: 	
§3.105(e) of this chapter.		For three months following hospital admis- sion for surgery	100
7015 Atrioventricular block: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection		Thereafter: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or;	
fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,	100	left ventricular dysfunction with an ejection fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater	100
angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-		than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
tion of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or, evidence of cardiac hypertrophy or dilata-	60	tion of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-	6
tion on electrocardiogram, echocardio- gram, or X-ray	30	tion on electrocardiogram, echocardio- gram, or X-ray	3
Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication or a pacemaker re- quired	10	Workload greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10
IOTE: Unusual cases of arrhythmia such as atrio- ventricular block associated with a supraventricular	10	7018 Implantable cardiac pacemakers: For two months following hospital admission	
arrhythmia or pathological bradycardia should be submitted to the Director, Compensation and Pen- sion Service. Simple delayed P-R conduction time, in the absence of other evidence of cardiac dis- ease, is not a disability.		for implantation or reimplantation Thereafter: Evaluate as supraventricular arrhythmias (DC 7010), ventricular arrhythmias (DC 7011), or atrioventricular block (DC 7015).	10
016 Heart valve replacement (prosthesis): For indefinite period following date of hos- pital admission for valve replacement	100	Minimum NOTE: Evaluate implantable Cardioverter-Defibrillators (AICD's) under DC 7011.	10
Thereafter: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or;		7019 Cardiac transplantation: For an indefinite period from date of hospital admission for cardiac transplantation Thereafter:	100
left ventricular dysfunction with an ejection fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload	100	Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60	fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,	10
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-		angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	6
tion on electrocardiogram, echocardio- gram, or X-ray	30	Minimum	30

DISEASES OF THE HEART-Continued

DISEASES OF THE HEART-Continued

DISEASES OF THE HEART—Continued		DISEASES OF THE HEART—Continued	
	Rat- ing		Rat- ing
NOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for cardiac trans-		Evaluate residuals of surgical correction ac- cording to organ systems affected.	
plantation. One year following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. 7020 Cardiomyopathy:		NOTE: A rating of 100 percent shall be assigned as of the date of admission for surgical correction. Six months following discharge, the appropriate dis- ability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be sub- ject to the provisions of §3.105(e) of this chapter.	
Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or;		7111 Aneurysm, any large artery: If symptomatic, or; for indefinite period from date of hospital admission for surgical	
left ventricular dysfunction with an ejection fraction of less than 30 percent More than one episode of acute congestive	100	correction Following surgery: Ischemic limb pain at rest, and; either deep	10
heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,		ischemic ulcers or ankle/brachial index of 0.4 or less Claudication on walking less than 25 yards	10
angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60	on a level grade at 2 miles per hour, and; persistent coldness of the extremity, one or more deep ischemic ulcers, or ankle/	
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-		brachial index of 0.5 or less Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, ab-	6
tion on electrocardiogram, echocardio- gram, or X-ray Workload of greater than 7 METs but not	30	sence of hair, dystrophic nails) or ankle/ brachial index of 0.7 or less Claudication on walking more than 100	4
greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10	yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less NOTE (1): The ankle/brachial index is the ratio of the	2
Diseases of the Arteries and Veins 7101 Hypertensive vascular disease (hypertension and isolated systolic hypertension):		systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brach- ial artery systolic blood pressure. The normal index is 1.0 or greater.	
Diastolic pressure predominantly 130 or more Diastolic pressure predominantly 120 or	60	NOTE (2): These evaluations are for involvement of a single extremity. If more than one extremity is af- fected, evaluate each extremity separately and	
more Diastolic pressure predominantly 110 or more, or; systolic pressure predominantly	40	combine (under §4.25), using the bilateral factor, if applicable. NOTE (3): A rating of 100 percent shall be assigned	
200 or more Diastolic pressure predominantly 100 or more, or, systolic pressure predominantly 160 or more, or, minimum evaluation for an individual with a history of diastolic pressure predominantly 100 or more who	20	as of the date of hospital admission for surgical correction. Six months following discharge, the ap- propriate disability rating shall be determined by mandatory VA examination. Any change in evalua- tion based upon that or any subsequent examina- tion shall be subject to the provisions of §3.105(e) of this chapter.	
requires continuous medication for control NOTE (1): Hypertension or isolated systolic hyper- tension must be confirmed by readings taken two	10	7112 Aneurysm, any small artery: Asymptomatic	
or more times on at least three different days. For purposes of this section, the term hypertension means that the diastolic blood pressure is predomi- nantly 90mm. or greater, and isolated systolic hy-		NOTE: If symptomatic, evaluate according to body system affected. Following surgery, evaluate re- siduals under the body system affected.	
pertension means that the systolic blood pressure is predominantly 160mm. or greater with a diastolic blood pressure of less than 90mm.		7113 Arteriovenous fistula, traumatic: With high output heart failure Without heart failure but with enlarged heart,	10
NOTE (2): Evaluate hypertension due to aortic insuffi- ciency or hyperthyroidism, which is usually the iso- lated systolic type, as part of the condition causing		wide pulse pressure, and tachycardia Without cardiac involvement but with edema, stasis dermatitis, and either ulcer- ation or cellulitis:	6
it rather than by a separate evaluation. 7110 Aortic aneurysm:		Lower extremity Upper extremity With edema or stasis dermatitis:	5 4
If five centimeters or larger in diameter, or; if symptomatic, or; for indefinite period from date of hospital admission for surgical correction (including any type of graft in-		Lower extremity Upper extremity 7114 Arteriosclerosis obliterans:	3) 2)
sertion) Precluding exertion	100 60	Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	10

§4.104

§4.104

DISEASES OF THE HEART-Continued

38 CFR Ch. I (7-1-05 Edition)

DISEASES OF THE HEART-Continued

	Rat- ing		Rat- ing
Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; either persistent coldness of the extremity or ankle/brachial index of 0.5 or less Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, ab- sence of hair, dystrophic nails) or ankle/ brachial index of 0.7 or less	60	NOTE: For purposes of this section, characteristic at- tacks consist of sequential color changes of the digits of one or more extremities lasting minutes to hours, sometimes with pain and paresthesias, and precipitated by exposure to cold or by emotional upsets. These evaluations are for the disease as a whole, regardless of the number of extremities in- volved or whether the nose and ears are involved. 7118 Angioneurotic edema:	
Claudication on walking more than 100 yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less	20	Attacks without laryngeal involvement last- ing one to seven days or longer and oc- curring more than eight times a year, or;	
NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brach- ial artery systolic blood pressure. The normal index is 1.0 or greater. NOTE (2): Evaluate residuals of aortic and large arte- rial bypass surgery or arterial graft as arterio-		attacks with laryngeal involvement of any duration occurring more than twice a year Attacks without laryngeal involvement last- ing one to seven days and occurring five to eight times a year, or; attacks with la- ryngeal involvement of any duration oc- curring once or twice a year	40
sclerosis obliterans. NOTE (3): These evaluations are for involvement of a		Attacks without laryngeal involvement last- ing one to seven days and occurring two	
single extremity. If more than one extremity is af- fected, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable. 7115 Thrombo-angiitis obliterans (Buerger's Dis-		to four times a year 7119 Erythromelalgia: Characteristic attacks that occur more than once a day, last an average of more than two hours each, respond poorly to treat-	10
ease): Ischemic limb pain at rest, and; either deep		ment, and that restrict most routine daily activities	10
ischemic ulcers or ankle/brachial index of 0.4 or less Claudication on walking less than 25 yards	100	Characteristic attacks that occur more than once a day, last an average of more than two hours each, and respond poorly to treatment, but that do not restrict most	
on a level grade at 2 miles per hour, and; either persistent coldness of the extremity or ankle/brachial index of 0.5 or less	60	routine daily activities Characteristic attacks that occur daily or	6
Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, ab- sence of hair, dystrophic nails) or ankle/		more often but that respond to treatment Characteristic attacks that occur less than daily but at least three times a week and that respond to treatment	30
brachial index of 0.7 or less Claudication on walking more than 100 yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less NOTE (1): The ankle/brachial index is the ratio of the	40 20	NOTE: For purposes of this section, a characteristic attack of erythromelalgia consists of burning pain in the hands, feet, or both, usually bilateral and symmetrical, with increased skin temperature and redness, occurring at warm ambient temperatures.	
systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brach- ial artery systolic blood pressure. The normal index is 1.0 or greater.		These evaluations are for the disease as a whole, regardless of the number of extremities involved. 7120 Varicose veins: With the following findings attributed to the	
JOTE (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under §4.25), using the bilateral factor		effects of varicose veins: Massive board- like edema with constant pain at rest Persistent edema or subcutaneous indura- tion, stasis pigmentation or eczema, and	100
(§4.26), if applicable. 117 Raynaud's syndrome:		Persistent edema and stasis pigmentation or eczema, with or without intermittent ulcer-	60
With two or more digital ulcers plus autoamputation of one or more digits and history of characteristic attacks	100	ation Persistent edema, incompletely relieved by	4
With two or more digital ulcers and history of characteristic attacks	60	elevation of extremity, with or without be- ginning stasis pigmentation or eczema Intermittent edema of extremity or aching	20
Characteristic attacks occurring at least daily	40	and fatigue in leg after prolonged standing or walking, with symptoms relieved by	
Characteristic attacks occurring four to six times a week Characteristic attacks occurring one to three	20	elevation of extremity or compression ho- siery	1(
times a week	10	Asymptomatic palpable or visible varicose veins	

DISEASES OF THE HEART-Continued

DISEASES OF THE HEART—Continued	k	DISEASES OF THE HEART—Continued
	Rat- ing	Rating
NOTE: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable. 7121 Post-phlebitic syndrome of any etiology: With the following findings attributed to venous disease: Massive board-like edema with constant pain at rest	100	Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evalua- tion based upon that or any subsequent examina- tion shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recur- rence or metastasis, rate on residuals.
Persistent edema or subcutaneous induration, stasis pigmentation or		(Authority: 38 U.S.C. 1155)
eczema, and persistent ulcera- tion Persistent edema and stasis pig-	60	[62 FR 65219, Dec. 11, 1997, as amended at 6 FR 37779, July 14, 1998]
mentation or eczema, with or without intermittent ulceration Persistent edema, incompletely re-	40	THE DIGESTIVE SYSTEM
lieved by elevation of extremity, with or without beginning stasis		§4.110 Ulcers.
pigmentation or eczema Intermittent edema of extremity or aching and fatigue in leg after prolonged standing or walking, with symptoms relieved by ele- vation of extremity or compres- sion hosiery	20 10 0	Experience has shown that the term "peptic ulcer" is not sufficiently spe- cific for rating purposes. Manifest dif- ferences in ulcers of the stomach or du odenum in comparison with those at an anastomotic stoma are sufficiently rec- ognized as to warrant two separat graduated descriptions. In evaluating the ulcer, care should be taken tha the findings adequately identify th particular location.
(§4.26), if applicable. 7122 Cold injury residuals:		84 111 Postgastroatomy syndromos
 With the following in affected parts: Arthralgia or other pain, numbness, or cold sensitivity plus two or more of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteo-arthritis) Arthralgia or other pain, numbness, or cold sensitivity plus tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, or X-ray abnormalities (osteoporosis, sub-articular punched out lesions, or steo-arthritis) 	30	§4.111 Postgastrectomy syndromes. There are various postgastrectomy symptoms which may occur following anastomotic operations of the stom ach. When present, those occurring during or immediately after eating and known as the "dumping syndrome" ar characterized by gastrointestinal complaints and generalized symptoms simulating hypoglycemia; those occurring from 1 to 3 hours after eating usually present definite manifestations of hypoglycemia.
osteoarthritis)	20	§4.112 Weight loss.
Arthralgia or other pain, numbness, or cold sensitivity	10	For purposes of evaluating condition in §4.114, the term "substantial weigh loss" means a loss of greater than 2 percent of the individual's baselin weight, sustained for three months o longer; and the term "minor weigh loss" means a weight loss of 10 to 2 percent of the individual's baselin weight, sustained for three months o

NOTE (2): Evaluate each affected part (e.g., hand, foot, ear, nose) separately and combine the ratings in accordance with §§ 4.25 and 4.26.

7123 Soft tissue sarcoma (of vascular origin)

DISEASES OF THE HEART-Continued

	ing
rating of 100 percent shall continue beyond ssation of any surgical, X-ray, antineoplastic therapy or other therapeutic procedure. Six after discontinuance of such treatment, the viate disability rating shall be determined by tory VA examination. Any change in evalua- ised upon that or any subsequent examina-	

ns ht 20 ne or ht 20 ne or weight, sustained for three months of longer. The term "inability to gain weight" means that there has been substantial weight loss with inability

100

§4.112

§4.113

to regain it despite appropriate therapy. "Baseline weight" means the average weight for the two-year-period preceding onset of the disease.

(Authority: 38 U.S.C. 1155)

[66 FR 29488, May 31, 2001]

§4.113 Coexisting abdominal conditions.

There are diseases of the digestive system, particularly within the abdomen, which, while differing in the site of pathology, produce a common disability picture characterized in the main by varying degrees of abdominal distress or pain, anemia and disturbances in nutrition. Consequently, certain coexisting diseases in this area, as indicated in the instruction under the title "Diseases of the Digestive System," do not lend themselves to distinct and separate disability evalua-tions without violating the fundamental principle relating to pyramiding as outlined in §4.14.

§4.114 Schedule of ratings—digestive system.

Ratings under diagnostic codes 7301 to 7329, inclusive, 7331, 7342, and 7345 to 7348 inclusive will not be combined with each other. A single evaluation will be assigned under the diagnostic code which reflects the predominant disability picture, with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation.

	Rat- ing
7200 Mouth, injuries of.	
Rate as for disfigurement and impairment of	
function of mastication.	
7201 Lips, injuries of.	
Rate as for disfigurement of face.	
7202 Tongue, loss of whole or part:	
With inability to communicate by speech	100
One-half or more	60
With marked speech impairment	30
7203 Esophagus, stricture of:	
Permitting passage of liquids only, with marked impairment of general health	80
Severe, permitting liquids only	50
Moderate	30
7204 Esophagus, spasm of (cardiospasm).	
If not amenable to dilation, rate as for the de- gree of obstruction (stricture).	
7205 Esophagus, diverticulum of, acquired.	
Rate as for obstruction (stricture).	
7301 Peritoneum, adhesions of:	

38 CFR Ch. I (7-1-05 Edition)

	Rat- ing
Severe; definite partial obstruction shown by X- ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction mani- fested by delayed motility of barium meal and	50
less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or ag- gravated by movements of the body, or occa- sional episodes of colic pain, nausea, con- stipation (perhaps alternating with diarrhea) or	30
abdominal distension Mild NOTE: Ratings for adhesions will be considered when there is history of operative or other traumatic or infectious (intraabdominal) proc- ess, and at least two of the following: disturb- ance of motility, actual partial obstruction, re- flex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations	10 0
of anemia and weight loss productive of defi- nite impairment of health	60
at least four or more times a year Moderate; recurring episodes of severe symp- toms two or three times a year averaging 10 days in duration; or with continuous moderate	40
manifestations Mild; with recurring symptoms once or twice	20
yearly	10
pacitating Severe; same as pronounced with less pro- nounced and less continuous symptoms with	100
definite impairment of health	60
transient episodes of vomiting or melena Moderate; with episodes of recurring symptoms	40
Several times a year	20
7307 Gastritis, hypertrophic (identified by gastro- scope):	10
Chronic; with severe hemorrhages, or large ul- cerated or eroded areas Chronic; with multiple small eroded or ulcerated	60
areas, and symptoms	30
toms	10
hypoglycemic symptoms, and weight loss with malnutrition and anemia	60

§4.114

	Rat- ing		Rat- ing
Moderate; less frequent episodes of epigastric	ing	Asymptomatic	iiig (
disorders with characteristic mild circulatory symptoms after meals but with diarrhea and weight loss	40	NOTE: Amebiasis with or without liver abscess is parallel in symptomatology with ulcerative coli-	
Mild; infrequent episodes of epigastric distress with characteristic mild circulatory symptoms		tis and should be rated on the scale provided for the latter. Similarly, lung abscess due to amebiasis will be rated under the respiratory	
or continuous mild manifestations 7309 Stomach, stenosis of. Rate as for gastric ulcer.	20	system schedule, diagnostic code 6809. 7322 Dysentery, bacillary. Rate as for ulcerative colitis	
7310 Stomach, injury of, residuals. Rate as peritoneal adhesions.		7323 Colitis, ulcerative: Pronounced; resulting in marked malnutrition,	
7311 Residuals of injury of the liver: Depending on the specific residuals, separately		anemia, and general debility, or with serious complication as liver abscess	10
evaluate as adhesions of peritoneum (diag- nostic code 7301), cirrhosis of liver (diagnostic		Severe; with numerous attacks a year and mal- nutrition, the health only fair during remissions	6
code 7312), and chronic liver disease without cirrhosis (diagnostic code 7345). 7312 Cirrhosis of the liver, primary biliary cirrhosis,		Moderately severe; with frequent exacerbations Moderate; with infrequent exacerbations	30
or cirrhotic phase of sclerosing cholangitis: Generalized weakness, substantial weight loss,		Severe symptoms	3) 1(
and persistent jaundice, or; with one of the fol- lowing refractory to treatment: ascites, hepatic		Mild or no symptoms 7325 Enteritis, chronic.	(
encephalopathy, hemorrhage from varices or portal gastropathy (erosive gastritis)	100	Rate as for irritable colon syndrome. 7326 Enterocolitis, chronic. Rate as for irritable colon syndrome.	
History of two or more episodes of ascites, he- patic encephalopathy, or hemorrhage from varices or portal gastropathy (erosive gas-		7327 Diverticulitis. Rate as for irritable colon syndrome, peritoneal	
tritis), but with periods of remission between attacks	70	adhesions, or colitis, ulcerative, depending upon the predominant disability picture.	
History of one episode of ascites, hepatic encephalopathy, or hemorrhage from varices		7328 Intestine, small, resection of: With marked interference with absorption and nutrition, manifested by severe impairment of	
or portal gastropathy (erosive gastritis) Portal hypertension and splenomegaly, with weakness, anorexia, abdominal pain, malaise,	50	health objectively supported by examination findings including material weight loss	60
and at least minor weight loss	30	With definite interference with absorption and nutrition, manifested by impairment of health	
inal pain, and malaise NOTE: For evaluation under diagnostic code	10	objectively supported by examination findings including definite weight loss Symptomatic with diarrhea, anemia and inability	40
7312, documentation of cirrhosis (by biopsy or imaging) and abnormal liver function tests must be present.		to gain weight NOTE: Where residual adhesions constitute the	20
7314 Cholecystitis, chronic: Severe; frequent attacks of gall bladder colic	30	predominant disability, rate under diagnostic code 7301.	
Moderate; gall bladder dyspepsia, confirmed by X-ray technique, and with infrequent attacks		7329 Intestine, large, resection of: With severe symptoms, objectively supported by examination findings	40
(not over two or three a year) of gall bladder colic, with or without jaundice Mild	10 0	With moderate symptoms With slight symptoms	20 10
7315 Cholelithiasis, chronic. Rate as for chronic cholecystitis.	Ŭ	NOTE: Where residual adhesions constitute the predominant disability, rate under diagnostic code 7301.	
7316 Cholangitis, chronic. Rate as for chronic cholecystitis.		7330 Intestine, fistula of, persistent, or after attempt at operative closure:	
 7317 Gall bladder, injury of. Rate as for peritoneal adhesions. 7318 Gall bladder, removal of: 		Copious and frequent, fecal discharge Constant or frequent, fecal discharge	100
With severe symptoms	30 10	Slight infrequent, fecal discharge Healed; rate for peritoneal adhesions. 7331 Peritonitis, tuberculous, active or inactive:	30
Nonsymptomatic Spleen, disease or injury of.	0	Active Inactive: See §§4.88b and 4.89.	100
See Hemic and Lymphatic Systems. 7319 Irritable colon syndrome (spastic colitis, mu- cous colitis, etc.):		7332 Rectum and anus, impairment of sphincter control: Complete loss of sphincter control	100
Severe; diarrhea, or alternating diarrhea and constipation, with more or less constant ab-		Extensive leakage and fairly frequent involuntary bowel movements	6
dominal distress Moderate; frequent episodes of bowel disturb-	30	Occasional involuntary bowel movements, ne- cessitating wearing of pad	3
ance with abdominal distress Mild; disturbances of bowel function with occa- sional episodes of abdominal distress	10 0	Constant slight, or occasional moderate leakage Healed or slight, without leakage	1(
7321 Amebiasis: Mild gastrointestinal disturbances, lower abdom-	U	7333 Rectum and anus, stricture of: Requiring colostomy Great reduction of lumen, or extensive leakage	100 50
inal cramps, nausea, gaseous distention, chronic constipation interrupted by diarrhea	10	Moderate reduction of lumen, or moderate con- stant leakage	30

§4.114

and hepatitis C):

Rating 7334 Rectum, prolapse of: Severe (or complete), persistent 50 Moderate, persistent or frequently recurring 30 Mild with constant slight or occasional moderate leakage 7335 Ano, fistula in. 10 Rate as for impairment of sphincter control. 7336 Hemorrhoids, external or internal: With persistent bleeding and with secondary anemia, or with fissures 20 Large or thrombotic, irreducible, with excessive redundant tissue, evidencing frequent recurrences 10 Mild or moderate 0 7337 Pruritus ani. Rate for the underlying condition. 7338 Hernia, inguinal: Large, postoperative, recurrent, not well supported under ordinary conditions and not read-ily reducible, when considered inoperable 60 Small, postoperative recurrent, or unoperated irremediable, not well supported by truss, or not readily reducible ... 30 Postoperative recurrent, readily reducible and 10 well supported by truss or belt Not operated, but remediable 0 Small, reducible, or without true hernia protru-0 sion NOTE: Add 10 percent for bilateral involvement, provided the second hernia is compensable. This means that the more severely disabling hernia is to be evaluated, and 10 percent, only, added for the second hernia, if the latter is of compensable degree. 7339 Hernia, ventral, postoperative: Massive, persistent, severe diastasis of recti muscles or extensive diffuse destruction or weakening of muscular and fascial support of abdominal wall so as to be inoperable 100 Large, not well supported by belt under ordinary conditions 40 Small, not well supported by belt under ordinary conditions, or healed ventral hernia or post-operative wounds with weakening of abdominal wall and indication for a supporting belt 20 Wounds, postoperative, healed, no disability, belt not indicated 7340 Hernia, femoral. 0 Rate as for inguinal hernia. 7342 Visceroptosis, symptomatic, marked 7343 Malignant neoplasms of the digestive system, 10 exclusive of skin growths 100 NOTE: A rating of 100 percent shall continue be-yond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of $\S3.105(e)$ of this chapter. If there has been no local recurrence or metastasis, rate on residuals. 7344 Benign neoplasms, exclusive of skin growths: Evaluate under an appropriate diagnostic code, depending on the predominant disability or the specific residuals after treatment. 7345 Chronic liver disease without cirrhosis (including hepatitis B, chronic active hepatitis, auto-immune hepatitis, hemochromatosis, drug-induced hepatitis, etc., but excluding bile duct disorders

38 CFR Ch. I (7-1-05 Edition)

Near-constant debilitating symptoms (such as fa- tigue, malaise, nausea, vomiting, anorexia,	
arthralgia, and right upper quadrant pain) Daily fatigue, malaise, and anorexia, with sub- stantial weight loss (or other indication of mal- nutrition), and hepatomegaly, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav- ing a total duration of at least six weeks during	100
the past 12-month period, but not occurring constantly Daily fatigue, malaise, and anorexia, with minor weight loss and hepatomegaly, or; incapaci- tating episodes (with symptoms such as fa- tigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav- ing a total duration of at least four weeks, but	60
less than six weeks, during the past 12-month period	40
less than four weeks, during the past 12- month period	20
 past 12-month period Nonsymptomatic NOTE (1): Evaluate sequelae, such as cirrhosis or malignancy of the liver, under an appropriate diagnostic code, but do not use the same signs and symptoms as the basis for evaluation under DC 7354 and under a diagnostic code for sequelae. (See § 4.14.). NOTE (2): For purposes of evaluating conditions under diagnostic code 7345, "incapacitating episode" means a period of acute signs and symptoms severe enough to require bed rest and treatment by a physician. NOTE (3): Hepatitis B infection must be confirmed by serologic testing in order to evaluate it under diagnostic code 7345. 7346 Hernia hiatal: 	10 0
Symptoms of pain, vomiting, material weight loss and hematemesis or melena with moderate anemia; or other symptom combinations pro- ductive of severe impairment of health Persistently recurrent epigastric distress with dysphagia, pyrosis, and regurgitation, accom- panied by substernal or arm or shoulder pain,	60
productive of considerable impairment of health	30
With two or more of the symptoms for the 30 percent evaluation of less severity	10
7347 Pancreatitis: With frequently recurrent disabling attacks of ab- dominal pain with few pain free intermissions and with steatorrhea, malabsorption, diarrhea and severe malnutrition	100

	Rat- ing
Moderately severe; with at least 4-7 typical at- tacks of abdominal pain per year with good re-	
mission between attacks	30
With at least one recurring attack of typical se- vere abdominal pain in the past year	10
NOTE 1: Abdominal pain in this condition must be confirmed as resulting from pancreatitis by	
appropriate laboratory and clinical studies. NOTE 2: Following total or partial pancrea-	
tectomy, rate under above, symptoms, min- imum rating 30 percent.	
7348 Vagotomy with pyloroplasty or gastro- enterostomy:	
Followed by demonstrably confirmative post-	
operative complications of stricture or con- tinuing gastric retention	40
With symptoms and confirmed diagnosis of alka- line gastritis, or of confirmed persisting diar- rhea	30
Recurrent ulcer with incomplete vagotomy	20
NOTE: Rate recurrent ulcer following complete vagotomy under diagnostic code 7305, min-	
imum rating 20 percent; and rate dumping syndrome under diagnostic code 7308.	
7351 Liver transplant: For an indefinite period from the date of hospital	
admission for transplant surgery	100
Minimum NOTE: A rating of 100 percent shall be assigned	30
as of the date of hospital admission for trans- plant surgery and shall continue. One year fol-	
lowing discharge, the appropriate disability rat- ing shall be determined by mandatory VA ex-	
amination. Any change in evaluation based	
upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.	
7354 Hepatitis C (or non-A, non-B hepatitis):	
With serologic evidence of hepatitis C infection and the following signs and symptoms due to hepatitis C infection:	
Near-constant debilitating symptoms (such as	
fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain)	100
Daily fatigue, malaise, and anorexia, with sub- stantial weight loss (or other indication of mal-	
nutrition), and hepatomegaly, or; incapacitating episodes (with symptoms such as fatigue,	
malaise, nausea, vomiting, anorexia,	
arthralgia, and right upper quadrant pain) hav- ing a total duration of at least six weeks during	
the past 12-month period, but not occurring constantly	60
Daily fatigue, malaise, and anorexia, with minor weight loss and hepatomegaly, or; incapaci-	
tating episodes (with symptoms such as fa-	
arthralgia, and right upper quadrant pain) hav-	
ing a total duration of at least four weeks, but less than six weeks, during the past 12-month	
period Daily fatigue, malaise, and anorexia (without	40
weight loss or hepatomegaly), requiring dietary restriction or continuous medication, or; inca-	
pacitating episodes (with symptoms such as	
fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav-	
ing a total duration of at least two weeks, but less than four weeks, during the past 12-	
month period	20

§4.115

	Rat- ing
Intermittent fatigue, malaise, and anorexia, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, ano- rexia, arthralgia, and right upper quadrant pain) having a total duration of at least one week, but less than two weeks, during the past 12-month period	10 0

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 34 FR 5063, Mar. 11, 1969; 40 FR 42540, Sept. 15, 1975; 41 FR 11301, Mar. 18, 1976; 66 FR 29488, May 31, 2001]

THE GENITOURINARY SYSTEM

§4.115 Nephritis.

Albuminuria alone is not nephritis, nor will the presence of transient albumin and casts following acute febrile illness be taken as nephritis. The glomerular type of nephritis is usually preceded by or associated with severe infectious disease; the onset is sudden, and the course marked by red blood cells, salt retention, and edema; it may clear up entirely or progress to a chronic condition. The nephrosclerotic type, originating in hypertension or arteriosclerosis, develops slowly, with minimum laboratory findings, and is associated with natural progress. Separate ratings are not to be assigned for disability from disease of the heart and any form of nephritis, on account of the close interrelationships of cardiovascular disabilities. If, however, absence of a kidney is the sole renal disability, even if removal was required because of nephritis, the absent kidney and any hypertension or heart disease will be separately rated. Also, in the event that chronic renal disease has progressed to the point where regular

§4.115a

dialysis is required, any coexisting hypertension or heart disease will be separately rated.

[41 FR 34258, Aug. 13, 1976, as amended at 59 FR 2527, Jan. 18, 1994]

§4.115a Ratings of the genitourinary system—dysfunctions.

Diseases of the genitourinary system generally result in disabilities related to renal or voiding dysfunctions, infections, or a combination of these. The following section provides descriptions of various levels of disability in each of these symptom areas. Where diagnostic codes refer the decisionmaker to these specific areas dysfunction, only the predominant area of dysfunction shall be considered for rating purposes. Since the areas of dysfunction described below do not cover all symptoms resulting from genitourinary diseases, specific diagnoses may include a description of symptoms assigned to that diagnosis.

-	
	Rat- ing
Renal dysfunction:	
Requiring regular dialysis, or precluding more than sedentary activity from one of the fol- lowing: persistent edema and albuminuria; or, BUN more than 80mg%; or, creatinine more than 8mg%; or, markedly decreased function of kidney or other organ systems, estpecially cardiovascular	100
Persistent edema and albuminuria with BUN 40 to 80mg%; or, creatinine 4 to 8mg%; or, gen- eralized poor health characterized by lethargy, weakness, anorexia, weight loss, or limitation of exertion	80
Constant albuminuria with some edema; or, defi- nite decrease in kidney function; or, hyper- tension at least 40 percent disabling under di-	
agnostic code 7101 Albumin constant or recurring with hyaline and granular casts or red blood cells; or, transient or slight edema or hypertension at least 10	60
percent disabling under diagnostic code 7101 Albumin and casts with history of acute nephritis; or, hypertension non-compensable under diag- nostic code 7101	30
Voiding dysfunction:	l o
Rate particular condition as urine leakage, fre- quency, or obstructed voiding	
Continual Urine Leakage, Post Surgical Urinary Diversion, Urinary Incontinence, or Stress In- continence:	
Requiring the use of an appliance or the wearing of absorbent materials which must be changed more than 4 times per day	60
Requiring the wearing of absorbent materials	60
which must be changed 2 to 4 times per day Requiring the wearing of absorbent materials	40
which must be changed less than 2 times per day	20

38 CFR Ch. I (7-1-05 Edition)

Daytime voiding interval between one and two hours, or; awakening to void three to four times per night 24 Daytime voiding interval between two and three hours, or; awakening to void two times per night 24 Daytime voiding interval between two and three hours, or; awakening to void two times per night 10 Obstructed voiding: 11 Urinary retention requiring intermittent or contin- uous catheterization 30 Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the fol- lowing: 30 1. Post void residuals greater than 150 cc. 2. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. 3. Recurrent urinary tract infections sec- ondary to obstruction. 4. 4. Stricture disease requiring periodic dilata- tion every 2 to 3 months 11 Obstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times 11		Rat- ing
Daytime voiding interval less than one hour, or; awakening to void five or more times per night 44 Daytime voiding interval between one and two hours, or; awakening to void three to four times per night 24 Daytime voiding interval between two and three hours, or; awakening to void two times per night 24 Obstructed voiding: 26 Urinary retention requiring intermittent or contin- uous catheterization 36 Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the fol- lowing: 36 1. Post void residuals greater than 150 cc. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections sec- ondary to obstruction. 4. Stricture disease requiring periodic dilata- tion every 2 to 3 months 10 Obstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times per year 10 Vurinary tract infection: Poor renal function: Rate as renal dysfunction. Recurrent hospitalization (greater than two times/year), and/or requiring continuous inten- sive management 30	Urinary frequency:	
Daytime voiding interval between one and two hours, or; awakening to void three to four times per night		
hours, or; awakening to void three to four times per night 24 Daytime voiding interval between two and three hours, or; awakening to void two times per night 24 Obstructed voiding: 10 Urinary retention requiring intermittent or contin- uous catheterization 30 Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the fol- lowing: 30 1. Post void residuals greater than 150 cc. 2. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections sec- ondary to obstruction. 4. Stricture disease requiring periodic dilata- tion every 2 to 3 months 10 Obstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times per year 10 Urininary tract infection: Poor renal function: Rate as renal dysfunction. Recurrent symptomatic infection requiring drain- age/frequent hospitalization (greater than two times/year), and/or requiring continuous inten- sive management 30 Long-term drug therapy, 1–2 hospitalizations per 30		40
times per night		
Daytime voiding interval between two and three hours, or; awakening to void two times per night		
hours, or; awakening to void two times per night 10 Obstructed voiding: 11 Urinary retention requiring intermittent or contin- uous catheterization 30 Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the fol- lowing: 30 1. Post void residuals greater than 150 cc. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections sec- ondary to obstruction. 4. Stricture disease requiring periodic dilata- tion every 2 to 3 months 10 Obstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times per year 10 Urininary tract infection: Poor renal function: Rate as renal dysfunction. Recurrent symptomatic infection requiring drain- age/frequent hospitalization (greater than two times/year), and/or requiring continuous inten- sive management 30 30 Long-term drug therapy, 1–2 hospitalizations per 30		20
night 10 Obstructed voiding: 11 Obstructed voiding: 11 Urinary retention requiring intermittent or continuous catheterization 30 Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the following: 31 1 Post void residuals greater than 150 cc. 2. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. 3. Recurrent urinary tract infections secondary to obstruction. 4. 4. Stricture disease requiring periodic dilatation every 2 to 3 months 10 Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year 0 Urninary tract infection: Poor renal function: Rate as renal dysfunction. Recurrent hospitalization (greater than two times/year), and/or requiring continuous intensive management 30 Long-fere drug therapy, 1–2 hospitalizations per 30		
Obstructed voiding: Urinary retention requiring intermittent or continuous catheterization 30 Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the following: 31 1. Post void residuals greater than 150 cc. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections secondary to obstruction. 4. Stricture disease requiring periodic dilatation every 2 to 3 months 11 Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year 11 Urninary tract infection: Poor renal function: Rate as renal dysfunction. 16 Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management 30		10
Urinary retention requiring intermittent or continuous catheterization 30 Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the following: 31 1. Post void residuals greater than 150 cc. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections secondary to obstruction. 4. Stricture disease requiring periodic dilatation every 2 to 3 months 10 Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year 10 Urninary tract infection: Recurrent hospitalization (greater than two times/year), and/or requiring continuous intensive management 30 3. Government symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year 30 Urninary tract infection: Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management 30		10
 uous catheterization		
Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of the following: 1. Post void residuals greater than 150 cc. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections secondary to obstruction. 4. Stricture disease requiring periodic dilatation every 2 to 3 months 100 Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year Urninary tract infection: Poor renal function: Rate as renal dysfunction. Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management 30		30
 slow or weak stream, decreased force of stream) with any one or combination of the following: Post void residuals greater than 150 cc. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). Recurrent urinary tract infections secondary to obstruction. Stricture disease requiring periodic dilatation every 2 to 3 months Uriniary tract infection: Rate as renal dysfunction. Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management Xong-term drug therapy, 1–2 hospitalizations per year 		
lowing: 1. Post void residuals greater than 150 cc. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections secondary to obstruction. 4. Stricture disease requiring periodic dilatation every 2 to 3 months tion every 2 to 3 months Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year Urninary tract infection: Poor renal function: Rate as renal dysfunction. Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management 30 Long-term drug therapy, 1–2 hospitalizations per		
1. Post void residuals greater than 150 cc. 2. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections sec- ondary to obstruction. 4. Stricture disease requiring periodic dilata- tion every 2 to 3 months Cobstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times per year Urninary tract infection: Rate as renal dysfunction. Recurrent symptomatic infection requiring drain- age/frequent hospitalization (greater than two times/year), and/or requiring continuous inten- sive management Suma String St	stream) with any one or combination of the fol-	
 Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). Recurrent urinary tract infections sec- ondary to obstruction. Stricture disease requiring periodic dilata- tion every 2 to 3 months		
flow rate (less than 10 cc/sec). 3. Recurrent urinary tract infections sec- ondary to obstruction. 4. Stricture disease requiring periodic dilata- tion every 2 to 3 months Obstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times per year		
 Recurrent urinary tract infections secondary to obstruction. Stricture disease requiring periodic dilatation every 2 to 3 months Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year Urninary tract infection: Poor renal function: Rate as renal dysfunction. Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management Song and a stricture of the symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management 		
ondary to obstruction. 4. Stricture disease requiring periodic dilata- tion every 2 to 3 months		
4. Stricture disease requiring periodic dilatation every 2 to 3 months 10 Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year 10 Urninary tract infection: 10 Poor renal function: Rate as renal dysfunction. 10 Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than two times/year), and/or requiring continuous intensive management 30		
tion every 2 to 3 months		
Obstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times per year		10
ture disease requiring dilatation 1 to 2 times per year		10
per year		
Poor renal function: Rate as renal dysfunction. Recurrent symptomatic infection requiring drain- age/frequent hospitalization (greater than two times/year), and/or requiring continuous inten- sive management		0
Recurrent symptomatic infection requiring drain- age/frequent hospitalization (greater than two times/year), and/or requiring continuous inten- sive management	Urninary tract infection:	
age/frequent hospitalization (greater than two times/year), and/or requiring continuous inten- sive management		
times/year), and/or requiring continuous inten- sive management		
sive management		
Long-term drug therapy, 1-2 hospitalizations per		
		30
, , ,		10

[59 FR 2527, Jan. 18, 1994; 59 FR 10676, Mar. 7, 1994]

§4.115b Ratings of the genitourinary system—diagnoses.

	Rat- ing
Note: When evaluating any claim in- volving loss or loss of use of one or more creative organs, refer to § 3.350 of this chapter to determine whether the veteran may be enti- tled to special monthly compensa- tion. Footnotes in the schedule indi- cate conditions which potentially establish entitlement to special monthly compensation; however, there are other conditions in this section which under certain cir- cumstances also establish entitle- ment to special monthly compensa- tion.	
7500 Kidney, removal of one: Minimum evaluation Or rate as renal dysfunction if there is nephritis, infection, or pathology of the other	30
7501 Kidney, abscess of: Rate as urinary tract infection	

§4.115b

		Rat- ing			Rat- ing
7502 Nephritis,			7517	Bladder, injury of:	
	nal dysfunction.			Rate as voiding dysfunction.	
7504 Pyeloneph			7518	Urethra, stricture of:	
	enal dysfunction or urinary			Rate as voiding dysfunction.	
dominar	ection, whichever is pre-		7519	Urethra, fistual of:	
7505 Kidney, tu				Rate as voiding dysfunction.	
	ccordance with §§4.88b or			Multiple urethroperineal fistulae	100
	lichever is appropriate.		7520	Penis, removal of half or more	30
	erosis, arteriolar:			Or rate as voiding dysfunction.	
	rding to predominant symp-		7521	Penis removal of glans	20
toms as	renal dysfunction, hyper-			Or rate as voiding dysfunction.	
tension	or heart disease. If rated		7522	Penis, deformity, with loss of erectile	
under th	e cardiovascular schedule,			$/er=20^{1}$.	
	, the percentage rating			Testis, atrophy complete:.	
	ould otherwise be assigned			Both—20 ¹	
	elevated to the next higher			One—0 ¹	
evaluatio			7524	Testis, removal:.	
7508 Nephrolith			1524	Both—30 ¹	
	hydronephrosis, except for			One-01	
	t stone formation requiring nore of the following:			One-0	
1. diet th				Note: In cases of the removal of one	
2. drug t				testis as the result of a service-in-	
	ive or non-invasive proce-			curred injury or disease, other than	
	more than two times/year	30		an undescended or congenitally un-	
7509 Hydronepl				developed testis, with the absence	
	ate as renal dysfunction.			or nonfunctioning of the other testis	
	acks of colic with infection			unrelated to service, an evaluation	
	osis), kidney function im-			of 30 percent will be assigned for the service-connected testicular	
		30		loss. Testis, underscended, or con-	
	acks of colic, requiring cath-	00		genitally undeveloped is not a rat-	
	asional attack of colic, not	20		able disability.	
	asional attack of colic, not ind not requiring catheter				
		10	7525	Epididymo-orchitis, chronic only:	
7510 Ureterolith				Rate as urinary tract infection.	
Rate as I	hydronephrosis, except for			For tubercular infections: Rate in ac-	
recurren	t stone formation requiring			cordance with §§4.88b or 4.89,	
	nore of the following:		7507	whichever is appropriate.	
1. diet th				Prostate gland injuries, infections, hy-	
2. drug t			per	trophy, postoperative residuals:	
	ive or non-invasive proce-			Rate as voiding dysfunction or urinary tract infection, whichever is pre-	
	more than two times/year	30		dominant.	
7511 Ureter, str	hydronephrosis, <i>except for</i>		7509	Malignant neoplasms of the genito-	
	t stone formation requiring			ary system	100
	nore of the following:		un		100
1. diet th					
2. drug t					
3. invas	ive or non-invasive proce-				
dures	more than two times/year	30			
	chronic, includes interstitial				
	ies, infectious and non-in-				
fectious:					
	biding dysfunction.				
	calculus in, with symptoms				
interfering with					
	biding dysfunction				
7516 Bladder, fi					
nale as vo	biding dysfunction or urinary				
tract inf					
tract inf dominar	ection, whichever is pre-				

§4.115b

38 CFR Ch. I (7-1-05 Edition)

	Rat- Rat-
	ing ing
 Note—Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local reoccurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant. 7529 Benign neoplasms of the genitourinary system: Rate as voiding dysfunction or renal dysfunction, whichever is predominant. 7530 Chronic renal disease requiring regular dialysis: Rate as renal dysfunction. 7531 Kidney transplant: Following transplant surgery	Or rate as renal dysfunction. 7533 Cystic diseases of the kidneys (poly- cystic disease, uremic medullary cystic disease, Medullary sponge kidney, and similar conditions): Rate as renal dysfunction. 7534 Atherosclerotic renal disease (renal artery stenosis or atheroembolic renal dis- ease): Rate as renal dysfunction. 7535 Toxic nephropathy (antibotics, radiocontrast agents, nonsteroidal anti-in- flammatory agents, heavy metals, and similar agents): Rate as renal dysfunction. 7536 Glomerulonephritis: Rate as renal dysfunction. 7537 Interstitial nephritis: Rate as renal dysfunction. 7538 Papillary necrosis: Rate as renal dysfunction. 7539 Renal amyloid disease: Rate as renal dysfunction. 7540 Disseminated intravascular coagula- tion with renal cortical necrosis: 30 Rate as renal dysfunction. 7541 Renal involvement in diabetes mellitus, sickle cell anemia, systemic lupus erythematosus, vasculitis, or other systemic disease processes. Rate as renal dysfunction. 7542 Neurogenic bladder: Rate as voiding dysfunction. ¹ Review for entitlement to special monthly corr pensation under § 3.350 of this chapter. [59 FR 2527, Jan. 18, 1994; 59 FR 14567, Mar. 25 1994, as amended at 59 FR 46339, Sept. 8, 1994

GYNECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST

§4.116 Schedule of ratings—gyneco-logical conditions and disorders of the breast.

Symptoms that require continuous treatment 100 Symptoms that do not require continuous treatment 00 7617 Uterus and both ovaries, removal of, complete: 1100 For three months after removal 150 7618 Uterus, removal of, including corpus: 1000 For three months after removal 100 Thereafter 130 7619 Ovary, removal of: 100 Thereafter 130 7619 Ovary, removal of: 100 Thereafter: 1300 1300 Complete removal of both ovaries 1300 Removal of one with or without 1400 partial removal of the other 1200 7620 Ovaries, atrophy of both, complete 1300 7622 Uterus, displacement of: 1200 7622 Uterus, displacement of: 300 7622 Uterus, displacement of: 300 With adhesions and irregular menstruation 100 7623 Pregnancy, surgical complications of: 300 With rectocele or cystocele 500 With rectocele or cystocele 500			Rating
birth are not disabilities for rating pur- poses. Chronic residuals of medical or surgical complications of pregnancy may be disabilities for rating purposes. Note 2: When evaluating any claim involv- ing loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury of. 7614 Fallopian tube, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of ficulding pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of ficulding pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. 7614 Cervix, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 Uterus, and beth ovaries, removal of, com- plete: For three months after removal		Note 1: Natural menopause, primary amenorrhea, and pregnancy and child-	
surgical complications of pregnancy may be disabilities for rating purposes. Note 2: When evaluating any claim involv- ing loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7611 Vagina, disease or injury of. 7612 Cervix, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms that do not require continuous treatment 300 7617 Uterus, renoval of, including corpus: For three months after removal 1000 7618 Uterus, renoval of one with or without partial r		birth are not disabilities for rating pur-	
be disabilities for rating purposes. Note 2: When evaluating any claim involv- ing loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7613 Uterus, disease or injury of. 7613 Uterus, disease or injury of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms that require continuous treatment			
Note 2: When evaluating any claim involv- ing loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms that require continuous treatment 300 Symptoms that require continuous treatment 100 7617 Uterus, and both ovaries, removal of, com- plete: For three months after removal 1100 7618 Uterus, prolapse: Complete removal of both ovaries Removal of one with or without partial removal of the other 120 7620 Ovaries, atrophy of both, complete 120 7622 Uterus, displacement of: Wit			
creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7611 Vaya, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury of. 7614 Fallopian tube, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of f(including pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms that require continuous treatment			
one or both breasts, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms not controlled by continuous treatment			
this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation, however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of ficituding pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms that require continuous treat- ment			
veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 Vulva disease, injury, or adhesions of. 7617 Cervix, disease, injury, or adhesions of. 7618 Deterus, disease, injury, or adhesions of. 7619 Ovary, disease, injury, or adhesions of. 7619 Ovary, disease, injury, or adhesions of. 7619 Ovary, disease, injury, or adhesions of. 7619 Covary, disease, injury, or adhesions of. 7617 Uterus and Experductive Organs (diag- nostic codes 7610 through 7615): Symptoms that require continuous treatment			
schedule indicate conditions which po- tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of fincluding pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms that require continuous treat- ment		veteran may be entitled to special	
tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of. 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury, or dhesions of. 7614 Fallopian tube, disease, injury, or adhesions of f (including pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of f (including pelvic inflammatory disease, [hiury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms not controlled by continuous treatment			
monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitle- ment to special monthly compensation. 7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms not controlled by continuous treatment		schedule indicate conditions which po- tentially establish entitlement to special	
any condition in this section might, under certain circumstances, establish entille- ment to special monthly compensation. 7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury, or 7613 Uterus, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of (including pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of (including pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms that require continuous treat- ment		monthly compensation; however, almost	
ment to special monthly compensation. 7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 General Rating Formula for Disease, Injury, or Ad- hesions of Female Reproductive Organs (diag- nostic codes 7610 through 7615): Symptoms not controlled by continuous treatment		any condition in this section might, under	
7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): Symptoms not controlled by continuous treatment 30 Symptoms that do not require continuous treatment 30 Symptoms that do not require continuous treatment 100 Thereafter 100 Thereafter 100 Thereafter 100 Thereafter 100 Thereafter: 100 Complete removal of both ovaries 100 For three months after removal 100 Thereafter: <		certain circumstances, establish entitle-	
vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of. 7613 Uterus, disease or injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 Ovary, disease, injury, or adhesions of. 7617 Ovary, disease, injury, or adhesions of. General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): Symptoms not controlled by continuous treatment Symptoms that require continuous treatment Symptoms that on trequire continuous treatment Correlet: For three months after removal 7618 Uterus, removal of, including corpus: For three months after removal 100 Thereafter: 130 7619 Ovary, removal of: For three months after removal 120 7620 Ovaries, atrophy of both, complete Complete, through vagina and introitus 50 7622 Uterus, displacement of: With marked displacement and frequent or continuous menstrual disturbances 300 7623 Pregnancy, surg	7610		
7611 Vagina, disease or injury of. 7612 Cervix, disease or injury, or. 7613 Uterus, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of. 7615 Ovary, disease, injury, or adhesions of. 7616 Fallopian tube, disease, injury, or adhesions of. 7617 Ovary, disease, injury, or adhesions of. 7618 Devic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): Symptoms not controlled by continuous treatment Symptoms that require continuous treatment 300 Symptoms that do not require continuous treatment 100 7617 Uterus and both ovaries, removal of, complete: 100 7618 Uterus, removal of, including corpus: 1100 7619 Ovary, removal of: 1300 7620 Ovaries, atrophy of both, complete 120 7621 Uterus, displacement of: 120 7622 Uterus, displacement of: 300 7623 Pregnancy, surgical complications of: 300 7624 <td></td> <td></td> <td></td>			
7613 Uterus, disease, injury, or adhesions of. 7614 Fallopian tube, disease, injury, or adhesions of 7615 Ovary, disease, injury, or adhesions of. General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): Symptoms not controlled by continuous treatment Symptoms that require continuous treatment Symptoms that on trequire continuous treatment Controlled by continuous treatment Thereatter 7617 Uterus, and both ovaries, removal of, complete: For three months after removal 1000 7618 Uterus, removal of, including corpus: For three months after removal 1000 7619 Ovary, removal of: For three months after removal 1000 Thereafter: 1200 Complete removal of both ovaries Removal of one with or without partial removal of the other 1200 7620 Ovaries, atrophy of both, complete 1200 7622 Uterus, displacement of: 320 With adhesions and irregular menstruation 320 7623 Pregnancy, surgical complications of: 320 With reloxation ore ystocele 320 <td>7611</td> <td>Vagina, disease or injury of.</td> <td></td>	7611	Vagina, disease or injury of.	
7614 Fallopian tube, disease, injury, or adhesions of (including pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): 300 Symptoms not controlled by continuous treatment 300 Symptoms that require continuous treatment 300 Symptoms that do not require continuous treatment 100 Symptoms that do not require continuous treatment 100 Thereafter 100 7618 Uterus, removal of, including corpus: For three months after removal 1100 Thereafter 120 7619 Ovary, removal of: For three months after removal 1100 Thereafter: 120 Complete removal of both ovaries 1300 Removal of one with or without partial removal of the other 120 7620 Ovaries, atrophy of both, complete 300 7622 Uterus, displacement of: 300 With marked displacement and frequent or continuous meatrual disturbances 300 7623 Pregnancy, surgical complications of: 300 With reloxation o			
of (including pelvic inflammatory disease (PID)). 7615 Ovary, disease, injury, or adhesions of. General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): Symptoms not controlled by continuous treatment Symptoms not controlled by continuous treatment 30 Symptoms that require continuous treatment 30 Symptoms that do not require continuous treatment 10 Thereafter 100 Complete removal of both ovaries 100 7619 Ovary, removal of: 100 7620 Ovaries, atrophy of both, compl			
General Rating Formula for Disease, Injury, or Adhesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): 300 Symptoms not controlled by continuous treatment 300 Symptoms that require continuous treatment 300 Symptoms that do not require continuous treatment 100 Symptoms that do not require continuous treatment 100 Thereafter 1100 7617 Uterus and both ovaries, removal of, complete: 1100 For three months after removal 150 7618 Uterus, removal of, including corpus: 1100 Thereafter 1300 7619 Ovary, removal of: 1400 For three months after removal 1100 Thereafter: 1300 Complete removal of both ovaries 1400 Removal of one with or without partial removal of the other 1200 7620 Ovaries, atrophy of both, complete 1200 7621 Uterus, displacement of: 320 With marked displacement and frequent or continuous mestrual disturbances 300 7622 Uterus, displacement of: 300 With adhesions and irregular menstruation 300 7623 Pregnancy, surgical complications of: 300 With relo			
hesions of Female Reproductive Organs (diagnostic codes 7610 through 7615): Symptoms not controlled by continuous treatment 30 Symptoms not controlled by continuous treatment 30 Symptoms that require continuous treatment 30 Symptoms that do not require continuous treatment 100 Thereafter 100 7617 Uterus and both ovaries, removal of, complete: 100 7618 Uterus, removal of, including corpus: 100 7618 Uterus, removal of, including corpus: 100 7619 Ovary, removal of, including corpus: 100 7619 Ovary, removal of 100 Thereafter 100 130 7619 Ovary, removal of 100 7620 Ovaries, atrophy of both, complete 100 7621 Uterus, prolapse: 20 Complete, through vagina and introitus 30 7622 Uterus, displacement of: 30 7623 Pregnancy, surgical complications of: 30 7624 Fistula, rectovaginal: 50 7624 Fistula, rectovaginal: 50 7624 Fistula, rectovaginal: 3		Ovary, disease, injury, or adhesions of.	
nostic codes 7610 through 7615): Symptoms not controlled by continuous treatment 30 Symptoms that require continuous treatment 100 Symptoms that do not require continuous treatment 100 Thereatment 100 Thereatment 100 Thereatment 100 Thereatment 100 Thereatment 100 Thereatter 100 Complete removal of both ovaries 130 Removal of one with or without partial removal of the other 120 7620 Ovaries, atrophy of both, complete 120 7621 Uterus, displacement of: 300 With marked displacement and frequent or continuous menstrual disturbances 300 7622 Uterus, displacement of: 300 With adh	Gener	al Rating Formula for Disease, Injury, or Ad-	
treatment 30 Symptoms that require continuous treatment 10 Symptoms that do not require continuous treatment 10 7617 Uterus and both ovaries, removal of, complete: 100 7617 Thereafter 100 7618 Uterus, removal of, including corpus: 100 7618 For three months after removal 1100 7619 Ovary, removal of, including corpus: 100 7619 For three months after removal 100 7619 Ovary, removal of: 100 7620 Ovary, removal of the other without partial removal of the other 100 7621 Uterus, prolapse: Complete, through vagina and introitus 100 7622 Uterus, displacement of: 30 30 7623 Pregnancy, surgical complications of: 30 7624 Fistula, rectovaginal: 50 With reclacele or cystocele 50 With relaxation of perineum 10 7624 Fistula, rectovaginal: 10			
Symptoms that require continuous treatment 100 Symptoms that do not require continuous treatment 00 7617 Uterus and both ovaries, removal of, complete: 100 For three months after removal 150 7618 Uterus, removal of, including corpus: 100 7618 Thereafter 150 7619 Ovary, removal of, including corpus: 100 7619 For three months after removal 1100 Thereafter 130 130 7619 Ovary, removal of: 1100 Thereafter: 130 130 7620 Ovaries, atrophy of both, complete 130 7621 Uterus, prolapse: 1200 Complete, through vagina and introitus 100 7622 Uterus, displacement of: 300 With marked displacement and frequent or continuous menstrual disturbances 300 7623 Pregnancy, surgical complications of: 300 With relaxation of perineum 100 100 7624 Fistula, rectovaginal: 300 7624 Fistula, fecal leakage at least once a day requiring wearing of pad 100 </td <td></td> <td></td> <td></td>			
ment 10 Symptoms that do not require continuous treatment 10 7617 Uterus and both ovaries, removal of, com- plete: 1100 For three months after removal 150 7618 Uterus, removal of, including corpus: 150 7619 Ovary, removal of, including corpus: 1100 7619 Ovary, removal of: 1300 7619 Ovary, removal of: 1400 7620 Ovaries, atrophy of both, complete 1200 7621 Uterus, prolapse: 1200 Complete, through vagina and introitus 500 7622 Uterus, displacement of: 300 With marked displacement and frequent or continuous menstrual disturbances 300 7623 Pregnancy, surgical complications of: 300 With reloxation of perineum 500 7624 Fistula, rectovaginal: 100 7624 Fistula, rectovaginal: 300 7624 Fistula, rectovaginal: 300 7624 Fistula, rectovaginal: 300 7624 Fistula, rectovaginal: 300 <td></td> <td>treatment</td> <td>30</td>		treatment	30
Symptoms that do not require continuous treatment			10
7617 Uterus and both ovaries, removal of, complete: 1100 For three months after removal 150 7618 Uterus, removal of, including corpus: 100 For three months after removal 130 7619 Ovary, removal of: 130 For three months after removal 130 7619 Ovary, removal of: 1400 Thereafter 00 130 Removal of one with or without 1400 1400 7620 Ovaries, atrophy of both, complete 120 7621 Uterus, displacement of: 120 With marked displacement and frequent or 300 7622 Verganacy, surgical complications of: 300 With adhesions and irregular menstruation 100 7623 Pregnancy, surgical complications of: 500 With reloxation of perineum 500 500 With reloxation of perineum 500 100 7624 Fistula, rectovaginal: 700 7624 Fistula, fecal leakage at least once a day 500 7624 Fistula, fecal leakage at least once a day 500		Symptoms that do not require continuous	
plete: 1 100 Thereafter 1 50 7618 Uterus, removal of, including corpus: 1 100 For three months after removal 1 100 Thereafter 1 300 7619 Ovary, removal of: For three months after removal 1 100 Thereafter 1 300 7619 Ovary, removal of: For three months after removal 1 100 Thereafter: 1 300 Complete removal of both ovaries 1 300 Removal of one with or without partial removal of the other 7620 Ovaries, atrophy of both, complete Complete, through vagina and introitus 1 200 7621 Uterus, gisplacement of: Nith marked displacement and frequent or 300 7622 Uterus, displacement of: With adhesions and irregular menstruation 100 7623 Pregnancy, surgical complications of: With relaxation of perineum 500 With relaxation of perineum 100 7624 Fistula, rectovaginal: 300 7624 Fistula, fecal leakage at least once a day 100	7617		0
For three months after removal 1100 Thereafter 1500 7618 Uterus, removal of, including corpus: For three months after removal 1100 7618 Uterus, removal of, including corpus: For three months after removal 1100 7619 Ovary, removal of: For three months after removal 1100 7619 Ovary, removal of: For three months after removal 1100 7619 Ovary, removal of: For three months after removal 1100 7620 Ovaries, atrophy of both, complete 120 7621 Uterus, prolapse: Complete, through vagina and introitus 120 7622 Uterus, displacement of: With marked displacement and frequent or continuous menstrual disturbances 300 7623 Pregnancy, surgical complications of: With relaxation of perineum 500 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day requiring wearing of pad 1000			
7618 Uterus, removal of, including corpus: For three months after removal 1 100 7619 Ovary, removal of: For three months after removal 1 100 7619 Ovary, removal of: For three months after removal 1 100 7619 Ovary, removal of: For three months after removal 1 100 7620 Ovaries, atrophy of both, complete 1 30 7620 Ovaries, atrophy of both, complete 1 20 7621 Uterus, prolapse: Complete, through vagina and introitus 1 20 7622 Uterus, displacement of: With marked displacement and frequent or continuous menstrual disturbances 30 7623 Pregnancy, surgical complications of: With relaxation of perineum 30 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day requiring wearing of pad 100		For three months after removal	1100
For three months after removal 1100 Thereafter 1200 7619 Ovary, removal of: For three months after removal 1100 7619 Ovary, removal of: For three months after removal 1100 Thereafter: 1100 Complete removal of both ovaries 1300 Removal of one with or without partial removal of the other 7620 Ovaries, atrophy of both, complete 7621 Uterus, prolapse: Complete, through vagina and introitus 1000 7622 Uterus, displacement of: With marked displacement and frequent or 300 Continuous menstrual disturbances 300 With adhesions and irregular menstruation 100 7623 Pregnancy, surgical complications of: With relaxation of perineum 500 With relaxation of perineum 1000 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day 1000	7040	Thereafter	¹ 50
Thereafter 1 300 7619 Ovary, removal of: For three months after removal 1 100 Thereafter: 1 100 Complete removal of both ovaries 1 300 Removal of one with or without 1 300 partial removal of the other 1 300 7620 Ovaries, atrophy of both, complete 1 200 7621 Uterus, prolapse: 1 200 Complete, through vagina and introitus 300 7622 Uterus, displacement of: 300 7623 With marked displacement and frequent or continuous menstrual disturbances 300 7624 Pregnancy, surgical complications of: 300 7624 Fistula, rectovaginal: 300 7624 Fistula, rectovaginal: <td>/618</td> <td></td> <td>1100</td>	/618		1100
7619 Ovary, removal of: For three months after removal			1 30
Thereafter: 1 300 Complete removal of both ovaries 1 300 Removal of one with or without 1 200 partial removal of the other 1 00 7620 Ovaries, atrophy of both, complete 1 200 7621 Uterus, prolapse: 1 200 Complete, through vagina and introitus 500 Incomplete 300 With marked displacement of: 300 With adhesions and irregular menstruation 100 7623 Pregnancy, surgical complications of: 500 With reloxation of perineum 500 7624 Fistula, rectovaginal: 100 7624 Fistula, fecal leakage at least once a day 1000	7619	Ovary, removal of:	
Complete removal of both ovaries Removal of one with or without partial removal of the other			1100
Removal of one with or without partial removal of the other 1 00 7620 Ovaries, atrophy of both, complete			1 30
7620 Ovaries, atrophy of both, complete 120 7621 Uterus, prolapse: Complete, through vagina and introitus 500 7622 Uterus, displacement of: With marked displacement and frequent or continuous menstrual disturbances 300 7623 Pregnancy, surgical complications of: With redocele or cystocele 300 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day requiring wearing of pad 100		Removal of one with or without	
 7621 Uterus, prolapse: Complete, through vagina and introitus 7622 Uterus, displacement of: With marked displacement and frequent or continuous menstrual disturbances 7623 Pregnancy, surgical complications of: With reclocele or cystocele 7624 Fistula, rectovaginal: Vagina fecal leakage at least once a day requiring wearing of pad 700 	7000		¹ 0
Complete, through vagina and introitus 50 Incomplete 30 7622 Uterus, displacement of: With marked displacement and frequent or 30 continuous menstrual disturbances 30 With adhesions and irregular menstruation 10 7623 Pregnancy, surgical complications of: With rectocele or cystocele 50 With relaxation of perineum 10 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day 100			120
Incomplete 30 7622 Uterus, displacement of: 30 With marked displacement and frequent or 30 With adhesions and irregular menstruation 10 7623 Pregnancy, surgical complications of: 30 With rectocele or cystocele 50 With relaxation of perineum 10 7624 Fistula, rectovaginal: 100 7624 requiring wearing of pad 100	1021		50
With marked displacement and frequent or continuous menstrual disturbances 30 With adhesions and irregular menstruation 10 7623 Pregnancy, surgical complications of: With rectocele or cystocele 50 With relaxation of perineum 10 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day requiring wearing of pad 100		Incomplete	30
continuous menstrual disturbances 30 With adhesions and irregular menstruation 10 7623 Pregnancy, surgical complications of: With rectocele or cystocele 50 With relaxation of perineum 10 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day 100	7622		
With adhesions and irregular menstruation 10 7623 Pregnancy, surgical complications of: With rectocele or cystocele 50 With relaxation of perineum 10 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day requiring wearing of pad 100			30
With rectocele or cystocele 50 With relaxation of perineum 10 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day requiring wearing of pad 100			10
With relaxation of perineum	7623	Pregnancy, surgical complications of:	
 7624 Fistula, rectovaginal: Vaginal fecal leakage at least once a day requiring wearing of pad		With rectocele or cystocele	
Vaginal fecal leakage at least once a day requiring wearing of pad 100	7624		
		Vaginal fecal leakage at least once a day	
Vaginal tecal leakage tour or more times			100
per week, but less than daily, requiring		Vaginal fecal leakage four or more times	
			60

§4.116

Ratin	
3	Vaginal fecal leakage one to three times per week requiring wearing of pad
	Vaginal fecal leakage less than once a
1	week
	Without leakage
	Fistula, urethrovaginal:
10	Multiple urethrovaginal fistulae
	Requiring the use of an appliance or the wearing of absorbent materials which must be changed more than four times
6	per day
	Requiring the wearing of absorbent mate- rials which must be changed two to four
4	times per day
	Requiring the wearing of absorbent mate- rials which must be changed less than
2	two times per day
	Breast, surgery of: Following radical mastectomy:
18	Both
15	One
	Following modified radical mastectomy:
16	Both
12	One
	Following simple mastectomy or wide local excision with significant alteration of size or form:
15	Both
13	One
	Following wide local excision without sig- nificant alteration of size or form:
	Both or one
	Note: For VA purposes:
	(1) Radical mastectomy means
	removal of the entire breast, un-
	derlying pectoral muscles, and
	regional lymph nodes up to the
	coracoclavicular ligament (2) Modified radical mastectomy
	means removal of the entire
	breast and axillary lymph nodes
	(in continuity with the breast).
	Pectoral muscles are left intact
	(3) Simple (or total) mastectomy
	means removal of all of the
	breast tissue, nipple, and a small portion of the overlying
	skin, but lymph nodes and mus- cles are left intact
	(4) Wide local excision (including
	partial mastectomy,
	lumpectomy, tylectomy, segmentectomy, and
	segmentectomy, and quadrantectomy) means re-
	moval of a portion of the breast
	tissue
	Maller and a subserve of an association of a
10	Malignant neoplasms of gynecological sys- or breast

n

§4.117

38 CFR Ch. I (7-1-05 Edition)

	Rating		Rating
Note: A rating of 100 percent shall con- tinue beyond the cessation of any sur- gical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rat- ing shall be determined by mandatory VA examination. Any change in evalua- tion based upon that or any subsequent examination shall be subject to the provi-		Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months. Requiring transfusion of platelets or red cells at least once per year but less than once every three months, or; infections recurring at least once per year but less than once every three months	60 30
sions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. 7628 Benign neoplasms of the gynecological sys- tem or breast. Rate according to impairment in function of the urinary or gynecological systems, or skin.		Requiring continuous medication for control NOTE: The 100 percent rating for bone marrow tra- shall be assigned as of the date of hospital admiss shall continue with a mandatory VA examinat months following hospital discharge. Any change uation based upon that or any subsequent exam shall be subject to the provisions of §3.105(e) chapter.	ion and ion six in eval- nination
7629 Endometriosis: Lesions involving bowel or bladder con- firmed by laparoscopy, pelvic pain or heavy or irregular bleeding not controlled by treatment, and bowel or bladder symptoms Pelvic pain or heavy or irregular bleeding		 7703 Leukemia: With active disease or during a treatment phase Otherwise rate as anemia (code 7700) or aplastic anemia (code 7716), whichever would result in the greater benefit. 	100
not controlled by treatment	30 10 Deensation	NOTE: The 100 percent rating shall continue beyond t sation of any surgical, radiation, antineoplastic therapy or other therapeutic procedures. Six month discontinuance of such treatment, the appropriate d rating shall be determined by mandatory VA exam Any change in evaluation based upon that or any quent examination shall be subject to the provis § 3.105(e) of this chapter. If there has been no recu rate on residuals.	chemo- hs after lisability nination. subse- sions of
[60 FR 19855, Apr. 21, 1995, as amended FR 6874, Feb. 14, 2002; 67 FR 37695, M 2002] THE HEMIC AND LYMPHATIC SYST	1ay 30,	7704 Polycythemia vera: During periods of treatment with myelosuppressants and for three months following cessation of myelosuppressant therapy	100 40
§4.117 Schedule of ratings-hemi	ic and	Stable, with or without continuous medica-	

of ratings—hemic and 117 Schedule of rat lymphatic systems.

	Rating
7700 Anemia, hypochromic-microcytic and megaloblastic, such as iron-deficiency and per- nicious anemia:	
Hemoglobin 5gm/100ml or less, with find- ings such as high output congestive heart failure or dyspnea at rest	100
beats per minute) or syncope (three epi- sodes in the last six months) Hemoglobin 8gm/100ml or less, with find- ings such as weakness, easy fatigability,	70
headaches, lightheadedness, or short- ness of breath	30
or headaches	10
NOTE: Evaluate complications of pernicious anemia, dementia or peripheral neuropathy, separately.	such as
7702 Agranulocytosis, acute: Requiring bone marrow transplant, or; re- quiring transfusion of platelets or red cells at least once every six weeks, or; infections recurring at least once every	100

six weeks

	Rate complications such as hypertension, gout, stroke prombotic disease separately.
7705	Thrombocytopenia, primary, idiopathic or im-

tion

10

100

·····, ····, ····, ···, ···, ···, ···,	1
mune:	
Platelet count of less than 20,000, with ac-	
tive bleeding, requiring treatment with	
medication and transfusions	100
Platelet count between 20,000 and 70,000,	
not requiring treatment, without bleeding	70
Stable platelet count between 70,000 and	
100,000, without bleeding	30
Stable platelet count of 100,000 or more,	
without bleeding	0
7706 Splenectomy	20
	20
NOTE: Rate complications such as systemic infection	ons with
encapsulated bacteria separately.	
7707 Spleen, injury of, healed.	
rior opicion, injury or, nealed.	

Rate for any residuals. 7709 Hodgkin's disease: With active disease or during a treatment phase

rence or metastasis, rate on residuals.

100

§4.118

	Rating		Rat- ing
7710 Adenitis, tuberculous, active or inactive. Rate under §§4.88c or 4.89 of this part,		With visible or palpable tissue loss and ei- ther gross distortion or asymmetry of	
whichever is appropriate. 7714 Sickle cell anemia:		three or more features or paired sets of	
With repeated painful crises, occurring in		features (nose, chin, forehead, eyes (in-	
skin, joints, bones or any major organs		cluding eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of	
caused by hemolysis and sickling of red		disfigurement	8
blood cells, with anemia, thrombosis and		With visible or palpable tissue loss and ei-	
infarction, with symptoms precluding even light manual labor	100	ther gross distortion or asymmetry of two	
With painful crises several times a year or	100	features or paired sets of features (nose,	
with symptoms precluding other than		chin, forehead, eyes (including eyelids),	
light manual labor	60	ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement	5
Following repeated hemolytic sickling cri-		With visible or palpable tissue loss and ei-	
ses with continuing impairment of health	30	ther gross distortion or asymmetry of one	
Asymptomatic, established case in remis- sion, but with identifiable organ impair-		feature or paired set of features (nose,	
ment	10	chin, forehead, eyes (including eyelids),	
NOTE: Sickle cell trait alone, without a history of dire		ears (auricles), cheeks, lips), or; with two	
tributable pathological findings, is not a ratable dis		or three characteristics of disfigurement With one characteristic of disfigurement	3
Cases of symptomatic sickle cell trait will be forwa		Note (1):The 8 characteristics of disfigure-	
the Director, Compensation and Pension Service, f	or con-	ment, for purposes of evaluation under	
sideration under §3.321(b)(1) of this chapter.		§4.118, are:	
715 Non-Hodgkin's lymphoma:		Scar 5 or more inches (13 or more cm.) in	
With active disease or during a treatment	400	length.	
phase	100	Scar at least one-quarter inch (0.6 cm.) wide at widest part.	
NOTE: The 100 percent rating shall continue beyond the		Surface contour of scar elevated or de-	
sation of any surgical, radiation, antineoplastic of therapy or other therapeutic procedures. Six month		pressed on palpation.	
discontinuance of such treatment, the appropriate d		Scar adherent to underlying tissue.	
rating shall be dtermined by mandatory VA exam		Skin hypo-or hyper-pigmented in an area	
Any change in evaluation based upon that or any		exceeding six square inches (39 sq. cm.).	
quent examination shall be subject to the provis		Skin texture abnormal (irregular, atrophic,	
§ 3.105(e) of this chapter. If there has been no loca rence or metastasis, rate on residuals.	r recui-	shiny, scaly, etc.) in an area exceeding six square inches (39 sq. cm.).	
7716 Aplastic anemia:		Underlying soft tissue missing in an area ex-	
Requiring bone marrow transplant, or; re-		ceeding six square inches (39 sq. cm.).	
quiring transfusion of platelets or red		Skin indurated and inflexible in an area ex-	
cells at least once every six weeks, or;		ceeding six square inches (39 sq. cm.).	
infections recurring at least once every	100	Note (2): Rate tissue loss of the auricle	
six weeks Requiring transfusion of platelets or red	100	under DC 6207 (loss of auricle) and ana- tomical loss of the eye under DC 6061	
cells at least once every three months,		(anatomical loss of both eyes) or DC	
or; infections recurring at least once		6063 (anatomical loss of one eye), as ap-	
every three months	60	propriate.	
Requiring transfusion of platelets or red		Note (3): Take into consideration	
cells at least once per year but less than once every three months, or; infections		unretouched color photographs when evaluating under these criteria.	
recurring at least once per year but less		7801 Scars, other than head, face, or neck, that are	
than once every three months	30	deep or that cause limited motion:	
Requiring continuous medication for control	10	Area or areas exceeding 144 square inches	
NOTE: The 100 percent rating for bone marrow tra	nsplant	(929 sq.cm.)	4
shall be assigned as of the date of hospital admissi		Area or areas exceeding 72 square inches	
shall continue with a mandatory VA examinati		(465 sq. cm.)	3
months following hospital discharge. Any change i uation based upon that or any subsequent exam		Area or areas exceeding 12 square inches (77 sq. cm.)	2
shall be subject to the provisions of §3.105(e)		Area or areas exceeding 6 square inches	_
chapter.		(39 sq. cm.)	1
		Note (1): Scars in widely separated areas,	
60 FR 49227, Sept. 22, 1995]		as on two or more extremities or on ante-	
		rior and posterior surfaces of extremities or trunk, will be separately rated and com-	
		bined in accordance with §4.25 of this	
THE SKIN			
THE SKIN		part.	
		Note (2): A deep scar is one associated	
		Note (2): A deep scar is one associated with underlying soft tissue damage.	
	Rat-	Note (2): A deep scar is one associated with underlying soft tissue damage.7802 Scars, other than head, face, or neck, that are	
	Rat- ing	Note (2): A deep scar is one associated with underlying soft tissue damage.	

§4.118

38 CFR Ch. I (7-1-05 Edition)

	Rat-		Rat
	ing		ing
Note (1): Scars in widely separated areas,		Note: Evaluate non-cutaneous (visceral)	
as on two or more extremities or on ante-		leishmaniasis under DC 6301 (visceral	
rior and posterior surfaces of extremities or trunk, will be separately rated and com-		leishmaniasis). 7809 Discoid lupus erythematosus or subacute cu-	
bined in accordance with §4.25 of this		taneous lupus erythematosus:	
part.		Rate as disfigurement of the head, face, or	
Note (2): A superficial scar is one not asso-		neck (DC 7800), scars (DC's 7801, 7802,	
ciated with underlying soft tissue damage.		7803, 7804, or 7805), or dermatitis (DC	
03 Scars, superficial, unstable	10	7806), depending upon the predominant	
Note (1): An unstable scar is one where, for		disability. Do not combine with ratings	
any reason, there is frequent loss of cov-		under DC 6350.	
ering of skin over the scar.		7811 Tuberculosis luposa (lupus vulgaris), active or	
Note (2): A superficial scar is one not asso-		inactive:	
ciated with underlying soft tissue damage. 04 Scars, superficial, painful on examination	10	Rate under §§ 4.88c or 4.89, whichever is appropriate.	
Note (1): A superficial scar is one not asso-	10	7813 Dermatophytosis (ringworm: of body, tinea	
ciated with underlying soft tissue damage.		corporis; of head, tinea capitis; of feet, tinea pedis;	
Note (2): In this case, a 10-percent evalua-		of beard area, tinea barbae; of nails, tinea	
tion will be assigned for a scar on the tip		unguium; of inguinal area (jock itch), tinea cruris):	
of a finger or toe even though amputation		Rate as disfigurement of the head, face, or	
of the part would not warrant a compen-		neck (DC 7800), scars (DC's 7801, 7802,	
sable evaluation.		7803, 7804, or 7805), or dermatitis (DC	
(See §4.68 of this part on the amputation		7806), depending upon the predominant	
rule.)		disability.	
05 Scars, other; Rate on limitation of function of		7815 Bullous disorders (including pemphigus	
affected part. 06 Dermatitis or eczema.		vulgaris, pemphigus foliaceous, bullous pemphigoid, dermatitis herpetiformis, epidermolysis	
More than 40 percent of the entire body or		bullosa acquisita, benign chronic familial	
more than 40 percent of exposed areas		pemphigus (Hailey-Hailey), and porphyria cutanea	
affected, or; constant or near-constant		tarda):	
systemic therapy such as corticosteroids		More than 40 percent of the entire body or	
or other immunosuppressive drugs re-		more than 40 percent of exposed areas	
quired during the past 12-month period	60	affected, or; constant or near-constant	
20 to 40 percent of the entire body or 20 to		systemic therapy such as corticosteroids	
40 percent of exposed areas affected, or;		or other immunosuppressive drugs re-	
systemic therapy such as corticosteroids		quired during the past 12-month period	
or other immunosuppressive drugs re-		20 to 40 percent of the entire body or 20 to	
quired for a total duration of six weeks or more, but not constantly, during the past		40 percent of exposed areas affected, or;	
12-month period	30	systemic therapy such as corticosteroids or other immunosuppressive drugs re-	
At least 5 percent, but less than 20 percent,		quired for a total duration of six weeks or	
of the entire body, or at least 5 percent,		more, but not constantly, during the past	
but less than 20 percent, of exposed		12-month period	
areas affected, or; intermittent systemic		At least 5 percent, but less than 20 percent,	
therapy such as corticosteroids or other		of the entire body, or at least 5 percent,	
immunosuppressive drugs required for a		but less than 20 percent, of exposed	
total duration of less than six weeks dur-		areas affected, or; intermittent systemic	
ing the past 12-month period	10	therapy such as corticosteroids or other	
Less than 5 percent of the entire body or		immunosuppressive drugs required for a	
less than 5 percent of exposed areas af- fected, and; no more than topical therapy		total duration of less than six weeks dur- ing the past 12-month period	
required during the past 12-month period	0	Less than 5 percent of the entire body or	
Or rate as disfigurement of the head, face,		exposed areas affected, and; no more	
or neck (DC 7800) or scars (DC's 7801,		than topical therapy required during the	
7802, 7803, 7804, or 7805), depending		past 12-month period	
upon the predominant disability.		Or rate as disfigurement of the head, face,	
07 American (New World) leishmaniasis		or neck (DC 7800) or scars (DC's 7801,	
mucocutaneous, espundia):		7802, 7803, 7804, or 7805), depending	
Rate as disfigurement of the head, face, or		upon the predominant disability.	
neck (DC 7800), scars (DC's 7801, 7802,		7816 Psoriasis:	
7803, 7804, or 7805), or dermatitis (DC		More than 40 percent of the entire body or	
7806), depending upon the predominant disability.		more than 40 percent of exposed areas affected, or; constant or near-constant	
Note: Evaluate non-cutaneous (visceral)		systemic therapy such as corticosteroids	
leishmaniasis under DC 6301 (visceral)		or other immunosuppressive drugs re-	
leishmaniasis).		guired during the past 12-month period	
08 Old World leishmaniasis (cutaneous, Oriental		20 to 40 percent of the entire body or 20 to	
sore):		40 percent of exposed areas affected, or;	
Rate as disfigurement of the head, face, or		systemic therapy such as corticosteroids	
neck (DC 7800), scars (DC's, 7801, 7802,		or other immunosuppressive drugs re-	
7803, 7804, or 7805), or dermatitis (DC		quired for a total duration of six weeks or	
7806), depending upon the predominant		more, but not constantly, during the past	
disabililty.		12-month period	

§4.118

	Rat- ing		Rat- ing
At least 5 percent, but less than 20 percent,		Note: If a skin malignancy requires therapy	
of the entire body, or at least 5 percent,		that is comparable to that used for sys-	
but less than 20 percent, of exposed		temic malignancies, i.e., systemic chemo-	
areas affected, or; intermittent systemic		therapy, X-ray therapy more extensive	
therapy such as corticosteroids or other		than to the skin, or surgery more exten-	
immunosuppressive drugs required for a		sive than wide local excision, a 100-per-	
total duration of less than six weeks dur-	10	cent evaluation will be assigned from the	
ing the past 12-month period	10	date of onset of treatment, and will con- tinue, with a mandatory VA examination	
Less than 5 percent of the entire body or		six months following the completion of	
exposed areas affected, and; no more than topical therapy required during the		such antineoplastic treatment, and any	
past 12-month period	0	change in evaluation based upon that or	
Or rate as disfigurement of the head, face,	- U	any subsequent examination will be sub-	
or neck (DC 7800) or scars (DC's 7801,		ject to the provisions of §3.105(e) of this	
7802, 7803, 7804, or 7805), depending		chapter. If there has been no local recur-	
upon the predominant disability.		rence or metastasis, evaluation will then	
Exfoliative dermatitis (erythroderma):		be made on residuals. If treatment is con-	
Generalized involvement of the skin, plus		fined to the skin, the provisions for a 100-	
systemic manifestations (such as fever,		percent evaluation do not apply.	
weight loss, and hypoproteinemia), and;		7819 Benign skin neoplasms:	
constant or near-constant systemic ther-		Rate as disfigurement of the head, face, or	
apy such as therapeutic doses of		neck (DC 7800), scars (DC's 7801, 7802,	
corticosteroids, immunosuppressive		7803, 7804, or 7805), or impairment of function.	
retinoids, PUVA (psoralen with long-wave			
ultraviolet-A light) or UVB (ultraviolet-B		7820 Infections of the skin not listed elsewhere (in- cluding bacterial, fungal, viral, treponemal and	
light) treatments, or electron beam ther- apy required during the past 12-month pe-		parasitic diseases):	
riod	100	Rate as disfigurement of the head, face, or	
Generalized involvement of the skin without	100	neck (DC 7800), scars (DC's 7801, 7802,	
systemic manifestations, and; constant or		7803, 7804, or 7805), or dermatitis (DC	
near-constant systemic therapy such as		7806), depending upon the predominant	
therapeutic doses of corticosteroids, im-		disability.	
munosuppressive retinoids, PUVA		7821 Cutaneous manifestations of collagen-vas-	
(psoralen with long-wave ultraviolet-A		cular diseases not listed elsewhere (including	
light) or UVB (ultraviolet-B light) treat-		scleroderma, calcinosis cutis, and dermato-	
ments, or electron beam therapy required		myositis):	
during the past 12-month period	60	More than 40 percent of the entire body or	
Any extent of involvement of the skin, and;		more than 40 percent of exposed areas	
systemic therapy such as therapeutic		affected, or; constant or near-constant	
doses of corticosteroids, immuno-		systemic therapy such as corticosteroids	
suppressive retinoids, PUVA (psoralen with long-wave ultraviolet-A light) or UVB		or other immunosuppressive drugs re- quired during the past 12-month period	60
(ultraviolet-B light) treatments, or electron		20 to 40 percent of the entire body or 20 to	00
beam therapy required for a total duration		40 percent of exposed areas affected, or;	
of six weeks or more, but not constantly,		systemic therapy such as corticosteroids	
during the past 12-month period	30	or other immunosuppressive drugs re-	
Any extent of involvement of the skin, and;		quired for a total duration of six weeks or	
systemic therapy such as therapeutic		more, but not constantly, during the past	
doses of corticosteroids, immuno-		12-month period	30
suppressive retinoids, PUVA (psoralen		At least 5 percent, but less than 20 percent,	
with long-wave ultraviolet-A light) or UVB		of the entire body, or at least 5 percent,	
(ultraviolet-B light) treatments, or electron		but less than 20 percent, of exposed	
beam therapy required for a total duration		areas affected, or; intermittent systemic	
of less than six weeks during the past 12- month period	10	therapy such as corticosteroids or other	
Any extent of involvement of the skin, and;		immunosuppressive drugs required for a total duration of less than six weeks dur-	
no more than topical therapy required dur-		ing the past 12-month period	10
ing the past 12-month period	0	Less than 5 percent of the entire body or	10
Malignant skin neoplasms (other than malig-	ľ	exposed areas affected, and; no more	
nt melanoma):		than topical therapy required during the	
Rate as disfigurement of the head, face, or		past 12-month period	0
neck (DC 7800), scars (DC's 7801, 7802,		Or rate as disfigurement of the head, face,	-
7803, 7804, or 7805), or impairment of		or neck (DC 7800) or scars (DC's 7801,	
function.		7802, 7803, 7804, or 7805), depending	
		upon the predominant disability.	
		7822 Papulosquamous disorders not listed else-	
		where (including lichen planus, large or small	
		plaque parapsoriasis, pityriasis lichenoides et	
		varioliformis acuta (PLEVA), lymphomatoid	
		papulosus, and pityriasis rubra pilaris (PRP)):	

§4.118

38 CFR Ch. I (7-1-05 Edition)

	Rat-			Rat-
Many them 40 means of the antime back and	ing		Deserved debilitation and a deserved as a	ing
More than 40 percent of the entire body or more than 40 percent of exposed areas			Recurrent debilitating episodes occurring at least four times during the past 12-month	
affected, and; constant or near-constant			period, and; requiring intermittent sys-	
systemic medications or intensive light therapy required during the past 12-month			temic immunosuppressive therapy for control	30
period	60		Recurrent episodes occurring one to three	30
20 to 40 percent of the entire body or 20 to			times during the past 12-month period,	
40 percent of exposed areas affected, or;			and; requiring intermittent systemic im-	10
systemic therapy or intensive light therapy required for a total duration of six weeks			munosuppressive therapy for control Or rate as disfigurement of the head, face,	10
or more, but not constantly, during the			or neck (DC 7800) or scars (DC's 7801,	
past 12-month period	30		7802, 7803, 7804, or 7805), depending	
At least 5 percent, but less than 20 percent,		7927	upon the predominant disability. Erythema multiforme; Toxic epidermal	
of the entire body, or at least 5 percent, but less than 20 percent, of exposed			rolysis:	
areas affected, or; systemic therapy or in-			Recurrent debilitating episodes occurring at	
tensive light therapy required for a total			least four times during the past 12-month	
duration of less than six weeks during the	10		period despite ongoing immuno- suppressive therapy	60
past 12-month period Less than 5 percent of the entire body or	10		Recurrent episodes occurring at least four	
exposed areas affected, and; no more			times during the past 12-month period,	
than topical therapy required during the			and; requiring intermittent systemic im- munosuppressive therapy	30
past 12-month period Or rate as disfigurement of the head, face,	0		Recurrent episodes occurring during the	30
or neck (DC 7800) or scars (DC's 7801,			past 12-month period that respond to	
7802, 7803, 7804, or 7805), depending			treatment with antihistamines or	
upon the predominant disability.			sympathomimetics, or; one to three epi- sodes occurring during the past 12-month	
7823 Vitiligo: With exposed areas affected	10		period requiring intermittent systemic im-	
With no exposed areas affected	0		munosuppressive therapy	10
7824 Diseases of keratinization (including icthyoses,			Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801,	
Darier's disease, and palmoplantar keratoderma):			7802, 7803, 7804, or 7805), depending	
With either generalized cutaneous involve- ment or systemic manifestations, and;			upon the predominant disability.	
constant or near-constant systemic medi-		7828	Acne:	
cation, such as immunosuppressive			Deep acne (deep inflamed nodules and pus- filled cysts) affecting 40 percent or more	
retinoids, required during the past 12- month period	60		of the face and neck	30
With either generalized cutaneous involve-	00		Deep acne (deep inflamed nodules and pus-	
ment or systemic manifestations, and;			filled cysts) affecting less than 40 percent of the face and neck, or; deep acne other	
intermittent systemic medication, such as			than on the face and neck	10
immunosuppressive retinoids, required for a total duration of six weeks or more, but			Superficial acne (comedones, papules,	
not constantly, during the past 12-month			pustules, superficial cysts) of any extent Or rate as disfigurement of the head, face,	0
period	30		or neck (DC 7800) or scars (DC's 7801,	
With localized or episodic cutaneous in-			7802, 7803, 7804, or 7805), depending	
volvement and intermittent systemic medi- cation, such as immunosuppressive		7000	upon the predominant disability.	
retinoids, required for a total duration of		7829	Chloracne: Deep acne (deep inflamed nodules and pus-	
less than six weeks during the past 12-			filled cysts) affecting 40 percent or more	
month period No more than topical therapy required dur-	10		of the face and neck	30
ing the past 12-month period	0		Deep acne (deep inflamed nodules and pus- filled cysts) affecting less than 40 percent	
7825 Urticaria:			of the face and neck, or; deep acne other	
Recurrent debilitating episodes occurring at			than on the face and neck	10
least four times during the past 12-month period despite continuous immuno-			Superficial acne (comedones, papules, pustules, superficial cysts) of any extent	0
suppressive therapy	60		Or rate as disfigurement of the head, face,	0
Recurrent debilitating episodes occurring at			or neck (DC 7800) or scars (DC's 7801,	
least four times during the past 12-month			7802, 7803, 7804, or 7805), depending	
period, and; requiring intermittent sys- temic immunosuppressive therapy for		7830	upon the predominant disability. Scarring alopecia:	
control	30	,000	Affecting more than 40 percent of the scalp	20
Recurrent episodes occurring at least four			Affecting 20 to 40 percent of the scalp	10
times during the past 12-month period, and; responding to treatment with antihis-		7004	Affecting less than 20 percent of the scalp	0
tamines or sympathomimetics	10	1031	Alopecia areata: With loss of all body hair	10
7826 Vasculitis, primary cutaneous:			With loss of hair limited to scalp and face	0
Recurrent debilitating episodes occurring at		7832	Hyperhidrosis:	
least four times during the past 12-month period despite continuous immuno-			Unable to handle paper or tools because of moisture, and unresponsive to therapy	30
suppressive therapy	60		Able to handle paper or tools after therapy	

§4.119

	_	
	Rat- ing	Ra in
7833 Malignant melanoma: Rate as scars (DC's 7801, 7802, 7803,	Tachycardia, which may be intermittent, and trem- or, or; continuous medication required for con-	
7804, or 7805), disfigurement of the head, face, or neck (DC 7800), or impairment of function (under the appropriate body sys- tem).	trol NOTE (1): If disease of the heart is the predomi- nant finding, evaluate as hyperthyroid heart dis- ease (DC 7008) if doing so would result in a	
Note: If a skin malignancy requires therapy that is comparable to that used for sys- temic malignancies, i.e., systemic chemo- therapy, X-ray therapy more extensive	higher evaluation than using the criteria above. NOTE (2): If ophthalmopathy is the sole finding, evaluate as field vision, impairment of (DC 6080); diplopia (DC 6090); or impairment of	
than to the skin, or surgery more exten- sive than wide local excision, a 100-per-	central visual acuity (DC 6061–6079). 7902 Thyroid gland, nontoxic adenoma of	
cent evaluation will be assigned from the date of onset of treatment, and will con-	With disfigurement of the head or neck	
tinue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be sub-	NOTE: If there are symptoms due to pressure on adjacent organs such as the trachea, larynx, or esophagus, evaluate under the diagnostic code for disability of that organ, if doing so would re- sult in a higher evaluation than using this diag-	
ject to the provisions of § 3.105(e). If there has been no local recurrence or metas-	nostic code. 7903 Hypothyroidism	
tasis, evaluation will then be made on re- siduals. If treatment is confined to the	Cold intolerance, muscular weakness, cardio- vascular involvement, mental disturbance (de-	
skin, the provisions for a 100-percent evaluation do not apply.	mentia, slowing of thought, depression), bradycardia (less than 60 beats per minute),	
	and sleepiness Muscular weakness, mental disturbance, and	
Authority: 38 U.S.C. 1155)	weight gain Fatigability, constipation, and mental sluggishness	
7 FR 49596, July 31, 2002; 67 FR 58448, 5 ept. 16, 2002]	58449, Fatigability, or; continuous medication required for control	
THE ENDOCRINE SYSTEM	7904 Hyperparathyroidism Generalized decalcification of bones, kidney stopes gastroitestinal symptoms (nausea	
4.119 Schedule of ratings—endoc	Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or	
	rine Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness	
4.119 Schedule of ratings—endoc	Prine Rat-	
4.119 Schedule of ratings—endoc system.	Rating Ration NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular residuals or as endocrine dysfunction.	-
 4.119 Schedule of ratings—endoc system. 200 Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 	Rating Rat- ing NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction.	-
 4.119 Schedule of ratings—endoc system. With the system of the system of the system. Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic 	Rating Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Batring Gastrointestinal symptoms and weakness NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular residuals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as convulsions, muscular spasms (tetany), or laryn-	
 4.119 Schedule of ratings—endoc system. Wight and the system of the system. Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or 	Rating Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rating Gastrointestinal symptoms and weakness NoTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular residuals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as convulsions, muscular spasms (tetany), or laryngeal stridor) plus either catract or evidence of increased intracranial pressure (such as	
 4.119 Schedule of ratings—endoc system. Mo Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic 	Rat- ing Rat- ing Note: Second	
 4.119 Schedule of ratings—endoc system. Water and the system of the system. Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms Emotional instability, tachycardia, fatigability, and 	Rat- ing Generalized stones, gastrointestinal continuous medication Rat- ing Generalized stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rat- ing Gastrointestinal symptoms and weakness Continuous medication required for control NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased	
 4.119 Schedule of ratings—endoc system. Weither Strategy and the system of the system of the system. Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms	Rat- ing Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rat- ing Gastrointestinal symptoms and weakness NoTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure 30 Continuous medication required for control 7907 Cushing's syndrome	
 4.119 Schedule of ratings—endoc system. 700 Hyperthyroidism 71yroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	Rat- ing Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rat- ing Gastrointestinal symptoms and weakness Rat- ing Continuous medication required for control NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure 30 Continuous medication required for control 10 7907 10 As active, progressive disease including loss of muscle strength, areas of osteoporosis, hyper-	
 4.119 Schedule of ratings—endoc system. Mo Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure Tachycardia, tremor, and increased pulse pres- sure or blood pressure Tachycardia, which may be intermittent, and trem- or, or; continuous medication required for con- trol NOTE (1): If disease of the heart is the predomi- nant finding, evaluate as hyperthyroid heart dis- ease (DC 7008) if doing so would result in a 	Rat- ing Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rat- ing Gastrointestinal symptoms and weakness NoTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure 30 Tootinuous medication required for control 7907 Cushing's syndrome 10 As active, progressive disease including loss of muscle strength, areas of osteoporosis, hyper- tension, weakness, and enlargement of pituitary or adrenal gland	
 4.119 Schedule of ratings—endoc system. 100 Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms	Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rat- ing Gastrointestinal symptoms and weakness Rat- ing Continuous medication required for control NoTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either catract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure 10 As active, progressive disease including loss of muscle strength, areas of osteoporosis, hyper- tension, weakness, and enlargement of pitui- tary or adrenal gland	
 4.119 Schedule of ratings—endoc system. 700 Hyperthyroidism 71yroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure Tachycardia, tremor, and increased pulse pressure or blood pressure Tachycardia, which may be intermittent, and tremor, or; continuous medication required for control. NOTE (1): If disease of the heart is the predominant finding, evaluate as hyperthyroid heart disease (DC 7008) if doing so would result in a higher evaluation than using the criteria above. NOTE (2): If ophthalmopathy is the sole finding, evaluate as field vision, impairment of (DC 6080); diplopia (DC 6090); or impairment of 	Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rating Gastrointestinal symptoms and weakness Continuous medication required for control Continuous medication required for control NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular residuals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as convulsions, muscular spasms (tetany), or laryngeal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of intracranial pressure 30 Tousing's syndrome 10 As active, progressive disease including loss of muscle strength, areas of osteoporosis, hypertension, weakness, and enlargement of pituitary or adrenal gland 10 Loss of muscle strength and enlargement of pituitary or adrenal gland With striae, obesity, moon face, glucose intolerance, and vascular fragility	
 4.119 Schedule of ratings—endoc system. 700 Hyperthyroidism 71yroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms	Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rat- ing Gastrointestinal symptoms and weakness Rat- ing Continuous medication required for control NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure 7907 Cushing's syndrome 10 As active, progressive disease including loss of muscle strength, areas of osteoporosis, hyper- tension, weakness, and enlargement of pitui- tary or adrenal gland Ucss of muscle strength and enlargement of pitui- tary or adrenal gland With striae, obesity, moon face, glucose intoler- ance, and vascular fragility NOTE: With recovery or control, evaluate as re- siduals of adrenal insufficiency or cardio- vascular, psychiatric, skin, or skeletal complica- tions under appropriate diagnostic code.	
 4.119 Schedule of ratings—endoc system. 900 Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Gastrointestinal symptoms and weakness Gastrointestinal symptoms and weakness Continuous medication required for control NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema) Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure Continuous medication required for control 7907 Cushing's syndrome As active, progressive disease including loss of muscle strength, areas of osteoporosis, hyper- tension, weakness, and enlargement of pituitary or adrenal gland Loss of muscle strength and enlargement of pitui- tary or adrenal gland With striae, obesity, moon face, glucose intoler- ance, and vascular fragility NOTE: With recovery or control, evaluate as re- siduals of adrenal insufficiency or cardio- vascular, psychiatric, skin, or skeletal complica- tions under appropriate diagnostic code. 7908 Acromegaly Evidence of increased intracranial pressure (such	1
 4.119 Schedule of ratings—endoc system. 900 Hyperthyroidism Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or astrointestinal symptoms Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or peptic ulcer), and weakness Rat- ing Gastrointestinal symptoms and weakness NoTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular re- siduals or as endocrine dysfunction. 7905 Hypoparathyroidism Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either catract or evidence of increased intracranial pressure (such as papilledema) 60 Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure (such as continuous medication required for control 7907 Cushing's syndrome 10 As active, progressive disease including loss of muscle strength, areas of osteoporosis, hyper- tension, weakness, and enlargement of pituitary or adrenal gland 10 Loss of muscle strength and enlargement of pitui- tary or adrenal gland With striae, obesity, moon face, glucose intoler- ance, and vascular fragility NOTE: With recovery or control, evaluate as re- siduals of adrenal insufficiency or cardio- vascular, psychiatric, skin, or skeletal complica- tions under appropriate diagnostic code.	

§4.120

	Rat- ing
Enlargement of acral parts or overgrowth of long bones, and enlarged sella turcica	30
Polyuria with near-continuous thirst, and more than two documented episodes of dehydration	
requiring parenteral hydration in the past year Polyuria with near-continuous thirst, and one or two documented episodes of dehydration re-	100
quiring parenteral hydration in the past year Polyuria with near-continuous thirst, and one or	60
more episodes of dehydration in the past year not requiring parenteral hydration	40
Polyuria with near-continuous thirst 7911 Addison's disease (Adrenal Cortical	20
Hypofunction)	60
Four or more crises during the past year Three crises during the past year, or; five or more	60
episodes during the past year One or two crises during the past year, or; two to four episodes during the past year, or; weak- ness and fatigability, or; corticosteroid therapy	40
required for control	20
 than an Addisonian crisis and may consist of anorexia, nausea, vomiting, diarrhea, dehydra- tion, weakness, malaise, orthostatic hypo- tension, or hypoglycemia, but no peripheral vascular collapse. NOTE (3): Tuberculous Addison's disease will be evaluated as active or inactive tuberculosis. If inactive, these evaluations are not to be com- bined with the graduated ratings of 50 percent or 30 percent for non-pulmonary tuberculosis 	
specified under §4.88b. Assign the higher rat- ing.	
 Pluriglandular syndrome Evaluate according to major manifestations. Diabetes mellitus 	
Requiring more than one daily injection of insulin, restricted diet, and regulation of activities (avoidance of strenuous occupational and rec- reational activities) with episodes of ketoacidosis or hypoglycemic reactions requir- ing at least three hospitalizations per year or weekly visits to a diabetic care provider, plus ei- ther progressive loss of weight and strength or complications that would be compensable if	
separately evaluated	100
ated Requiring insulin, restricted diet, and regulation of	60
activities	40
glycemic agent and restricted diet	20 10

38 CFR Ch. I (7-1-05 Edition)

	Rat- ing
 NOTE (1): Evaluate compensable complications of diabetes separately unless they are part of the criteria used to support a 100 percent evaluation. Noncompensable complications are considered part of the diabetic process under diagnostic code 7913. NOTE (2): When diabetes mellitus has been conclusively diagnosed, do not request a glucose tolerance test solely for rating purposes. 7914 Neoplasm, malignant, any specified part of the endocrine system. NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residu- 	100
 als. 7915 Neoplasm, benign, any specified part of the endocrine system rate as residuals of endocrine dysfunction. 7916 Hyperpituitarism (prolactin secreting pituitary dysfunction) 7917 Hyperaldosteronism (benign or malignant) 7918 Pheochromocytoma (benign or malignant) NOTE: Evaluate diagnostic codes 7916, 7917, and 7918 as malignant or benign neoplasm as appropriate. 7919 C-cell hyperplasia of the thyroid NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. 	100

NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

§4.120 Evaluations by comparison.

Disability in this field is ordinarily to be rated in proportion to the impairment of motor, sensory or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, injury to the skull, etc. In rating disability from the conditions in the preceding sentence refer to the appropriate schedule. In rating peripheral nerve injuries and their residuals, attention should be

given to the site and character of the injury, the relative impairment in motor function, trophic changes, or sensory disturbances.

§4.121 Identification of epilepsy.

When there is doubt as to the true nature of epileptiform attacks, neurological observation in a hospital adequate to make such a study is necessary. To warrant a rating for epilepsy, the seizures must be witnessed or verified at some time by a physician. As to frequency, competent, consistent lay testimony emphasizing convulsive and immediate post-convulsive characteristics may be accepted. The frequency of seizures should be ascertained under the ordinary conditions of life (while not hospitalized).

§4.122 Psychomotor epilepsy.

The term psychomotor epilepsy refers to a condition that is characterized by seizures and not uncommonly by a chronic psychiatric disturbance as well.

(a) Psychomotor seizures consist of episodic alterations in conscious control that may be associated with automatic states, generalized convulsions, random motor movements (chewing, lip smacking, fumbling), hallucinatory phenomena (involving taste, smell, sound, vision), perceptual illusions (deja vu, feelings of loneliness, strangeness, macropsia, micropsia, dreamy states), alterations in thinking (not open to reason), alterations in memory, abnormalities of mood or affect (fear, alarm, terror, anger, dread, wellbeing), and autonomic disturbances (sweating, pallor, flushing of the face, visceral phenomena such as nausea, vomiting, defecation, a rising feeling of warmth in the abdomen). Automatic states or automatisms are characterized by episodes of irrational, irrelevant, disjointed, unconventional, asocial, purposeless though seemingly coordinated and purposeful, confused or inappropriate activity of one to several minutes (or, infrequently, hours) duration with subsequent amnesia for the seizure. Examples: A person of high social standing remained seated, muttered angrily, and rubbed the arms of his chair while the National Anthem was being played; an apparently normal person suddenly disrobed in public; a man traded an expensive automobile for an antiquated automobile in poor mechanical condition and after regaining conscious control, discovered that he had signed an agreement to pay an additional sum of money in the trade. The seizure manifestations of psychomotor epilepsy vary from patient to patient and in the same patient from seizure to seizure.

(b) A chronic mental disorder is not uncommon as an interseizure manifestation of psychomotor epilepsy and may include psychiatric disturbances extending from minimal anxiety to severe personality disorder (as distinguished from developmental) or almost complete personality disintegration (psychosis). The manifestations of a chronic mental disorder associated with psychomotor epilepsy, like those of the seizures, are protean in character.

§4.123 Neuritis, cranial or peripheral.

Neuritis, cranial or peripheral, characterized by loss of reflexes, muscle atrophy, sensory disturbances, and constant pain, at times excruciating, is to be rated on the scale provided for injury of the nerve involved, with a maximum equal to severe, incomplete, paralysis. See nerve involved for diagnostic code number and rating. The maximum rating which may be assigned for neuritis not characterized by organic changes referred to in this section will be that for moderate, or with sciatic nerve involvement, for moderately severe, incomplete paralysis.

§4.124 Neuralgia, cranial or peripheral.

Neuralgia, cranial or peripheral, characterized usually by a dull and intermittent pain, of typical distribution so as to identify the nerve, is to be rated on the same scale, with a maximum equal to moderate incomplete paralysis. See nerve involved for diagnostic code number and rating. Tic douloureux, or trifacial neuralgia, may be rated up to complete paralysis of the affected nerve.

§4.124a

§4.124a Schedule of ratings—neurological conditions and convulsive disorders.

[With the exceptions noted, disability from the following diseases and their residuals may be rated from 10 percent to 100 percent in proportion to the impairment of motor, sensory, or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, etc., referring to the appropriate bodily system of the schedule. With partial loss of use of one or more extremities from neurological lesions, rate by comparison with the mild, moderate, severe, or complete paralysis of peripheral nerves]

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM

	Rat- ing
8000 Encephalitis, epidemic, chronic:	
As active febrile disease	100
Rate residuals, minimum	10
Brain, new growth of:	
8002 Malignant	100
NOTE: The rating in code 8002 will be continued	
for 2 years following cessation of surgical,	
chemotherapeutic or other treatment modality.	
At this point, if the residuals have stabilized,	
the rating will be made on neurological residu-	
als according to symptomatology. Minimum rating	30
8003 Benign, minimum	60
Rate residuals, minimum	10
8004 Paralysis agitans:	10
Minimum rating	30
8005 Bulbar palsy	100
8007 Brain, vessels, embolism of.	
8008 Brain, vessels, thrombosis of.	
8009 Brain, vessels, hemorrhage from:	
Rate the vascular conditions under Codes 8007	
through 8009, for 6 months	100
Rate residuals, thereafter, minimum	10
8010 Myelitis:	
Minimum rating	10
8011 Poliomyelitis, anterior:	
As active febrile disease	100
Rate residuals, minimum	10
8012 Hematomyelia:	100
For 6 months Rate residuals, minimum	100
8013 Syphilis, cerebrospinal.	10
8014 Syphilis, meningovascular.	
8015 Tabes dorsalis.	
NOTE: Rate upon the severity of convulsions, pa-	
ralysis, visual impairment or psychotic involve-	
ment, etc.	
8017 Amyotrophic lateral sclerosis:	
Minimum rating	30
8018 Multiple sclerosis:	
Minimum rating	30
8019 Meningitis, cerebrospinal, epidemic:	
As active febrile disease	100
Rate residuals, minimum	10
8020 Brain, abscess of:	
As active disease	100

38 CFR Ch. I (7-1-05 Edition)

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

	Rat- ing
Rate residuals, minimum Spinal cord, new growths of:.	10
8021 Malignant	100
Minimum rating	30
8022 Benign, minimum rating	60
Rate residuals, minimum	10
8023 Progressive muscular atrophy:	
Minimum rating 8024 Syringomyelia:	30
Minimum rating	30
8025 Myasthenia gravis: Minimum rating	30
 NOTE: It is required for the minimum ratings for residuals under diagnostic codes 8000–8025, that there be ascertainable residuals. Determinations as to the presence of residuals not capable of objective verification, i.e., head-aches, dizziness, fatigability, must be approached on the basis of the diagnosis recorded; subjective residuals will be accepted when consistent with the disease and not more likely attributable to other disease or no disease. It is of exceptional importance that when ratings are assigned, the diagnostic codes utilized as bases of evaluation be cited, in addition to the codes identifying the diagnoses. 8045 Brain disease due to trauma: Purely neurological disabilities, such as hemiplegia, epileptform seizures, facial nerve paralysis, etc., following trauma to the brain, will be rated under the diagnostic code (e.g., 8045–8207). Purely subjective complaints such as headache, dizziness, insomnia, etc., recognized as symptomatic of brain trauma, will be rated 10 percent and no more under diagnostic code 9304. This 10 percent rating will not be combined with any other rating for a disability due to brain trauma. Ratings in excess of 10 percent for brain disease due to trauma under diagnostic code 9304 are not assignable in the absence of a diagnosis of multi-infarct dementia associated with brain trauma. 	

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

DISEASES OF THE CRANIAL NERVES

§4.124a

SYSTEM—Continued			Rat-
	Rat- ing		ing
 Purely neurological disabilities, such as hemiplegia, cranial nerve paralysis, etc., due to cerebral arteriosclerosis will be rated under the diagnostic codes dealing with such specific disabilities, with citation of a hyphenated diagnostic code (e.g., 8046–8207). Purely subjective complaints such as headache, dizziness, tinnitus, insomnia and irritability, recognized as symptomatic of a properly diagnosed cerebral arteriosclerosis, will be rated 10 percent and no more under diagnostic code 9305. This 10 percent rating will not be combined with any other rating for a disability due to cerebral or generalized arteriosclerosis. Ratings in excess of 10 percent for cerebral arteriosclerosis are not assignable in the absence of a diagnosis of multi-infarct dementia with cerebral arteriosclerosis. NOTE: The ratings under code 8046 apply only when the diagnostic of cerebral arteriosclerosis 		Disability from lesions of peripheral portions of first, second, third, fourth, sixth, and eighth nerves will be rated under the Organs of Spe- cial Sense. The ratings for the cranial nerves are for unilateral involvement; when bilateral, combine but without the bilateral factor. Fifth (trigeminal) cranial nerve 8205 Paralysis of: Complete	50 30 10 30
is substantiated by the entire clinical picture and not solely on findings of retinal arterio- sclerosis.		NOTE: Dependent upon relative loss of innerva- tion of facial muscles. 8307 Neuritis.	10
MISCELLANEOUS DISEASES	Rat- ing	8407 Neuralgia. Ninth (glossopharyngeal) cranial nerve. 8209 Paralysis of: Complete	30
 8100 Migraine: With very frequent completely prostrating and prolonged attacks productive of severe economic inadaptability With characteristic prostrating attacks occurring on an average once a month over last several months 	50 30	Incomplete, severe	20 10
With characteristic prostrating attacks averaging one in 2 months over last several months With less frequent attacks	10 0 30 10 0	 8210 Paralysis of: Complete	50 30 10
myoclonic type): Rate as tic; convulsive; severe cases	60 100 80 50 30 10	nial nerve. 8211 Paralysis of: Complete	30 20 10
 Rate as Sydenham's chorea. This, though a familial disease, has its onset in late adult life, and is considered a ratable disability. 8107 Athetosis, acquired. Rate as chorea. 8108 Narcolepsy. Rate as for epilepsy, petit mal. 		Complete Incomplete, severe Incomplete, moderate NOTE: Dependent upon loss of motor function of tongue. 8312 Neuritis. 8412 Neuralgia.	50 30 10

§4.124a

DISEASES OF THE PERIPHERAL NERVES

38 CFR Ch. I (7-1-05 Edition)

DISEASES OF THE PERIPHERAL NERVES— Continued

Schedule of ratings	Rat	ing			
Schedule of railings	Major Minor		Schedule of ratings		ing
The term "incomplete paralysis," with this and other peripheral nerve injuries, indi- cates a degree of lost or impaired func- tion substantially less than the type pic- ture for complete paralysis given with each nerve, whether due to varied level of the nerve lesion or to partial regenera- tion. When the involvement is wholly sensory, the rating should be for the mild, or at most, the moderate degree. The ratings for the peripheral nerves are for unilateral involvement; when bilateral,			8613 Neuritis. 8713 Neuralgia. The musculospiral nerve (radial nerve) 8514 Paralysis of: Complete; drop of hand and fingers, wrist and fingers perpetually flexed, the thumb adducted falling within the line of the outer border of the index finger; can not extend hand at wrist, extend proximal phalanges of fingers,	Major	Minor
combine with application of the bilateral factor. Upper radicular group (fifth and sixth cervicals) 8510 Paralysis of: Complete; all shoulder and elbow move- ments lost or severely affected, hand and wrist movements not affected Incomplete: Severe	70 50 40	60 40 30	extend thumb, or make lateral move- ment of wrist; supination of hand, ex- tension and flexion of elbow weak- ened, the loss of synergic motion of extensors impairs the hand grip seri- ously; total paralysis of the triceps oc- curs only as the greatest rarity Incomplete: Severe Moderate Mild	70 50 30 20	60 40 20
Mild 8610 Neuritis. 8710 Neuralgia. Middle radicular group 8511 Paralysis of:	20	20	8714 Neuralgia. NOTE: Lesions involving only "dissociat communis digitorum" and "paralysis bel communis digitorum," will not exceed th ing under code 8514.	ow the e	xtensor
Complete; adduction, abduction and ro- tation of arm, flexion of elbow, and ex- tension of wrist lost or severely af- fected	70 50 40 20 70	60 40 30 20	The median nerve 8515 Paralysis of: Complete; the hand inclined to the ulnar side, the index and middle fingers more extended than normally, consid- erable atrophy of the muscles of the thenar eminence, the thumb in the plane of the hand (ape hand); pronation incomplete and defective, absence of flexion of index finger and feeble flexion of middle fingers remain extended; cannot flex distal phalanx of thumb, defective opposition and abduction of the thumb, at right angles to palm; flexion of wrist weak- ened; pain with trophic disturbances Incomplete:	70 500	60 40
Severe	50 40 20 90 70 40 20	40 30 20 80 60 30 20	Moderate	30 10	20 10
			weakened	60	50
			Severe Moderate Mild	40 30 10	30 20 10

DISEASES OF THE PERIPHERAL NERVES— Continued

Only a divide of matting an	Rating		
Schedule of ratings	Major	Minor	
8616 Neuritis. 8716 Neuralgia.			
Musculocutaneous nerve			
8517 Paralysis of: Complete; weakness but not loss of flex- ion of elbow and supination of forearm	30	20	
Incomplete: Severe Moderate	20 10	20 10	
Mild 8617 Neuritis. 8717 Neuralgia.	0	0	
Circumflex nerve			
8518 Paralysis of: Complete; abduction of arm is impos- sible, outward rotation is weakened; muscles supplied are deltoid and teres minor	50	40	
Incomplete: Severe Moderate Mild 8618 Neuritis. 8718 Neuralgia.	30 10 0	20 10 0	
Long thoracic nerve			
8519 Paralysis of: Complete; inability to raise arm above shoulder level, winged scapula de- formity	30	20	
Incomplete: Severe	20	20	
Moderate Mild	10 0	10 0	
NOTE: Not to be combined with lost motion level.	above s	houlder	
8619 Neuritis. 8719 Neuralgia.			
NOTE: Combined nerve injuries should the erence to the major involvement, or if tent, consider radicular group ratings.			

	Rating
Sciatic nerve	
8520 Paralysis of:	
Complete; the foot dangles and drops,	
no active movement possible of mus-	
cles below the knee, flexion of knee weakened or (very rarely) lost	80
Incomplete:	00
•	
Severe, with marked muscular atrophy	60
Moderately severe	40
Moderate	20
Mild	10

§4.124a

	Rating
8620 Neuritis. 8720 Neuralgia.	
External popliteal nerve (common	
peroneal)	
8521 Paralysis of: Complete; foot drop and slight droop first phalanges of all toes, cann dorsiflex the foot, extension (dors flexion) of proximal phalanges of too lost; abduction of foot lost, adductio weakened; anesthesia covers enti dorsum of foot and toes Incomplete:	ot al es on re 40
Severe Moderate	
Mild	
Musculocutaneous nerve (superficial peroneal)	
8522 Paralysis of: Complete; eversion of foot weakened Incomplete:	30
Severe	
Moderate Mild	
8622 Neuritis.	0
8722 Neuralgia.	
Anterior tibial nerve (deep peroneal)	
8523 Paralysis of: Complete; dorsal flexion of foot lost	30
Incomplete: Severe	20
Moderate	10
Mild 8623 Neuritis.	0
8723 Neuralgia.	
Internal popliteal nerve (tibial)	
8524 Paralysis of: Complete; plantar flexion lost, frar adduction of foot impossible, flexio and separation of toes abolished; r muscle in sole can move; in lesions the nerve high in popliteal fossa, pla	on no of n-
tar flexion of foot is lost	
Severe Moderate Mild	20
8624 Neuritis.8724 Neuralgia.	
Posterior tibial nerve	
8525 Paralysis of: Complete; paralysis of all muscles sole of foot, frequently with painful p ralysis of a causalgic nature; toes ca not be flexed; adduction is weakene plantar flexion is impaired	a- n- d;
Incomplete:	
Severe Moderate	20 10

§4.124a

	Rating
Mild 8625 Neuritis. 8725 Neuralgia.	10
Anterior crural nerve (femoral)	
8526 Paralysis of: Complete; paralysis of quadriceps exten- sor muscles Incomplete:	40
Severe Moderate Mild 8626 Neuritis.	30 20 10
8726 Neuralgia. Internal saphenous nerve	
8527 Paralysis of: Severe to complete Mild to moderate 8627 Neuritis. 8727 Neuralgia.	10 0
Obturator nerve	
 8528 Paralysis of: Severe to complete Mild or moderate 8628 Neuritis. 8728 Neuralgia. 	10 0
External cutaneous nerve of thigh	
 8529 Paralysis of: Severe to complete Mild or moderate 8629 Neuritis. 8729 Neuralgia. 	10 0
Ilio-inguinal nerve	
 8530 Paralysis of: Severe to complete Mild or moderate	10 0
8540 Soft-tissue sarcoma (of neurogenic origin)	100
NOTE: The 100 percent rating will be co for 6 months following the cessation of s X-ray, antineoplastic chemotherapy o therapeutic procedure. At this point, if th been no local recurrence or metastas rating will be made on residuals.	surgical, r other ere has

THE EPILEPSIES

	Rat- ing
A thorough study of all material in §§ 4.121 and 4.122 of the preface and under the ratings for epilepsy is necessary prior to any rating ac- tion.	
8910 Epilepsy, grand mal.	
Rate under the general rating formula for major seizures.	
8911 Epilepsy, petit mal.	

38 CFR Ch. I (7-1-05 Edition)

THE EPILEPSIES—Continued

	Rat- ing
Rate under the general rating formula for minor	
seizures.	
NOTE (1): A major seizure is characterized by the generalized tonic-clonic convulsion with	
unconsciousness.	
NOTE (2): A minor seizure consists of a brief interruption in consciousness or conscious control associated with staring or rhythmic blinking of the eyes or nodding of the head ("pure" petit mal), or sudden jerking move- ments of the arms, trunk, or head (myoclonic type) or sudden loss of postural control (akinetic type).	
General Rating Formula for Major and Minor Ep-	
ileptic Seizures:	
Averaging at least 1 major seizure per month over the last year	100
Averaging at least 1 major seizure in 3 months over the last year; or more than	
10 minor seizures weekly	80
Averaging at least 1 major seizure in 4	
months over the last year; or 9–10 minor seizures per week	60
At least 1 major seizure in the last 6 months	
or 2 in the last year; or averaging at least	
5 to 8 minor seizures weekly	40
At least 1 major seizure in the last 2 years; or at least 2 minor seizures in the last 6	
months	20
A confirmed diagnosis of epilepsy with a	
history of seizures	10
NOTE (1): When continuous medication is shown necessary for the control of epilepsy, the min-	
imum evaluation will be 10 percent. This rating	
will not be combined with any other rating for	
epilepsy.	
NOTE (2): In the presence of major and minor seizures, rate the predominating type.	
NOTE (3): There will be no distinction between	
diurnal and nocturnal major seizures.	
8912 Epilepsy, Jacksonian and focal motor or sen-	
sory. 8913 Epilepsy, diencephalic.	
8913 Epilepsy, diencephalic. Rate as minor seizures, except in the presence	
of major and minor seizures, rate the predomi-	
nating type.	
8914 Epilepsy, psychomotor.	
Major seizures: Psychomotor seizures will be rated as major	
seizures under the general rating formula	
when characterized by automatic states	
and/or generalized convulsions with un-	
consciousness. Minor seizures:	
Psychomotor seizures will be rated as minor	
seizures under the general rating formula	
when characterized by brief transient epi-	
sodes of random motor movements, hallu-	
cinations, perceptual illusions, abnormali- ties of thinking, memory or mood, or auto-	
nomic disturbances.	
Mental Disorders in Epilepsies: A nonpsychotic	organic

Mental Disorders in Epilepsies: A nonpsychotic organic brain syndrome will be rated separately under the appropriate diagnostic code (e.g., 9304 or 9307). In the absence of a di-agnosis of non-psychotic organic psychiatric disturbance (psy-chotic, psychoneurotic or personality disorder) if diagnosed and shown to be secondary to or directly associated with epi-lepsy will be rated separately. The psychotic or psychroneurotic disorder will be rated under the appropriate diagnostic code. The personality disorder will be rated as a dementia (e.g., diagnostic code 9304 or 9307).

Epilepsy and Unemployability: (1) Rating specialists must bear in mind that the epileptic, although his or her seizures are controlled, may find employment and rehabilitation difficult of attainment due to employer reluctance to the hiring of the epileptic

epieptic. (2) Where a case is encountered with a definite history of unemployment, full and complete development should be un-dertaken to ascertain whether the epilepsy is the determining factor in his or her inability to obtain employment. (3) The assent of the claimant should first be obtained for

(a) The assent of the clamatic should list be obtained to permission to conduct this economic and social survey. The purpose of this survey is to secure all the relevant facts and data necessary to permit of a true judgment as to the reason for his or her unemployment and should include information or to:

as to: (a) Education; (b) Occupations prior and subsequent to service; (c) Places of employment and reasons for termination; (d) Wages received; (e) Number of seizures. (4) Upon completion of this survey and current examination, the case should have rating board consideration. Where in the judgment of the rating board the veteran's unemployability is que to epilepsy and jurisdiction is not vested in that body by reason of schedular evaluations, the case should be sub-mitted to the Director, Compensation and Pension Service.

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 40 FR 42540, Sept. 15, 1975; 41 FR 11302, Mar. 18, 1976; 43 FR 45362, Oct. 2, 1978; 54 FR 4282, Jan. 30, 1989; 54 FR 49755, Dec. 1, 1989; 55 FR 154, Jan. 3, 1990; 56 FR 51653, Oct. 15, 1991; 57 FR 24364. June 9. 1992]

MENTAL DISORDERS

§4.125 Diagnosis of mental disorders.

(a) If the diagnosis of a mental disorder does not conform to DSM-IV or is not supported by the findings on the examination report, the rating agency shall return the report to the examiner to substantiate the diagnosis.

(b) If the diagnosis of a mental disorder is changed, the rating agency shall determine whether the new diagnosis represents progression of the prior diagnosis, correction of an error in the prior diagnosis, or development of a new and separate condition. If it is not clear from the available records what the change of diagnosis represents, the rating agency shall return the report to the examiner for a determination.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.126 Evaluation of disability from mental disorders.

(a) When evaluating a mental disorder, the rating agency shall consider the frequency, severity, and duration of psychiatric symptoms, the length of remissions, and the veteran's capacity for adjustment during periods of remission. The rating agency shall assign an

evaluation based on all the evidence of record that bears on occupational and social impairment rather than solely on the examiner's assessment of the level of disability at the moment of the examination.

(b) When evaluating the level of disability from a mental disorder, the rating agency will consider the extent of social impairment, but shall not assign an evaluation solely on the basis of social impairment.

(c) Delirium, dementia, and amnestic and other cognitive disorders shall be evaluated under the general rating formula for mental disorders; neurologic deficits or other impairments stemming from the same etiology (e.g., a head injury) shall be evaluated separately and combined with the evaluation for delirium, dementia, or amnestic or other cognitive disorder (see §4.25).

(d) When a single disability has been diagnosed both as a physical condition and as a mental disorder, the rating agency shall evaluate it using a diagnostic code which represents the dominant (more disabling) aspect of the condition (see §4.14).

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.127 Mental retardation and personality disorders.

Mental retardation and personality disorders are not diseases or injuries for compensation purposes, and, except as provided in §3.310(a) of this chapter, disability resulting from them may not be service-connected. However, dis-ability resulting from a mental disorder that is superimposed upon mental retardation or a personality disorder may be service-connected.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.128 Convalescence ratings following extended hospitalization.

If a mental disorder has been assigned a total evaluation due to a continuous period of hospitalization lasting six months or more, the rating agency shall continue the total evaluation indefinitely and schedule a mandatory examination six months after the veteran is discharged or released to

§4.129

nonbed care. A change in evaluation based on that or any subsequent examination shall be subject to the provisions of \$3.105(e) of this chapter.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.129 Mental disorders due to traumatic stress.

When a mental disorder that develops in service as a result of a highly stressful event is severe enough to bring about the veteran's release from active military service, the rating agency shall assign an evaluation of not less than 50 percent and schedule an examination within the six month period following the veteran's discharge to de-

38 CFR Ch. I (7–1–05 Edition)

termine whether a change in evaluation is warranted.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.130 Schedule of ratings—mental disorders.

The nomenclature employed in this portion of the rating schedule is based upon the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, of the American Psychiatric Association (DSM-IV). Rating agencies must be thoroughly familiar with this manual to properly implement the directives in §4.125 through §4.129 and to apply the general rating formula for mental disorders in §4.130. The schedule for rating for mental disorders is set forth as follows:

Rating

9201	Schizophrenia, disorganized type	
9202	Schizophrenia, catatonic type	
9203	Schizophrenia, paranoid type	
9204	Schizophrenia, undifferentiated type	
	Schizophrenia, residual type; other and unspecified types	
9208	Delusional disorder	
	Psychotic disorder, not otherwise specified (atypical psychosis)	
9211	Schizoaffective disorder	
	Delirium, Dementia, and Amnestic and Other Cognitive Disorders	
9300	Delirium	
9301	Dementia due to infection (HIV infection, syphilis, or other systemic or intracranial infections)	
9304	Dementia due to head trauma	
9305	Vascular dementia	
	Dementia of unknown etiology	
9312	Dementia of the Alzheimer's type	
	Dementia due to other neurologic or general medical conditions (endocrine disorders, metabolic disorders,	
	's disease, brain tumors, etc.) or that are substance-induced (drugs, alcohol, poisons)	
9327	Organic mental disorder, other (including personality change due to a general medical condition)	
	Anxiety Disorders	
	Generalized anxiety disorder	
	Specific (simple) phobia; social phobia	
	Obsessive compulsive disorder	
	Other and unspecified neurosis	
	Post-traumatic stress disorder	
	Panic disorder and/or agoraphobia	
9413	Anxiety disorder, not otherwise specified	
	Dissociative Disorders	
9416	Dissociative amnesia; dissociative fugue; dissociative identity disorder (multiple personality disorder)	
9417	Depersonalization disorder	
	Somatoform Disorders	
9421	Somatization disorder	
9422	Pain disorder	
9423	Undifferentiated somatoform disorder	
9424	Conversion disorder	
0405		

Schizophrenia and Other Psychotic Disorders

9425 Hypochondriasis

§4.130

		Rating
-	Mood Disorders	
9431	Cyclothymic disorder	
9432		
9433		
9434		
9435	Mood disorder, not otherwise specified	
	Chronic Adjustment Disorder	
9440	Chronic adjustment disorder General Rating Formula for Mental Disorders:	
	Total occupational and social impairment, due to such symptoms as: gross impairment in thought processes or communication; persistent delusions or hallucinations; grossly inappro- priate behavior; persistent danger of hurting self or others; intermittent inability to perform ac- tivities of daily living (including maintenance of minimal personal hygiene); disorientation to	
	time or place; memory loss for names of close relatives, own occupation, or own name Occupational and social impairment, with deficiencies in most areas, such as work, school, fam- ily relations, judgment, thinking, or mood, due to such symptoms as: suicidal ideation; obses- sional rituals which interfere with routine activities; speech intermittently illogical, obscure, or irrelevant; near-continuous panic or depression affecting the ability to function independently,	100
	appropriately and effectively; impaired impulse control (such as unprovoked irritability with pe- riods of violence); spatial disorientation; neglect of personal appearance and hygiene; dif-	
	ficulty in adapting to stressful circumstances (including work or a worklike setting); inability to establish and maintain effective relationships	70
	Occupational and social impairment with reduced reliability and productivity due to such symp- toms as: flattened affect; circumstantial, circumlocutory, or stereotyped speech; panic attacks more than once a week; difficulty in understanding complex commands; impairment of short-	
	and long-term memory (e.g., retention of only highly learned material, forgetting to complete tasks); impaired judgment; impaired abstract thinking; disturbances of motivation and mood; difficulty in establishing and maintaining effective work and social relationships	50
	periods of inability to perform occupational tasks (although generally functioning satisfactorily, with routine behavior, self-care, and conversation normal), due to such symptoms as: de- pressed mood, anxiety, suspiciousness, panic attacks (weekly or less often), chronic sleep impairment, mild memory loss (such as forgetting names, directions, recent events)	30
	Occupational and social impairment due to mild or transient symptoms which decrease work ef- ficiency and ability to perform occupational tasks only during periods of significant stress, or;	
	symptoms controlled by continuous medication	10
	A mental condition has been formally diagnosed, but symptoms are not severe enough either to interfere with occupational and social functioning or to require continuous medication	0
	Eating Disorders	
0520	Anorexia nervosa	
9520 9521		
	Self-induced weight loss to less than 80 percent of expected minimum weight, with incapaci-	
	tating episodes of at least six weeks total duration per year, and requiring hospitalization	
	more than twice a year for parenteral nutrition or tube feeding	100
	Self-induced weight loss to less than 85 percent of expected minimum weight with incapaci-	
	tating episodes of six or more weeks total duration per year	60
	Self-induced weight loss to less than 85 percent of expected minimum weight with incapaci- tating episodes of more than two but less than six weeks total duration per year	30
	Binge eating followed by self-induced vomiting or other measures to prevent weight gain, or re- sistance to weight gain even when below expected minimum weight, with diagnosis of an eat-	00
	ing disorder and incapacitating episodes of up to two weeks total duration per year	10
	sistance to weight gain even when below expected minimum weight, with diagnosis of an eat- ing disorder but without incapacitating episodes	0
	ing decider but without incapacitating episodes	0

NOTE: An incapacitating episode is a period during which bed rest and treatment by a physician are required.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996]

§4.149

DENTAL AND ORAL CONDITIONS

X4.140 INCSCIVCU	§4.1	149	Reserved	11
------------------	------	-----	----------	----

§4.150 Schedule of ratings—dental and oral conditions.

		Rat- ing
9900	Maxilla or mandible, chronic osteomyelitis or	
oste	eoradionecrosis of:	
	Rate as osteomyelitis, chronic under diag-	
9901	nostic code 5000. Mandible, loss of, complete, between angles	100
9902	Mandible, loss of approximately one-half:	100
	Involving temporomandibular articulation	50
9903	Not involving temporomandibular articulation	30
9903	Mandible, nonunion of: Severe	30
	Moderate	10
	NOTE—Dependent upon degree of motion	
0004	and relative loss of masticatory function.	
9904	Mandible, malunion of: Severe displacement	20
	Moderate displacement	10
	Slight displacement	0
	NOTE—Dependent upon degree of motion	
	and relative loss of masticatory function.	
9905 tion	Temporomandibular articulation, limited mo-	
uon	Inter-incisal range:	
	0 to 10 mm	40
	11 to 20 mm	30
	21 to 30 mm	20
	31 to 40 mm Range of lateral excursion:	10
	0 to 4 mm	10
	NOTE-Ratings for limited inter-incisal move-	
	ment shall not be combined with ratings	
	for limited lateral excursion.	
9906	Ramus, loss of whole or part of:	
	Involving loss of temporomandibular articu- lation	
	Bilateral	50
	Unilateral	30
	Not involving loss of temporomandibular ar-	
	ticulation Bilateral	30
	Unilateral	20
9907	Ramus, loss of less than one-half the sub-	20
star	nce of, not involving loss of continuity:	
	Bilateral	20
9908	Unilateral	10 30
9908	Condyloid process, loss of, one or both sides Coronoid process, loss of:	30
5505	Bilateral	20
	Unilateral	10
9911	Hard palate, loss of half or more:	
	Not replaceable by prosthesis	30
9912	Replaceable by prosthesis Hard palate, loss of less than half of:	10
3312	Not replaceable by prosthesis	20
	Replaceable by prosthesis	0
9913	Teeth, loss of, due to loss of substance of	
bod	y of maxilla or mandible without loss of con-	
tinui	ity:	
unu	Where the lost masticatory surface cannot be restored by suitable prosthesis:	
unu		
unu	Loss of all teeth	40
	Loss of all upper teeth	40 30
	Loss of all teeth Loss of all upper teeth Loss of all lower teeth	
	Loss of all teeth Loss of all upper teeth Loss of all lower teeth All upper and lower posterior teeth	30 30
	Loss of all teeth Loss of all upper teeth Loss of all lower teeth	30

38 CFR Ch. I (7-1-05 Edition)

		Rat- ing
	All upper anterior teeth missing	10
	All lower anterior teeth missing All upper and lower teeth on one	10
	side missing	10
	Where the loss of masticatory surface can	
	be restored by suitable prosthesis NOTE—These ratings apply only to bone	0
	loss through trauma or disease such as	
	osteomyelitis, and not to the loss of the	
	alveolar process as a result of periodontal	
	disease, since such loss is not considered	
	disabling.	
9914	Maxilla, loss of more than half:	
	Not replaceable by prosthesis	100
	Replaceable by prosthesis	50
9915	Maxilla, loss of half or less:	
	Loss of 25 to 50 percent:	40
	Not replaceable by prosthesis	40
	Replaceable by prosthesis Loss of less than 25 percent:	30
	Not replaceable by prosthesis	20
	Replaceable by prosthesis	20
9916	Maxilla, malunion or nonunion of:	l v
00.0	Severe displacement	30
	Moderate displacement	10
	Slight displacement	0

[59 FR 2530, Jan. 18, 1994]

APPENDIX A TO PART 4—TABLE OF AMENDMENTS AND EFFECTIVE DATES SINCE 1946

Sec.	
4.16	Last sentence; March 1, 1963.
4.17	October 7, 1948.
4.17a	March 1, 1963.
4.29	Introductory portion preceding paragraph (a) March 1, 1963.
	Paragraph (a) "first day of continuous hos pitalization"; April 8, 1959.
	Paragraph (a) "terminated last day of month" December 1, 1962.
	Paragraph (a) penultimate sentence; November 13, 1970.
	Paragraph (b); April 8, 1959.
	Paragraph (c); August 16, 1948.
	Paragraph (d); August 16, 1948.
	Paragraph (e); March 1, 1963.
	Paragraph (f); August 9, 1976.
	NOTE: Application of this section to psycho
	neurotic and psychophysiologic disorders et
	fective October 1, 1961.
4.30	Introductory portion of paragraph (a) preceding
	subparagraph (1); July 6, 1950.
	Paragraph (a)(1); June 9, 1952.
	Paragraph (a)(2); June 9, 1952.
	Paragraph (a)(3); June 9, 1952. Effective as to outpatient treatment March 10, 1976.
	Paragraph (b)(1); March 1, 1963.
	Paragraph (b)(2); August 9, 1976.
4.55	Paragraph (b) first sentence; March 1, 1963.
4.63	June 17, 1948.
4.64	October 1, 1956.
4.71a	Diagnostic Code 5000—60 percent; February 1 1962.
	Diagnostic Code 5000 NOTE (2):
	First three sentences; July 10, 1956.
	Last sentence; July 6, 1950.
	Diagnostic Code 5002-100 percent, 60 per
	cent, 40 percent, 20 percent; March 1, 1963.

Pt. 4, App.A

Sec.		Sec.	
	Diagnostic Code 5003; July 6, 1950. Diagnostic Code 5012—NOTE; March 10, 1976. In sentence following DC 5024: "except gout which will be created under 5002". Moreb 1		Dia Dia
	which will be rated under 5002"; March 1, 1963. Diagnostic Code 5051; Diagnostic Code 5052;		Dia Dia Dia
	Diagnostic Code 5053; Diagnostic Code 5053;		Dia
	Diagnostic Code 5055; September 9, 1975. Diagnostic Code 5056;		Dia
	Diagnostic Code 5164—60 percent; June 9, 1952.		Dia
	Diagnostic Code 5172; July 6, 1950. Diagnostic Code 5173; June 9, 1952.		
	Diagnostic Code 5255 "or hip"; July 6, 1950. Diagnostic Code 5257—Evaluation; July 6,		Di
	1950. Diagnostic Code 5297—(Removal of one rib)		Dia
	"or resection of 2 or more"; August 23, 1948.		Di
	Diagnostic Code 5297—NOTE (2): Reference to lobectomy; pneumonectomy and graduated ratings; February 1, 1962.		No
4.70	Diagnostic Code 5298; August 23, 1948.		
4.73	Diagnostic Code 5324; February 1, 1962. Diagnostic Code 5327; March 10, 1976.		
4.78	Diagnostic Code 5328; March 10, 1976. Last sentence; December 1, 1963.		La
4.84a	Diagnostic Code 6029—Note; August 23, 1948. Diagnostic Code 6035; September 9, 1975.	4.114	Dia
	Diagnostic Code 6076—60%: Vision 1 eye 15/ 200 and other eye 20/100; August 23, 1948.		Dia
	Diagnostic Code 6080-Note-"as to 38 U.S.C.		Dia
	1114(L)"; July 6, 1950. Diagnostic Code 6081—Words "unilateral",		
4.84b	"minimal" and all of Note; March 10, 1976. Removed-December 18, 1987 (text redesig-		Dia
4.85	nated § 4.871, December 18, 1987) March 23, 1956. December 18, 1987.		Dia
4.86 4.86a	March 23, 1956. December 18, 1987. March 23, 1956. December 18, 1987.		Dia
4.87	Tables VI and VII replaced by new Tables VI		Di
4.87a	Vla and VII December 18, 1987. Diagnostic Codes 6277 through 6297; March		Dia
	23, 1956; removed December 18, 1987. (Text from §4.84b redesignated §4.87a, December 18, 1987).		Di
4.88a	Diagnostic Code 6304—Notes (1) and (2); August 23, 1948.		Di
	Diagnostic Code 6309; March 1, 1963. Diagnostic Code 6350; 80% Evaluation and Cri-		Di
	terion for 60% and 30% Evaluations; March 10, 1976. Other Evaluations and Note; March		Di
4.89	1, 1963. Ratings for nonpulmonary TB; December 1,		Di
4.97	1949. Diagnostic Code 6600—100% Evaluations and		Dia Dia
	Criteria for 60%; September 9, 1975. Diagnostic Code 6602—Criteria for all Evalua-		Dia
	tions and Note; September 9, 1975. Diagnostic Code 6603; September 9, 1975.		Dia
	Second note following Diagnostic Code 6724;		
	December 1, 1949. Diagnostic Code 6802—Criteria for all Evalua-		Dia
	tions; September 9, 1975. Diagnostic Code 6819—Note; March 10, 1976. Diagnostic Code 6821—Evaluations and Note; August 23, 1948.	4.115a	Dia Dia Dia Dia
4.104	Diagnostic Code 7000—30 percent; July 6, 1950.		Dia
	Diagnostic Code 7000—100 percent inactive "with signs of congestive failure upon any ex-		Dia
	ertion beyond rest in bed" revoked; Diagnostic Code 7005—80 percent revoked;	4.116a	Dia
			. 01

Diagnostic Code 7007—80 percent revoked; Diagnostic Code 7015—100 percent Evaluation. Criteria for All Evaluations and NOTES (1) and (2); September 9, 1975. Diagnostic Code 7016; September 9, 1975. Diagnostic Code 7017;
Diagnostic Code 7100–20 percent; July 6, 1950.
Diagnostic Code 7101 "or more"; September 1, 1960.
Diagnostic Code 7101—NOTE (2); September 9, 1975.
Diagnostic Code 7110—Criteria for 100 percent, NOTE and 60 percent and 20 percent Evalua- tions; September 9, 1975.
Diagnostic Code 7111—NoTE; September 9, 1975.
Diagnostic Codes 7114, 7115, 7116, and NOTE; June 9, 1952.
Diagnostic Code 7117 and NOTE; June 9, 1952. NOTE following Diagnostic Code 7120; July 6, 1950.
Diagnostic Code 7121—100 percent Criterion and Evaluation and 60 percent Criterion; March 10, 1976. Criteria for 30 percent and 10 percent and NOTE; July 6, 1950.
Last sentence of NOTE following Diagnostic Code 7122; July 6, 1950. Diagnostic Codes 7304 and 7305—Evaluations;
November 1, 1962.
Diagnostic Code 7308—Evaluations; April 8, 1959.
Diagnostic Code 7312—70% Evaluation and 50% Evaluation and Criterion; March 10, 1976.
Diagnostic Code 7313—20% Evaluation; March 10, 1976.
Diagnostic Code 7319—Evaluations; November 1, 1962.
Diagnostic Code 7321—Evaluations and Note; July 6, 1950.
Diagnostic Code 7328—Evaluations and Note; November 1, 1962.
Diagnostic Code 7329—Evaluations and Note; November 1, 1962.
Diagnostic Code 7330—60% Evaluation; No- vember 1, 1962.
Diagnostic Code 7332—60% Evaluation; No- vember 1, 1962.
Diagnostic Code 7334—50% and 30% Evalua- tions; July 6, 1950.
Diagnostic Code 7334—10% Evaluation; No- vember 1, 1962.
Diagnostic Code 7339—Criterion for 20% Eval- uation; March 10, 1976.
Diagnostic Code 7343—Note; March 10, 1976. Diagnostic Code 7345—100%, 60% and 30%
Evaluations; August 23, 1948. Diagnostic Code 7345—10% Evaluation; Feb-
ruary 17, 1955. Diagnostic Code 7345—10% Evaluation; Feb-
ruary 17, 1955. Diagnostic Code 7346—Evaluations; February
1, 1962. Diagnostic Code 7347; September 9, 1975.
Diagnostic Code 7348; March 10, 1976. Diagnostic Code 7500—Note; July 6, 1950.
Diagnostic Code 7519—20%, 40% and 60% Evaluations; March 10, 1976.
Diagnostic Code 7524—Note; July 6, 1950.
Diagnostic Code 7524—Note; July 6, 1950. Diagnostic Code 7528—Note; March 10, 1976.
Diagnostic Code 7530; September 9, 1975. Diagnostic Code 7531; September 9, 1975.
Diagnostic Code 7627—Note; March 10, 1976.

Pt. 4, App. B

Sec.	
4.117	Diagnostic Code 7703—Evaluations; August 23, 1948.
	Diagnostic Code 7709-Note; March 10, 1976. Evaluations; June 9, 1952.
	Diagnostic Code 7714; September 9, 1975.
4.118	Diagnostic Code 7714, September 9, 1975. Diagnostic Code 7801—Note (2); July 6, 1950. Diagnostic Code 7804—Note; July 6, 1950.
4.119	Diagnostic Code 7900—10% Evaluation; and Notes (2) and (3); August 13, 1981.
	Diagnostic Code 7902—20% Evaluation; August 13. 1981.
	Diagnostic Code 7903—10% Evaluation; August 13, 1981.
	Diagnostic Code 7905—10% Evaluation; August 13, 1981.
	Diagnostic Code 7907—60% Evaluation; August 13, 1981.
	Diagnostic Code 7909-40% and 20% Evalua- tion; August 13, 1981.
	Diagnostic Code 7911—Evaluations and Note; March 1, 1963; 40% and 20% Evaluations; August 13, 1981.
	Diagnostic Code 7913—Note; September 9, 1975.
4.122	Diagnostic Code 7914—Note; March 10, 1976. October 1, 1961.
4.124a	Diagnostic Code 8002, NOTE;
	Diagnostic Code 8021, NOTE;
	Diagnostic Code 8045; October 1, 1961.
	Diagnostic Code 8046; October 1, 1961.
	Diagnostic Code 8100—Evaluations; June 9, 1953.
	Diagnostic Codes 8910 through 8914; October 1, 1961.
	Diagnostic Codes 8910 through 8914 General Rating Formula—Criteria and Evaluations; September 9, 1975.
4.125– 4.132	All Diagnostic Codes under Mental Disorders; October 1, 1961, except as to evaluation for Diagnostic Codes 9500 through 9511; Sep- tember 9, 1975.

[29 FR 6718, May 22, 1964, as amended at 34 FR 5064, Mar. 11, 1969; 40 FR 42541, Sept. 15, 1975; 41 FR 11291, Mar. 18, 1976; 41 FR 34258, Aug. 13, 1976; 43 FR 45362, Oct. 2, 1978; 46 FR 43666, Aug. 31, 1981; 52 FR 44122, Nov. 18, 1987; 52 FR 46439, Dec. 7, 1987]

APPENDIX B TO PART 4-NUMERICAL INDEX OF DISABILITIES

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag- nos- tic Code No.	
5000	Osteomyelitis, acute, subacute, or chronic.
5001	Bones and Joints, tuberculosis of.
5002	Arthritis, rheumatoid (atrophic).
5003	Arthritis, degenerative, hypertrophic, or osteoarthritis.
5004	Arthritis, gonorrheal.
5005	Arthritis, pneumococcic.
5006	Arthritis, typhoid.
5007	Arthritis, syphilitic.
5008	Arthritis, streptococcic.
5009	Arthritis, other types.
5010	Arthritis, due to trauma.
5011	Bones, caisson disease of.
5012	Bones, new growths of, malignant.

38 CFR Ch. I (7-1-05 Edition)

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag- nos- tic Code No.	
5013	Osteoporosis, with joint manifestations.
5014	Osteomalacia.
5015	Bones, new growths of, benign.
5016	Osteitis deformans.
5017	Gout.
5018	Hydrarthrosis, intermittent.
5019	Bursitis.
5020	Synovitis.
5021	Myositis.
5022	
5023	Myositis ossificans.
5024	Tenosynovitis.
	COMBINATIONS OF DISABILITIES
5100	Anatomical loss of both hands and both feet.
5101	Loss of use of both hands and both feet.
5102	Anatomical loss of both hands and one foot.
5103	Anatomical loss of both feet and one hand.
5104	Loss of use of both hands and one foot.
5105	Loss of use of both feet and one hand.
5106	Anatomical loss of both hands.
5107	Anatomical loss of both feet.
5108	Anatomical loss of one hand and one foot.
5109	Loss of use of both hands.
5110	Loss of use of both feet.
5111	Loss of use of one hand and one foot.

AMPUTATIONS: UPPER EXTREMITY

	Arm, amputation of:
5120	Disarticulation.
5121	Above insertion of deltoid.
5122	Below insertion of deltoid.
	Forearm, amputation of:
5123	Above insertion of pronator teres.
5124	Below insertion of pronator teres.
5125	Hand, loss of use of.
5126	Five digits of one hand, amputation of:
	Four digits of one hand, amputation of:
5127	Thumb, index, middle and ring.
5128	Thumb, index, middle and little.
5129	Thumb, index, ring and little.
5130	Thumb, middle, ring and little.
5131	Index, middle, ring and little.
	Three digits of one hand, amputation of:
5132	Thumb, index and middle.
5133	Thumb, index and ring.
5134	Thumb, index and little.
5135	Thumb, middle and ring.
5136	Thumb, middle and little.
5137	Thumb, ring and little.
5138	Index, middle and ring.
5139	Index, middle and little.
5140	Index, ring and little.
5141	Middle, ring and little.
	Two digits of one hand, amputation of:
5142	Thumb and index.
5143	Thumb and middle.
5144	Thumb and ring.
5145	Thumb and little.
5146	Index and middle.
5147	Index and ring.
5148	Index and little.
5149	Middle and ring.
5150	Middle and little.
5151	Ring and little.
5152	Thumb, amputation of.
5153	Index finger, amputation of.

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

	[ACOTE, SOBACOTE, ON CHINOMIC DISEASES]
Diag-	
nos-	
tic Code	
No.	
5154 5155	Middle finger, amputation of.
5155	Ring finger, amputation of. Little finger, amputation of.
	AMPUTATIONS: LOWER EXTREMITY
	Thigh, amputation of:
5160	Disarticulation.
5161	Upper third.
5162	Middle or lower thirds.
5163	Leg, amputation of: With defective stump.
5164	With loss of natural knee action.
5165	At a lower level.
5166	Forefoot, amputation proximal to metatarsal bones.
5167	Foot, loss of use of.
5170	Toes, all, amputation of, without metatarsal loss.
5171 5172	Toe, great, amputation of. Toe, other, amputation of.
5172	Toes, three or more, amputation of, not including
-	great toe.
	THE SHOULDER AND ARM
5200	Scapulohumeral articulation, ankylosis of.
5200 5201	Arm, limitation of motion of.
5202	Humerus, other impairment of.
5203	Clavicle or scapula, impairment of.
	THE ELBOW AND FOREARM
5205	Elbow, ankylosis of.
5206 5207	Forearm, limitation of flexion of. Forearm, limitation of extension of
5208	Forearm, flexion limited to 100° and extension to 45°.
5209	Elbow, other impairment of.
5210	Radius and ulna, nonunion of, with flail false joint.
5211	Ulna, impairment of.
5212 5213	Radius, impairment of. Supination and pronation, impairment of.
5210	
	THE WRIST AND HAND
5214	Wrist, ankylosis.
5215	Wrist, limitation of motion of.
5216	Five digits of one hand, unfavorable ankylosis of.
5217 5218	Four digits of one hand, unfavorable ankylosis of. Three digits of one hand, unfavorable ankylosis of.
5219	Two digits of one hand, unfavorable ankylosis of.
5220	Five digits of one hand, favorable ankylosis of.
5221	Four digits of one hand, favorable ankylosis of.
5222	Three digits of one hand, favorable ankylosis of.
5223 5224	Two digits of one hand, favorable ankylosis of.
5224 5225	Thumb, ankylosis of. Index finger, ankylosis of.
5226	Middle finger, ankylosis of.
5227	Finger, any other, ankylosis of.
	THE HIP AND THIGH
5250	Hip, ankylosis of.
5251	Thigh, limitation of extension of.
5252	Thigh, limitation of flexion of.
5253	Thigh, impairment of.
5254	Hip, flail joint.

Pt. 4, App. B

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag- nos- tic Code No.	
5257	Knee, other impairment of.
5258	Cartilage, semilunar, dislocated.
5050	Contilence consilument removal of

- 5259
- Cartilage, semilunar, removal of. Leg, limitation of flexion of. Leg, limitation of extension of. Tibia and fibula, impairment of. 5260
- 5261
- 5262
- 5263 Genu recurvatum.

THE ANKLE

- 5270 Ankle, ankylosis of.
- 5271 Ankle, limited motion of.
- 5272 Subastragalar or tarsal joint, ankylosis of.
- 5273 Os calcis or astragalus, malunion of.
- 5274 Astragalectomy.

SHORTENING OF THE LOWER EXTREMITY

- 5275 Bones, of the lower extremity, shortening of.
 - - THE FOOT
 - Flatfoot, acquired. Weak foot, bilateral.
- 5278 Claw foot (pes cavus), acquired. 5279
- Metatarsalgia, anterior (Morton's disease). Hallux valgus. 5280
- 5281 Hallux rigidus.

5276

5277

- 5282 Hammer toe.
- 5283 Tarsal, or metatarsal bones, malunion of, or nonunion of.
- 5284 Foot injuries, other.

THE SPINE

- 5285 Vertebra, fracture of, residuals.
- 5286 Spine, complete bony fixation (ankylosis) of. Spine, ankylosis of, cervical.
- 5287
- 5288 Spine, ankylosis of, dorsal. 5289
- Spine, ankylosis of, lumbar. Spine, limitation of motion of, cervical. 5290
- 5291 Spine, limitation of motion of, dorsal.
- 5292 Spine, limitation of motion of, lumbar.
- 5293 Intervertebral disc syndrome.
- 5294 Sacroiliac injury and weakness.
- 5295 Lumbosacral strain.

THE SKULL

5296 Skull, loss of part of, both inner and outer tables.

THE RIBS

5297 Ribs, removal of.

THE COCCYX

Coccyx, removal of.	
MUSCLE INJURIES	

E201	Group I-Extrinsic muscles of shoulder girdle	

- Group I-Extrinsic muscles of shoulder girdle. Group II-Extrinsic muscles of shoulder girdle. 5302
- Group III—Intrinsic muscles of shoulder girdle. Group IV—Intrinsic muscles of shoulder girdle. 5303
- 5304
- 5305 Group V—Flexor muscles of the elbow. 5306
- Group VI-Extensor muscles of the elbow. Group VII-Muscles arising from internal condyle of 5307 . humerus.

5256 Knee, ankylosis of.

Femur, impairment of.

THE KNEE AND LEG

5254

5255

5298

Pt. 4, App. B

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

38 CFR Ch. I (7-1-05 Edition)

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

	[ACOTE, SOBACOTE, ON ONNONIC DISEASES]		[ACOTE, SUBACOTE, ON CHINOMIC DISEASES]
Diag-		Diag-	
nos-		nos-	
tic		tic	
Code No.		Code No.	
5308	Group VIII—Muscles arising mainly from external condyle of humerus.	6054	Blindness in both eyes having only light perception and anatomical loss of one hand and one foot.
5309	Group IX—Intrinsic muscles of the hand.	6055	Blindness in both eyes having only light perception
5310	Group X—Intrinsic muscles of the foot.	0000	and loss of use of both hands.
5311	Group XI—Posterior and lateral muscles of the leg.	6056	Blindness in both eyes having only light perception
5312	Group XII—Anterior muscles of the leg.		and loss of use of both feet.
5313	Group XIII—Posterior thigh group.	6057	Blindness in both eyes having only light perception
5314	Group XIV—Anterior thigh group.		and loss of use of one hand and one foot.
5315 5316	Group XV—Mesial thigh group.	6058	Blindness in both eyes having only light perception
5310	Group XVI—Pelvic girdle group 1. Group XVII—Pelvic girdle group 2.	6059	and anatomical loss of one hand.
5318	Group XVIII—Pelvic girdle group 3.	0059	Blindness in both eyes having only light perception and anatomical loss of one foot.
5319	Group XIX—Muscles of the abdominal wall.	6060	Blindness in both eyes having only light perception
5320	Group XX—Spinal muscles.	0000	and loss of use of one hand.
5321	Group XXI—Muscles of respiration.	6061	Blindness in both eyes having only light perception
5322	Group XXII—Lateral, supra and infrahyoid group.		and loss of use of one foot.
5323	Group XXIII—Lateral and posterior muscles of the neck.	6062	Blindness in both eyes having only light perception.
5324	Diaphragm, rupture of.		IMPAIRMENT OF CENTRAL VISUAL ACUITY
5325	Muscle injury, facial muscles.		
5326	Muscle hernia.		Blindness, anatomical loss, one eye:
	DISEASES OF THE EYE	6063	Other blind (5/200 or less).
		6064	Other impaired (20/200 or less).
6000	Uveitis.	6065 6066	Other impaired. Other normal.
6001	Keratitis.	0000	Blindness, light perception only one eye:
6002	Scleritis.	6067	Other blind (5/200 or less).
6003	Iritis.	6068	Other impaired (20/200 or less).
6004	Cyclitis.	6069	Other impaired.
6005 6006	Choroiditis. Retinitis.	6070	Other normal.
6007	Hemorrhage, intra-ocular, recent.		Blindness, total (5/200 or less):
6008	Retina, detachment of.	6071	Both eyes.
6009	Eye, injury of, unhealed.		Blindness, total one eye (5/200 or less):
6010	Eye, tuberculosis of.	6072	Other impaired (20/200 or less).
6011	Retina, localized scars.	6073	Other impaired.
6012	Glaucoma, congestive or inflammatory.	6074	Other normal. Blindness, partial (20/200 or less):
6013	Glaucoma, simple, primary, noncongestive.	6075	Both eyes.
6014	New growths, malignant, eyeball.		One eye:
6015 6016	New growths, benign, eyeball and adnexa.	6076	Other impaired.
6017	Nystagmus, central. Conjunctivitis, trachomatous, chronic.	6077	Other normal.
6018	Conjunctivitis, other, chronic.		Blindness, partial:
6019	Ptosis, eyelids.	6078	Both eyes.
6020	Ectropion.	6079	One eye only.
6021	Entropion.	6080	Field vision, impairment of.
6022	Lagophthalmos.	6081	Scotoma, pathological.
6023	Eyebrows, loss of.	6090	Muscle function, ocular, impairment of.
6024	Eyelashes, loss of.	6091	Symblepharon.
6025	Epiphora.	6092	Diplopia, due to limited muscle function.
6026	Neuritis, optic.		IMPAIRMENT OF AUDITORY ACUITY
6027 6028	Cataract, traumatic. Cataract, senile, and others.		
6028	Aphakia.	6100	0% evaluation based on Table VII
6030	Accommodation, paralysis of.	6101	10% evaluation based on Table VII
6031	Dacryocystitis.	6102	20% evaluation based on Table VII
6032	Eyelids, loss of portion of.	6103	30% evaluation based on Table VII
6033	Lens, crystalline, dislocation of.	6104	40% evaluation based on Table VII
6034	Pterygium.	6105	50% evaluation based on Table VII
		6106	60% evaluation based on Table VII
	COMBINATIONS OF DISABILITIES	6107	70% evaluation based on Table VII
6050	Blindness in both eyes having only light perception	6108	80% evaluation based on Table VII
0000	and anatomical loss of both hands and both feet	6109 6110	90% evaluation based on Table VII

6050	Blindness in both eyes having only light perception
	and anatomical loss of both hands and both feet.
6051	Blindness in both eyes having only light perception
	and loss of use of both hands and both foot

- and loss of use of both hands and both feet. Blindness in both eyes having only light perception and anatomical loss of both hands. 6052
- Blindness in both eyes having only light perception and anatomical loss of both feet. 6053

DISEASES OF THE EAR

100% evaluation based on Table VII.

- 6200 Otitis media, suppurative, chronic.
- Otitis media, catarrhal, chronic. Otosclerosis. 6201 6202

6110

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag- nos- tic Code No.	
6203 6204 6205 6206 6207 6208 6209 6210 6211 6260	Otitis interna. Labyrinthitis. Meniere's syndrome. Mastoiditis. Auricle, loss or deformity. New growths, malignant, ear. New growths, benign, ear. Auditory canal, disease of. Tympanic membrane, perforation of. Tinnitus.
	OTHER SENSE ORGANS
6275 6276	Smell, loss of sense of. Taste, loss of sense of.
	SYSTEMIC DISEASES
6300 6301 6302 6304	Cholera, Asiatic. Kala-azar (visceral leishmaniasis). Leprosy. Malaria.

6301	Kala-azar (visceral leishmaniasis).
6302	Leprosy.
6304	Malaria.
6305	Filariasis.
6306	Oroya fever.
6307	Plague.
6308	Relapsing fever.
6309	Rheumatic fever.
6310	Syphilis, unspecified.
6311	Tuberculosis, military.
6313	Avitaminosis.
6314	Beriberi.
6315	Pellagra.
6316	Brucellosis (Malta or undulant fever).
6317	Typhus, scrub.
6350	Lupus erythematosus, systemic.

RESPIRATORY SYSTEM

	THE NOSE AND THROAT
6501	Rhinitis, atrophic, chronic.
6502	Septum, nasal, deflection of.
6504	Nose, loss of part of, or scars.
6510	Sinusitis, pansinusitis, chronic.
6511	Sinusitis, ethmoid, chronic.
6512	Sinusitis, frontal, chronic.
6513	Sinusitis, maxillary, chronic.
6514	Sinusitis, sphenoid, chronic.
6515	Laryngitis, tuberculous.
6516	Laryngitis, chronic.
6517	Larynx, injuries of, healed.
6518	Laryngectomy.
6519	Aphonia, organic.
6520	Larynx, stenosis of.
	THE TRACHEA AND BRONCHI

6600 Bronchitis, chronic. 6601

6602

Bronchiectasis. Asthma, bronchial.

THE LUNGS AND PLEURA

- 6701 Tuberculosis, pulmonary, chronic, far advanced, active.
- 6702 Tuberculosis, pulmonary, chronic, moderately ad-vanced, active.
- Tuberculosis, pulmonary, chronic, minimal, active. Tuberculosis, pulmonary, chronic, active, advance-ment unspecified. 6703 6704

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag- nos- tic Code	
No.	
6707	Tuberculosis, pulmonary, chronic, far advanced, ac- tive.
6708	Tuberculosis, pulmonary, chronic, moderately ad- vanced, active.
6709	Tuberculosis, pulmonary, chronic, minimal, active.
6710 6721	 Tuberculosis, pulmonary, chronic, active, advance- ment unspecified. Tuberculosis, pulmonary, chronic, far advanced, inac-
0721	tive.
6722	Tuberculosis, pulmonary, chronic, moderately ad- vanced, inactive.
6723 6724	Tuberculosis, pulmonary, chronic, minimal, inactive.
0724	Tuberculosis, pulmonary, chronic, inactive, advance- ment unspecified.
6725	Tuberculosis, pulmonary, chronic, far advanced, inac- tive.
6726	Tuberculosis, pulmonary, chronic, moderately ad- vanced, inactive.
6727	Tuberculosis, pulmonary, chronic, minimal, inactive.
6728	Tuberculosis, pulmonary, chronic, inactive, advance- ment unspecified.
6732	Pleurisy, tuberculous.
6800	Anthracosis.
6801	Silicosis.
6802	Pneumoconiosis, unspecified.
6803	Actinomycosis of lung.
6804	Streptotrichosis of lung.
6805	Blastomycosis of lung.
6806	Sporotrichosis of lung.
6807	Aspergillosis of lung.
6808	Mycosis of lung, unspecified.
6809	Lung, abscess of.
6810	Pleurisy, serofibrinous.
6811	Pleurisy, purulent (empyema).
6812	Fistula, bronchocutaneous, or bronchopleural.
6813	Lung, permanent collapse of.
6814 6815	Pneumothorax, spontaneous.
6816	Pneumonectomy. Lobectomy.
6817	Lung, chronic passive congestion of.
6818	Pleural cavity, injuries, residuals of, including gunshot
	wounds.
6819	New growths, malignant, any specified part of res- piratory system.
6820	New growths, benign, any specified part of respiratory system.
6821	Coccidioidomycosis.
	THE CARDIOVASCULAR SYSTEM
	THE HEART
7000	Rheumatic heart disease.
7001	Endocarditis, bacterial, subacute.
7002	Pericarditis, bacterial or rheumatic, acute.
7003	Adhesions, pericardial.
7004	Syphilitic heart disease.
7005	Arteriosclerotic heart disease.
7006	Myocardium, infarction of, due to thrombosis or embo- lism.
7007 7008	Hypertensive heart disease.
7008	Hyperthyroid heart disease.

- 7010 7011 7012 7013 7014
- Auricular fibrillation, paroxysmal. Auricular fibrillation, paroxysmal. Auricular fibrillation, permanent.
- Tachycardia, paroxysmal.
- Sinus tachycardia. Auriculoventricular block. 7015

457

Pt. 4, App. B

Pt. 4, App. B

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag-		Diag-	
nos- tic		nos- tic	
Code		Code	
No.		No.	
	THE ARTERIES AND VEINS	7344	New growths, benign, any specified part of digestive system.
7100	Arteriosclerosis, general.	7345	Hepatitis, infectious.
7101	Hypertensive vascular disease (essential arterial hy-	7346	Hernia, hiatal.
7110	pertension). Aorta or branches, aneurysm of.		THE GENITOURINARY SYSTEM
7111	Artery, any large artery, aneurysm of.		
7112	Artery, small aneurysmal dilatation.	7500	Kidney, removal of.
7113	Arteriovenous aneurysm, traumatic.	7501	Kidney, abscess of.
7114	Arteriosclerosis obliterans.	7502	Nephritis, chronic.
7115	Thrombo-angliitis obliterans (Buerger's disease).	7503	Pyelitis.
7116 7117	Claudication, intermittent. Raynaud's disease.	7504 7505	Pyelonephritis, chronic. Kidney, tuberculosis of, active.
7118	Angioneurotic edema.	7507	Nephrosclerosis, arteriolar.
7119	Erythromelalgia.	7508	Nephrolithiasis.
7120	Varicose veins.	7509	Hydronephrosis.
7121	Phlebitis.	7510	Ureterolithiasis.
7122	Frozen feet, residuals of (Immersion foot).	7511	Ureter, stricture of.
	THE DIGESTIVE SYSTEM	7512 7513	Cystitis, chronic. Cystitis, interstitial (Hunner), submucous or elusive
		7515	ulcer.
7200	Mouth, injuries of.	7514	Bladder, tuberculosis of.
7201	Lips, injuries of.	7515	Bladder, calculus in.
7202	Tongue, loss of, whole or part.	7516	Bladder, fistula of.
7203	Esophagus, stricture of.	7517	Bladder, injury of.
7204 7205	Esophagus, spasm of (cardiospasm). Esophagus, diverticulum of, acquired.	7518	Urethra, stricture of.
7301	Peritoneum, adhesions of.	7519 7520	Urethra, fistula of. Penis, removal of half or more.
7304	Ulcer, gastric.	7520	Penis, removal of glans.
7305	Ulcer, duodenal.	7522	Penis, deformity, with loss of erectile power.
7306	Ulcer, marginal (gastrojejunal).	7523	Testis, atrophy, complete.
7307	Gastritis, hypertrophic.	7524	Testis, removal of.
7308 7309	Postgastrectomy syndromes. Stomach, stenosis of.	7525	Epididymo-orchitis (tuberculous).
7309	Stomach, injury of, residuals.	7526	Prostate gland, resection or removal.
7311	Liver, injury of.	7527	Prostate gland injuries, infectious hypertrophy, post- operative residuals.
7312	Liver, cirrhosis of.	7528	New growths, malignant, any specified part of genito-
7313	Liver, abscess of, residuals.		urinary system.
7314	Cholecystitis, chronic.	7529	New growths, benign, any specified part of genito-
7315 7316	Cholelithiasis, chronic.		urinary system.
7310	Cholangitis, chronic. Gall bladder, injury of.		
7318	Gall bladder, removal of.		GYNECOLOGICAL CONDITIONS
7319	Irritable colon syndrome (spastic colitis, mucous coli-	7610	Vulvovaginitis.
	tis, etc.).	7611	Vaginitis.
7321	Amebiasis.	7612	Cervicitis.
7322	Dysentery, bacillary.	7613	Metritis.
7323 7324	Colitis, ulcerative. Distomiasis, intestinal or hepatic.	7614 7615	Salpingitis.
7325	Enteritis, chronic.	7615	Oophoritis. Uterus and ovaries, removal of, complete.
7326	Enterocolitis, chronic.	7618	Uterus, removal of, including corpus.
7327	Diverticulitis.	7619	Ovaries, removal of.
7328	Intestine, small, resection of.	7620	Ovaries, atrophy of both.
7329	Intestine, large, resection of.	7621	Uterus, prolapse.
7330 7331	Intestine, fistula of. Peritonitis, tuberculous, active.	7622	Uterus, displacement of.
7332	Rectum and anus, impairment of sphincter control.	7623 7624	Pregnancy, surgical complications of. Fistula, rectovaginal.
7333	Rectum and anus, stricture of.	7624	Fistula, urethrovaginal.
7334	Rectum, persistent prolapse of.	7626	
7335	Ano, fistula in.	7627	New growth, malignant, gynecological system, or
7336	Hemorrhoids, external or internal.		mammary glands.
7337	Pruritus ani.		
7338 7339	Hernia, inguinal. Hernia, ventral.		THE HEMIC AND LYMPHATIC SYSTEMS
7340	Hernia, femoral.	7700	Anemia, pernicious.
7341	Wounds, incised, healed, abdominal wall.	7701	Anemia, secondary.
7342	Visceroptosis.	7702	Agranulocytosis, acute.
7343	New growths, malignant, any specified part of diges-	7703	Leukemia.
	tive system.	7704	Polycythemia, primary.

38 CFR Ch. I (7-1-05 Edition)

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag- nos- tic Code No.	
7705	Purpura hemorrhagica.
7706	Splenectomy.
7707	Spleen, injury of, healed.
7709	Lymphogranulomatosis (Hodgkin's disease).
7710	Adenitis, cervical, tuberculous.
7711	Adenitis, axillary, tuberculous.
7712	Adenitis, inguinal, tuberculous.
7713	Adenitis, secondary.
	THE SKIN
7800	Scars, disfiguring, head, face or neck.
7801	Scars, burns, third degree.
7802	Scars, burns, second degree.
7803	Scars, superficial, poorly nourished.
7804	Scars, superficial, tender and painful.
7805	Scars, others.
7806	Eczema.
7807	Leishmaniasis, americana (mucocutaneous, espundia).
7808	Leishmaniasis, old world (cutaneous, oriental sore).
7809	Lupus erythematosus, discoid.
7810	Pinta.
7811	Tuberculosis luposa (lupus vulgaris).
7812	Verruga peruana.
7813	Dermatophytosis.
7814	Tinea barbae.
7815	Pemphigus.
7816	Psoriasis.
7817	Dermatitis exfoliativa.
7818	New growths, malignant, skin.
7819	New growths, benign, skin.

Hyperthyroidism. 7900

- 7901 Thyroid gland, toxic adenoma of.
- 7902 Thyroid gland, non-toxic adenoma of,
- 7903 Hypothyroidism.
- 7904 Hyperparathyroidism (osteitis fibrosa cystica).
- 7905 Hypoparathyroidism. Hyperpituitarism (pituitary basophilism, Cushing's syn-7907
- drome). Hyperpituitarism (acromegaly or gigantism).
- 7908
- Hypopituitarism (diabetes inspidus). 7909 7910 Hyperadrenia (adrenogenital syndrome). Addison's disease.
- 7911
- Pluriglandular syndromes. 7912
- 7913 Diabetes mellitus.
- New growths, malignant, endocrine system. 7914
- New growths, benign, endocrine system. 7915

NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

8000 Encephalitis, epidemic, chronic.

- Brain, new growth of:
- 8002 Malignant. 8003 Benign.
- 8004
- Paralysis agitans. 8005
- Bulbar palsy. Brain, vessels, embolism of. 8007
- 8008 Brain, vessels, thrombosis of.
- Brain, vessels, hemorrhage from. 8009
- Myelitis. 8010
- 8011 Poliomyelitis, anterior.
- 8012 Hematomvelia.
- 8013 Syphilis, cerebrospinal
- 8014 Syphilis, meningovascular.
- Tabes dorsalis. 8015

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

- Diag-nos-tic Code No. 8017 Amyotrophic lateral sclerosis. 8018 Multiple sclerosis. 8019 Meningitis, cerebrospinal, epidemic. Brain, abscess of. Spinal cord, new growths: 8020 8021 Malignant. Benign. 8022 8023 Progressive muscular atrophy. 8024 Syringomyelia. Myasthenia gravis. Brain disease due to trauma. 8025 8045 8046 Cerebral arteriosclerosis. 8100 Migraine. 8103 Tic, convulsive. Paramyoclonus multiplex (convulsive state, myoclonic 8104 type). 8105 Chorea, Sydenham's. 8106 Chorea, Huntington's. Athetosis, acquired. 8107 8108 Narcolepsy. THE CRANIAL NERVES
- 8205 Fifth (trigeminal) cranial nerve, paralysis of.
- Seventh (facial) cranial nerve, paralysis of 8207
- 8209 Ninth (glossopharyngeal) cranial nerve, paralysis of.
- 8210 Tenth (pneumogastric, vagus) cranial nerve, paralysis
- of. Eleventh (spinal accessory, external branch) cranial 8211 nerve, paralysis of.
- Twelfth (hypoglossal) cranial nerve, paralysis of. 8212
- 8305 Fifth (trigeminal) cranial nerve, neuritis.
- 8307
- Seventh (facial) cranial nerve, neuritis. Ninth (glossopharyngeal) cranial nerve, neuritis. 8309
- Tenth (pneumogastric, vagus) cranial nerve, neuritis. 8310
- Eleventh (spinal accessory, external branch) cranial nerve, neuritis. 8311
- 8312 Twelfth (hypoglossal) cranial nerve, neuritis
- 8407 8409 Seventh (facial) cranial nerve, neuralgia. Ninth (glossopharyngeal) cranial nerve, neuralgia.
- 8410 Tenth (pneumogastric, vagus) cranial nerve, neuralgia
- Eleventh (spinal accessory, external branch) cranial 8411 nerve, neuralgia.
- 8412 Twelfth (hypoglossal) cranial nerve, neuralgia.

PERIPHERAL NERVES: PARALYSIS

- 8510 Upper radicular group (fifth and sixth cervicals), paralysis of.
- 8511 Middle radicular group, paralysis of.
- 8512 8513 Lower radicular group, paralysis of.
- All radicular groups, paralysis of.
- 8514 The musculospiral nerve (radial nerve), paralysis of.
- 8515 8516 The median nerve, paralysis of. The ulnar nerve, paralysis of.
- 8517 Musculocutaneous nerve, paralysis of.
- 8518 Circumflex nerve, paralysis of. Long thoracic nerve, paralysis of.
- 8519
- 8520 The sciatic nerve, paralysis of. 8521
- External popliteal nerve (common peroneal), paralysis of. 8522 Musculocutaneous nerve (superficial peroneal), paral-
- ysis of. Anterior tibial nerve (deep peroneal), paralysis of.
- 8523
- 8524 Internal popliteal nerve (tibial), paralysis of.
- Posterior tibial nerve, paralysis of. Anterior crural nerve (femoral), paralysis of. 8525
- 8526 8527
- Internal saphenous nerve, paralysis of. 8528 Obturator nerve, paralysis of.

Pt. 4, App. B

Pt. 4, App. B

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag-		Diag-	
nos-		nos-	
tic Code		tic Code	
No.		No.	
8529	External cutaneous nerve of thigh, paralysis of.	9203	Schizophrenic reaction, paranoid type.
8530	Ilio-inguinal nerve, paralysis of.	9204	Schizophrenic reaction, chronic undifferentiated type.
		9205	Schizophrenic reaction, other.
	PERIPHERAL NERVES: NEURITIS	9206	Manic depressive reaction.
		9207	Psychotic depressive reaction.
8610	Upper radicular group (fifth and sixth cervicals), neu-	9208	Paranoid reaction (specify).
	ritis.	9209	Involutional psychotic reaction.
8611	Middle radicular group, neuritis.	9210	Psychotic reaction, other.
8612	Lower radicular group, neuritis.		·,····
8613	All radicular groups, neuritis.		ORGANIC BRAIN DISORDERS
8614	The musculospiral nerve (radial nerve), neuritis.		
8615	The median nerve, neuritis.	9300	Acute brain syndrome (associated with infection, trau-
8616	The ulnar nerve, neuritis.		ma, circulatory disturbance, etc.).
8617	Musculocutaneous nerve, neuritis.	9301	Chronic brain syndrome associated with central nerv-
8618	Circumflex nerve, neuritis.		ous system syphilis (all forms).
8619	Long thoracic nerve, neuritis.	9302	Chronic brain syndrome associated with intracranial
8620	The sciatic nerve, neuritis.		infections other than syphilis.
8621	External popliteal nerve (common peroneal), neuritis.	9303	Chronic brain syndrome associated with intoxication.
8622	Musculocutaneous nerve (superficial peroneal), neu-	9304	Chronic brain syndrome associated with brain trauma.
0000	ritis.	9305	Chronic brain syndrome associated with cerebral arte-
8623	Anterior tibial nerve (deep peroneal), neuritis.		riosclerosis.
8624	Internal popliteal nerve (tibial) neuritis.	9306	Chronic brain syndrome associated with circulatory
8625	Posterior tibial nerve, neuritis.		disturbance other than cerebral arteriosclerosis.
8626	Anterior crural nerve (femoral), neuritis.	9307	Chronic brain syndrome associated with convulsive
8627	Internal saphenous nerve, neuritis.		disorder (idiopathic epilepsy).
8628	Obturator nerve, neuritis.	9308	Chronic brain syndrome associated with disturbance
8629	External cutaneous nerve of thigh, neuritis.		of metabolism, growth or nutrition.
8630	Ilio-inguinal nerve, neuritis.	9309	Chronic brain syndrome associated with intracranial
			neoplasm.
	PERIPHERAL NERVES: NEURALGIA	9310	Chronic brain syndrome associated with diseases of
8710	Upper radicular group (fifth and sixth cervicals), neu-		unknown or uncertain cause.
0710	ralgia.	9311	Chronic brain syndrome of unknown cause.
8711	Middle radicular group, neuralgia.		
8712	Lower radicular group, neuralgia.		PSYCHONEUROTIC DISORDERS
8713	All radicular groups, neuralgia.		
8714	The musculospiral nerve (radial nerve), neuralgia.	9400	Anxiety reaction.
8715	The median nerve, neuralgia.	9401	Dissociative reaction.
8716	The ulnar nerve, neuralgia.	9402	Conversion reaction.
8717	Musculocutaneous nerve, neuralgia.	9403	Phobic reaction.
8718	Circumflex nerve, neuralgia.	9404	Obsessive compulsive reaction.
8719	Long thoracic nerve, neuralgia.	9405	Depressive reaction.
8720	The sciatic nerve, neuralgia.	9406	Psychoneurotic reaction, other.
8721	External popliteal nerve (common peroneal), neu-		
	ralgia.		PSYCHOPHYSIOLOGIC DISORDERS
8722	Musculocutaneous nerve (superficial peroneal), neu-	0500	Developmente la plate proportion
	ralgia.	9500	Psychophysiologic skin reaction.
8723	Anterior tibial nerve (deep peroneal), neuralgia.	9501	Psychophysiologic cardiovascular reaction.
8724	Internal popliteal nerve (tibial), neuralgia.	9502	Psychophysiologic gastrointestinal reaction.
8725	Posterior tibial nerve, neuralgia.	9503	Psychophysiologic nervous system reaction.
8726	Anterior crural nerve (femoral), neuralgia.	9504	Psychophysiologic reaction, other.
8727	Internal saphenous nerve, neuralgia.		
8728	Obturator nerve, neuralgia.		DENTAL AND ORAL CONDITIONS
8729	External cutaneous nerve of thigh neuralgia.	9900	Maxilla or mandible, osteomyelitis of.
8730	llio-inguinal nerve, neuralgia.	9901	Mandible, loss of, complete, between angles.
		9902	Mandible, loss of approximately one-half.
	THE EPILEPSIES	9902 9903	Mandible, nonunion of.
0010	Failer and start	9903 9904	Mandible, malunion of.
8910	Epilepsy, grand mal.	9904 9905	Temporomandibular articulation, limited motion of.
8911	Epilepsy, petit mal.	9905 9906	Ramus, loss of whole or part of.
8912	Jacksonian type.	9908 9907	Ramus, loss of less than one-half the substance of,
8913	Epilepsy, diencephalic.	3301	not involving loss of continuity.
8914	Epilepsy, psychomotor.	9908	Condyloid process, loss of, one or both sides.
		9908	Coronoid process, loss of.
	PSYCHOTIC DISORDERS	9909 9910	Maxilla, loss of whole or part of substance of, non-
		3310	
9200	Schizophranic reaction simple type		union of or malunion of
9200 9201	Schizophrenic reaction, simple type.	9011	union of, or malunion of. Hard palate, loss of balf or more
9200 9201 9202	Schizophrenic reaction, simple type. Schizophrenic reaction, hebephrenic type. Schizophrenic reaction, catatonic type.	9911 9912	union of, or malunion of. Hard palate, loss of half or more. Hard palate, loss of less than half of.

38 CFR Ch. I (7-1-05 Edition)

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

	[··· ,·· ·· ,· · · · · · · · · ·
Diag	-
nos	
tic	
Cod	
No	
920	Schizophrenic reaction, paranoid type.
920	
920	
920	
920	
920	
920	
921	
	ORGANIC BRAIN DISORDERS
930	ma, circulatory disturbance, etc.).
930	Chronic brain syndrome associated with central nerv- ous system syphilis (all forms).
930	
000	
930	· · · · · · · · · · · · · · · · · · ·
930	
930	 Chronic brain syndrome associated with cerebral arte- riosclerosis.
930	Chronic brain syndrome associated with circulatory disturbance other than cerebral arteriosclerosis.
930	
930	
930	
931	
931	
	PSYCHONEUROTIC DISORDERS
940	Anxiety reaction.
940	- ,
940	
940	
940	
940	•
940	S Psychoneurotic reaction, other.
	PSYCHOPHYSIOLOGIC DISORDERS
950	Psychophysiologic skin reaction.
950	Psychophysiologic cardiovascular reaction.
950	Psychophysiologic gastrointestinal reaction.
950	
950	
	DENTAL AND ORAL CONDITIONS
990	Maxilla or mandible, osteomyelitis of.
990	
990	· · · · · · · · · · · · · · · · · · ·
990	

- 460

[ACUTE, SUBACUTE, OR CHRONIC DISEASES]

Diag- nos- tic Code No.						
0012	Tooth	loss of	duo to	loss of	f cubetanco	of body of

9913 Teeth, loss of, due to loss of substance of body of maxilla or mandible.

[29 FR 6718, May 22, 1964, as amended at 34 FR 5064, Mar. 11, 1969, 52 FR 44122, Nov. 18, 1987; 53 FR 24938, July 1, 1988]

APPENDIX C TO PART 4—ALPHABETICAL INDEX OF DISABILITIES

	Diag- nostic Code No.
Abscess:	
Brain	8020
Kidney	7501
Liver	7313
Lung	6809
Actinomycosis, lung	6803
Addison's disease	7911
Adenitis, secondary	7713
Adenoma, thyroid:	
Nontoxic	7902
Toxic	7901
Adhesions:	
Pericardial	7003
Peritoneum	7301
Agranulocytosis	7702
Amebiasis	7321
Amputation:	
Arm:	
Disarticulation	5120
Above deltoid	5121
Below deltoid	5122
Feet, both, and hand, one	5103
Feet, both	5105
Finger (digit) individual:	5107
Thumb	5152
Index	5152
Middle	5154
Ring	5154
Little	5155
Fingers (digits) of one hand:	5150
Five	5126
Four, thumb, index, middle, ring	5120
Four, thumb, index, middle, little	5127
Four, thumb, index, ring, little	5120
Four, thumb, middle, ring, little	5129
Four, index, middle, ring, little	5130
	5131
Three, thumb, index, middle	5132
Three, thumb, index, ring Three, thumb, index, little	5133
Three, thumb, middle, ring	5135
Three, thumb, middle, little	5136
Three, thumb, ring, little	5137
Three, index, middle, ring	5138
Three, index, middle, little	5139
Three, index, ring, little	5140
Three, middle, ring, little	5141
Two, thumb, index	5142
Two, thumb, middle	5143
Two, thumb, ring	5144
Two, thumb, little	5145
Two, index, middle	5146
Two, index, ring	5147
Two, index, little	5148

	Diag- nostic Code No.
Two, middle, ring	5149
Two, middle, little	5150
Two, ring, little	5151
Forearm:	
Above pronator teres	5123
Below pronator teres	5124
Forefoot Hand, one, and foot, one	5166 5108
Hands, both, and feet, both	5100
Hands, both, and foot, one	5102
Hands, both	5106
Leg:	
With defective stump	5163
With loss of natural knee action	5164
At lower level	5165
Thigh: Disarticulation	5160
Upper third	5160
Middle or lower thirds	5162
Toe, great	5171
Toe, other, with removal metatarsal head	5172
Toes, all	5170
Toes, three or more	5173
Anemia:	
Pernicious	7700
Secondary	7701
Aorta or branches	7110
Arteriovenous, traumatic	7113
Artery	7111
Angioneurotic edema	7118
Ankylosis:	
Ankle	5270
Elbow	5205
Finger (digit) individual:	5004
Thumb Index	5224 5225
Middle	5225
Other	5227
Fingers (digits) of one hand, unfavorable:	
Five	5216
Four	5217
Three	5218
Two	5219 5250
Hip Knee	5256
Scapulohumeral	5200
Spine:	
Complete	5286
Cervical	5287
Dorsal	5288
Lumbar	5289
Subastragular or Tarsal Wrist	5272 5214
Anthracosis	6800
Aphakia	6029
Aphonia, organic	6519
Arteriosclerosis:	
Cerebral	8046
General	7100
Obliterans	7114
Arteriosclerotic heart disease	7005
Atrophic (rheumatoid)	5002
Gonorrheal	5002
Hypertrophic (degenerative)	5003
Other types	5009
Pneumococcic	5005
Streptococcic	5008
Syphilitic	5007
Traumatic	5010
Typhoid	5006

Pt. 4, App. C

Pt. 4, App. C

	Diag- nostic Code No.
Aspergillosis, lung	6807
Asthma, bronchial	6602
Astragalectomy	5274
Athetosis	8107
Atrophy:	
Muscular, progressive	8023
Ovaries, both	7620
Testis, both Auditory canal, disease	7523 6210
Avitaminosis	6313
Beriberi	6314
Blastomycosis, lung	6805
Blindness, anatomical loss, one eye:	
Other blind (5/200 or less)	6063
Other impaired (20/200 or less)	6064
Other impaired	6065
Other normal	6066
Blindness, light perception only:	
Both eyes	6062
One eye: Other blind, 5/200 or less	6067
Other impaired, 20/200 or less	6067 6068
Other impaired	6069
Other normal	6070
Blindness, light perception only and loss or loss of	0070
use of hands and/or feet	6050-
	6061
Blindness, total (5/200 or less): Both eyes	6071
One eye:	
Other impaired, (20/200 or less)	6072
Other impaired	6073
Other normal	6074
Blindness, partial (20/200 or less): Both eyes One eye:	6075
Other impaired	6076
Other normal	6077
Blindness, partial:	
Both eyes	6078
One eye only	6079
Block, auricular ventricular	7015
Bones, Caisson disease of	5011
Bones and joints, tuberculosis of	5001
Bronchiectasis	6601
Bronchitis	6600
Buerger's disease Brucellosis	7115 6316
Bursitis	5019
Caisson disease	5011
Calculus, bladder	7515
Cataract:	
Senile and others	6028
Traumatic	6027
Cervicitis	7612
Cholangitis	7316
Cholecystitis	7314
Cholelithiasis	7315
Cholera, Asiatic	6300
Chorea:	0100
Huntington's Sydenham's	8106
Choroiditis	8105 6005
Claw-foot (pes cavus) acquired	5278
Cirrhosis of liver	7312
Claudication, intermittent	7116
Coccidioidomycosis	6821
Colitis:	JOLI
Mucous (See Colon syndrome, irritable)	7319
Spastic (See Colon syndrome, irritable)	7319
Ulcerative	7323
Collapse, lung, permanent	6813

38 CFR Ch. I (7-1-05 Edition)

	Diag- nostic Code No.
Colon syndrome, irritable	7319
Congestion, lung, passive	6817
Conjunctivitis:	001
Trachomatous	6017
Other	6018 5298
Cushing's syndrome	7907
Cyclitis	6004
Cystitis:	
Chronic	7512
Interstitial (Hunner)	7513
Dacryocystitis	6031
Deafness	04.00
0% evaluation based on Table VII	6100
10% evaluation based on Table VII 20% evaluation based on Table VII	6101 6102
30% evaluation based on Table VII	6103
40% evaluation based on Table VII	6104
50% evaluation based on Table VII	6105
60% evaluation based on Table VII	6106
70% evaluation based on Table VII	6107
80% evaluation based on Table VII	6108
90% evaluation based on Table VII	6109
100% evaluation based on Table VII	6110
Deflection, nasal septum	6502
Dermatitis, exfoliativa	7817 7813
Dermatophytosis Diabetes mellitus	7913
Diabetes insipidus	7909
Diaphragm, rupture	5324
Dilation, aneurysmal artery	7112
Diplopia Disease:	6090
Addison's	7911
Hodgkin's	7709
Morton's	5279
Raynaud's Dislocation:	7117
Cartilage, semilunar	5258
Lens, crystalline	6033
Disorders, mental:	
Organic brain disorders:	
Organic brain disorders: Acute brain syndrome	9300
Acute brain syndrome Chronic brain syndrome associated with:	9300
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis	
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than	9301
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis	9301 9302
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication	9301 9302 9303
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis	9301 9302 9303 9304
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis	9301 9302 9303 9304
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis	9301 9302 9303 9304 9305
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi-	9301 9302 9303 9304 9305 9306
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy)	9301 9302 9303 9304 9305 9306
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or	9301 9302 9303 9304 9305 9306 9306
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition	9301 9302 9303 9304 9305 9306 9307 9308
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm	9301 9302 9303 9304 9305 9306 9307 9308
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition	9300 9301 9302 9303 9304 9305 9306 9306 9307 9306 9309 9309 9309
Acute brain syndrome Chronic brain syndrome associated with: Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Unknown cause	9301 9302 9304 9304 9306 9306 9306 9306 9308
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause	9301 9302 9303 9304 9306 9306 9306 9307 9306 9309 9310 9311
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Unknown cause Psychoneurotid disorders:	9301 9302 9304 9305 9306 9306 9306 9307 9306 9306 9310 9311 9400
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Unknown cause Psychoneurotic disorders: Anxiety reaction	930 9302 9302 9304 9306 9306 9306 9306 9306 9310 9311 9400
Acute brain syndrome Chronic brain syndrome associated with: Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Unknown cause Psychoneurotic disorders: Anxiety reaction Dissociative reaction Conversion reaction	9301 9302 9303 9304 9306 9306 9306 9306 9306 9306 9310 9311 9400 9402
Acute brain syndrome Chronic brain syndrome associated with: Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Vunknown cause Psychoneuroit disorders: Anxiety reaction Dissociative reaction Phobic reaction Obsessive compulsive reaction	9301 9302 9303 9306 9306 9306 9307 9308 9309 9311 9400 9401 9402 9402 9402
Acute brain syndrome Chronic brain syndrome associated with: Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Unknown cause Psychoneurotic disorders: Anxiety reaction Dissociative reaction Obsessive compulsive reaction Obsessive compulsive reaction Depressive reaction	9301 9302 9303 9304 9306 9306 9306 9307 9300 9300 9311 9400 9402 9402 9402 9402
Acute brain syndrome Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Intoxication Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Unknown cause Psychoneurotic disorders: Anxiety reaction Conversion reaction Obsessive compulsive reaction Depressive reaction Psychoneurotic reaction, other	9301 9302 9303 9304 9306 9306 9306 9307 9300 9300 9311 9400 9402 9402 9402 9402
Acute brain syndrome Chronic brain syndrome associated with: Chronic brain syndrome associated with: Central nervous system syphilis Intracranial infections other than syphilis Brain trauma Cerebral arteriosclerosis Circulatory disturbance other than cerebral arteriosclerosis Convulsive disorder (idiopathic epi- lepsy) Disturbance of metabolism, growth or nutrition Intracranial neoplasm Diseases of unknown or uncertain cause Unknown cause Psychoneurotic disorders: Anxiety reaction Dissociative reaction Obsessive compulsive reaction Obsessive compulsive reaction Depressive reaction	9301 9302 9304 9305 9306 9306 9307 9308 9308

Diag-nostic Code No. Psychophysiologic gastrointestinal reac-9502 tion Psychophysiologic nervous system reaction 9503 Psychophysiologic reaction, other 9504 Psychotic disorders: Schizophrenic reaction: Simple type . 9200 Hebephrenic type 9201 Catatonic type 9202 Paranoid type 9203 Chronic undifferentiated type 9204 9205 Other Manic depressive reaction 9206 Psychotic depressive reaction 9207 9208 Paranoid reaction Involutional psychotic reaction 9209 9210 Psychotic reaction, other Distomiasis, intestinal 7324 Diverticulitis, intestinal Diverticulum of esophagus 7327 7205 Dupuytren's contracture-see Ankylosis, fingers. 7322 Dysentery, bacillary Ectropion 6020 7806 7118 Eczema .. Edema, angioneurotic Embolism, brain Emphysema (No DC; follows DC 6602). 8007 8000 Encephalitis 7001 7325 Endocarditis, bacterial, subacute Enteriocolitis 7326 Entropion 6021 Enucleation, eye, see Blindness. Epilepsy: Grand mal 8910 Petit mal 8911 Jacksonian 8912 Diencephalic 8913 Psychomotor 8914 Epiphora (lacrymal duct) 6025 7119 6032 Hemoglobinuric, see Malaria. Malta Oroya 6316 6306 6308 6309 Relapsing Rheumatic Undulant 6316 Fibrillation, auricular: Paroxysmal 7011 Permanent 7012 Filariasis 6305 Fistula: 7335 Ano Bladder 7516 Bronchocutaneous or bronchopleural 6812 Intestine 7330 Rectovaginal 7624 7625 5254 Urethra Flail hip Flatfoot (pes planus) acquired 5276 Flutter, auricular 7010 Fracture, vertebra, residuals of 5285 7122 Gastritis, hypertrophic 7307 Genu, recurvatum 5263

Fever:

Glaucoma:

Congestive

Noncongestive

Diag-nostic Code No. Gout . 5017 Growths, new benign: Bones, joints and muscles 5015 Brain Digestive system 8003 7344 Ear Endocrine system 6209 7915 Eyeball and adnexa 6015 Genitourinary system 7529 Respiratory 6820 Skin Spinal cord 7819 8022 Growths, new, malignant: 5012 Bones 8002 7343 Brain Digestive system 6208 Ear Endocrine system 7914 6014 Eyeball only Genitourinary system Gynecological system or mammary glands 7528 7627 Respiratory 6819 Skin ... 7818 Spinal cord 8021 Hallux rigidus 5281 Hallux valous 5280 Hammer toe Hematomyelia 5282 8012 Hemorrhage: 8009 Brain ... Intraocular 6007 Hemorrhoids Hepatitis, infectious 7336 7345 . Hernia: Femoral 7340 7346 Hiatal Inguinal 7338 Muscle 5326 Ventral 7339 7709 Hodakin's disease Hydrarthrosis, intermittent 5018 Hvdronephrosis 7509 Hyperadrenia 7910 Hyperparathyroidism 7904 Hyperpituitarism: Acromegaly or gigantism 7908 Cushing's syndrome Hypertensive heart disease 7907 7007 Hypertensive vascular disease 7101 Hyperthyroid heart disease 7008 Hyperthyroidism 7900 Hypoadrenia Hypoparathyroidism 7911 7905 Hypopituitarism 7909 Hypothyroidism 7903 Immersion foot 7122 Impairment: Auditory acuity, see Deafness. Clavicle 5203 Elbow Eye (field vision) 5209 6080 Eye (muscle function) 6090 5255 5202 Knee Radius 5257 5212 Sphincter control 7332 5213 Supination and pronation Thigh, motion 5253 Tibia and fibula 5262 Ulna . 5211 Visual acuity, see Blindness. Infarction of myocardium 7006

Pt. 4, App. C

6012

6013

Pt. 4, App. C

	Diag- nostic Code No.
Injury:	
Bladder	7517
Gall bladder	7317
Eye, unhealed	6009
Foot	5284
Larynx	6517
Lips	7201
Liver	7311
Mouth	7200
Muscle:	
Facial	5325 5301
Group I Group II	5301
Group III	5302
Group IV	5304
Group V	5305
Group VI	5306
Group VII	5307
Group VIII	5308
Group IX	5309
Group X	5310
Group XI	5311
Group XII	5312
Group XIII	5313
Group XIV	5314
Group XV	5315 5316
Group XVI Group XVII	5310
Group XVIII	5318
Group XIX	5319
Group XX	5320
Group XXI	5321
Group XXII	5322
Group XXIII	5323
Pleural cavity	6818
Prostate	7527
Sacroiliac	5294
Spleen	7707
Stomach, residuals	7310
Tongue, whole or part Intervertebral disc	7202 5293
Iritis	6003
Kala-azar	6301
Keratitis	6001
Labyrinthitis	6204
Lagophthalmos	6022
Laryngectomy	6518
Laryngitis	6516
Leishmaniasis:	
Americana	7807
Old World	7808
Lens, crystalline, dislocation of	6033
Leprosy	6302
Leukemia	7703
Limitation of extension:	5207
Forearm	5261
Thigh	5251
Limitation of field vision	6080
Limitation of flexion:	0000
Forearm	5206
Leg	5260
Thigh	5252
Limitation of flexion and extension:	
Forearm	5208
Limitation of motion:	
Ankle	5271
Arm	5201
Cervical	5290
Dorsal	5291
Lumbar Temporomandibular articulation	5292 9905

38 CFR Ch. I (7-1-05 Edition)

	Diag- nostic Code No.
Wrist	5215
Limitation, pronation	5213
Limitation, supination	5213
Limitation of muscle function, eye	6090 6816
Loss:	0010
Auricle or deformity	6207
Condyloid process	9908
Coronoid process Eyebrows	9909 6023
Eyelashes	6024
Mandible:	
Complete	9901
One-half Maxilla	9902 9910
Teeth	9910
Nose, loss of part, or scars	6504
Palate, hard:	
Half or more	991
Less than half Ramus:	9912
Less than one-half substance	9907
Whole or part	9906
Skull, part	5296
Smell, sense of	6275
Taste, sense of Tongue or part	6270 7202
Others, see Amputation, removal, etc.	1202
Loss of use:	
Feet, both	5110
Feet, both, and hand, one	510
Foot, one Hand, one	516 512
Hand, one, and foot, one	511
Hands, both, and feet, both	510 ⁻
Hands, both, and foot, one	5104
Hands, both Lupus, erythematosus, discoid	5109 7809
Lupus, erythematosus systemic (disseminated)	6350
Lupus, vulgaris	781
Lymphogranulomatosis	7709
Malaria Malunion:	6304
Clavicle	5203
Os calcis (or astragalus)	5273
Mandible	9904
Maxilla (or nonunion)	9910 5203
Scapula Tarsal or metatarsal (or nonunion)	520
Others, see Impairment.	0201
Mastoiditis	6206
Meniere's disease	620
Meningitis, cerebrospinal Mental disorders—see Disorders, mental.	8019
Metatarsalgia	5279
Metritis	7613
Migraine	8100
Muscle injury, <i>see</i> Injury, muscle. Myasthenia gravis	802
Mycosis, lung, unspecified	6808
Myelitis	801
Myositis	502
Myositis ossificans	502
Narcolepsy Nephritis, chronic	810 750
Nephrolithiasis	750
Nephrosclerosis, arteriolar	750
Neuralgia:	
Cranial nerves:	~
	840 840

	Diag- nostic Code No.
Tenth (pneumogastric, vagus) Eleventh (spinal accessory, external	8410
branch)	8411
Twelfth (hypoglossal) Peripheral nerves:	8412
Upper radicular group	8710
Middle radicular group	8711
Lower radicular group	8712
All radicular groups	8713
Musculospiral Median	8714 8715
Ulnar	8716
Musculocutaneous	8717
Circumflex	8718
Long thoracic	8719
Sciatic	8720
External popliteal	8721
Musculocutaneous (superficial peroneal)	8722
Anterior tibial	8723
Internal popliteal	8724
Posterior tibial Anterior crural	8725 8726
Internal saphenous	8726 8727
Obturator	8728
External cutaneous, thigh	8729
llio-inguinal	8730
Neuritis, optic	6026
Neuritis:	
Cranial nerves:	
Fifth (trigeminal)	8305
Seventh (facial)	8307
Ninth (glossopharyngeal)	8309
Tenth (pneumogastric, vagus)	8310
Eleventh (spinal accessory, external	0011
branch)	8311 8312
Twelfth (hypoglossal) Peripheral:	0012
Upper radicular group	8610
Middle radicular group	8611
Lower radicular group	8612
All radicular groups	8613
Musculospiral	8614
Median	8615
Ulnar	8616
Musculocutaneous	8617
Circumflex	8618
Long thoracic	8619
Sciatic	8620 8621
External popliteal Musculocutaneous (superficial peroneal)	8622
Anterior tibial	8623
Internal popliteal	8624
Posterior tibial	8625
Anterior crural	8626
Internal saphenous	8627
Obturator	8628
External cutaneous, thigh	8629
Ilio-inguinal	8630
Non-union of bones:	0000
Mandible Radius and Ulna	9903 5210
Tibia and fibula	5210 5262
Others, see Impairment.	5202
Nystagmus, central	6016
Oophoritis	7615
Oroya fever	6306
Osteitis deformans	5016
Osteomalacia	5014
Osteomyelitis, jaw	9900
Osteomyelitis	5000
Osteoporosis	5013
Otitis externa	6210

	Diag- nostic Code No.
Otitis interna Otitis media:	6203
Catarrhal	6201
Suppurative	6200
Otosclerosis	6202
Palsy, bulbar	8005
Paralysis:	6020
Accommodation	6030 8004
Agitans Paralysis, nerve: Cranial:	0004
Fifth (trigeminal)	8205
Seventh (facial)	8207
Ninth (glossopharyngeal)	8209
Tenth (pneumogastric, vagus)	8210
Eleventh (spiral accessory, external	
branch)	8211
Twelfth (hypoglossal) Peripheral:	8212
Upper radicular group	8510
Middle radicular group	8511
Lower radicular group	8512
All radicular groups	8513
Musculospiral	8514
Median	8515
Ulnar	8516
Musculocutaneous Circumflex	8517 8518
Long thoracic	8519
Sciatic	8520
External popliteal	8521
Musculocutaneous (superficial peroneal)	8522
Anterior tibial	8523
Internal popliteal	8524
Posterior tibial	8525
Anterior crural Internal saphenous	8526 8527
Obturator	8528
External cutaneous, thigh	8529
Ilio-inguinal	8530
Paramyoclonus multiplex	8104
Pellagra	6315
Pemphigus	7815
Penis, deformity of Perforation: Tympanic membrane	7522 6211
Pericarditis	7002
Periostitis	5022
Pes cavus	5278
Pes planus	5276
Phlebitis	7121
Pinta	7810
Plague	6307
Purulent (empyema) Serofibrinous	6811 6810
Pluriglandular syndrome	7912
Pneumoconiosis	6802
Pneumonectomy	6815
Pneumothorax, spontaneous	6814
Poliomyelitis, anterior	8011
Polycythemia	7704 7623
Pregnancy, surgical complications of Prolapse:	7623
Rectum	7334
Uterus	7621
Pronation, limitation of	5213
	7337
Pruritis, ani	
Pruritis, ani Psoriasis	7816
Pruritis, ani Psoriasis Psychiatric disorders, <i>see</i> Disorders, mental.	
Pruritis, ani Psoriasis	7816 6034 6019

Pt. 4, App. C

Pt. 4, App. C

	Diag- nostic Code No.
Pyelitis	7503
Pyelonephritis, chronic	7504
Raynaud's disease	7117
Removal:	
Auricle or deformity	6207
Cartilage, semilunar	5259 5298
Coccyx Gall bladder	7318
Kidney	7500
Mammary glands	7626
Ovaries, both	7619
Penis, half or more	7520
Penis, glans	7521
Prostate, or resection	7526 5297
Ribs Testis	7524
Uterus	7618
Uterus and ovaries	7617
Others, see Amputation, loss, etc.	
Resection:	
Intestine:	
Large	7329
Small	7328
Stomach Retina, detachment of	7308 6008
Retinitis	6008
Rheumatic fever	6309
Rheumatic heart disease	7000
Rhinitis: Atrophic	6501
Rupture, diaphragm	5324
Salpingitis	7614
Scars:	
Burns, second degree	7802
Burns, third degree	7801
Head, etc., disfiguring Retina	7800 6011
Superficial, tender	7804
Superficial, with ulceration	7803
Others	7805
Scleritis	6002
Sclerosis:	
Amyotrophic, lateral	8017
Multiple	8018
Scotoma, pathological	6081 5275
Shortening, leg Silicosis	6801
Sinusitis:	0001
Ethmoid	6511
Frontal	6512
Maxillary	6513
Pansinusitis	6510
Sphenoid	6514
Spasm, esophagus	7204 7706
Splenectomy Sporotrichosis, lung	6806
Stenosis:	0000
Larynx	6520
Stomach	7309
Strain, lumbosacral	5295
Streptotrichosis, lung	6804
Stricture:	
Esophagus	7203
Rectum, anus	7333
Ureter Urethra	7511 7518
Supination, limitation of	5213
Symblepharon	6091
Syndrome:	5001
Cushing's	7907
Intervertebral disc	5293
Meniere's	6205
Pluriglandular	7912

38 CFR Ch. I (7-1-05 Edition)

	Diag- nostic Code No.
Postgastrectomy	7308
Synovitis	5020
Syphilis:	
Cerebrospinal	8013
Meningovascular	8014
Unspecified Syphilitic heart disease	6310 7004
Syringomyelia	8024
Tabes dorsalis	8015
Tachycardia:	
Paroxysmal	7013
Sinus	7014
Tenosynovitis	5024
Thrombo-anglitis obliterans	7115
Thrombophlebitis	7121
Thrombosis, brain	8008
Tic, convulsive Tinea barbae	8103 7814
Tinnitus	6260
Tuberculosis:	0200
Adenitis, tuberculous:	
Axillary	7711
Cervical	7710
Inguinal	7712
Bladder	7514
Bones and joints	5001
Epididymo-orchitis, tuberculous	7525
Eye	6010
Kidney	7505
Laryngitis, tuberculous	6515
Luposa Miliary	7811 6311
Nonpulmonary, inactive (see §4.89)	0311
Peritonitis, tuberculous	7331
Pleurisy, tuberculous	6732
Pulmonary:	
Active:	
Far advanced	6701 &
	6707
Moderately advanced	6702 &
	6708
Minimal	6703 &
Advancement unapositied	6709
Advancement unspecified	6704 & 6710
Inactive:	0/10
Far advanced	6721 &
	6725
Moderately advanced	6722 &
	6726
Minimal	6723 &
	6727
Advancement unspecified	6724 &
	6728
Tympanic membrane, perforation of	6211
Typhus, scrub	6317
Ulcer:	7005
Duodenal Gastric	7305 7304
Marginal	7304
Undescended testis (see Note under DC 7524).	7000
Uterus, displacement of	7622
Ureterolithiasis	7510
Uveitis	6000
Vaginitis	7611
Varicose veins	7120
Verruga peruana	7812
Vertebra, fracture	5285
Visceroptosis	7342
Vision, impairment of, see Blindness.	7610
Vulvovaginitis	5277
	5211

	Diag- nostic Code No.
Wound, incised, abdominal wall	7341

[29 FR 6718, May 22, 1964, as amended at 34 FR 5064, Mar. 11, 1969; 52 FR 44122, Nov. 18, 1987; 53 FR 24938, July 1, 1988]

PART 5 [RESERVED]

PART 6—UNITED STATES GOVERNMENT LIFE INSURANCE

Age

Sec. 6.1 Misstatement of age.

PREMIUMS

6.2 Premium rate.

POLICIES

6.3 Incontestability of United States Government life insurance.

BENEFICIARY OF UNITED STATES GOVERNMENT LIFE INSURANCE

- 6.4 Proof of age, relationship and marriage.
- 6.5 Conditional designation of beneficiary.
- 6.6 Change of beneficiary.
- 6.7 Claims of creditors, taxation.

OPTIONAL SETTLEMENT

- 6.8 Selection, revocation and election.
- 6.9 Election of optional settlement by beneficiary.
- 6.10 Options.

DIVIDENDS

- 6.11 How dividends are paid.
- 6.12 Special dividends.

LOANS

6.13 Policy loans.

CASH VALUE

- 6.14 Cash value; other than special endowment at age 96 plan policy.
- 6.15 Cash value; special endowment at age 96 plan policy.
- 6.16 Payment of cash value in monthly installments.

INDEBTEDNESS

6.17 Collection of any indebtedness.

TOTAL PERMANENT DISABILITY BENEFITS

6.18 Other disabilities deemed to be total and permanent.

DEATH BENEFITS

- 6.19 Evidence to establish death of the insured.
- DETERMINATION OF LIABILITY UNDER SEC-TIONS 302 AND 313, WORLD WAR VETERANS' ACT, 1924, SECTIONS 607 AND 602(V)(2), NA-TIONAL SERVICE LIFE INSURANCE ACT, 1940, AS AMENDED, AND SECTIONS 1921 AND 1957 OF TITLE 38, UNITED STATES CODE

6.20 Jurisdiction.

APPEALS

6.21 Guardian: definition and authority.

AUTHORITY: 38 U.S.C. 501, 1940-1963, 1981-1988, unless otherwise noted.

Age

§6.1 Misstatement of age.

If the age of the insured under a United States Government life insurance policy has been understated, the amount of the insurance payable under the policy shall be such exact amount as the premium paid would have purchased at the correct age; if overstated, the excess of premiums paid shall be refunded without interest. Guaranteed surrender and loan values will be modified accordingly. The age of the insured will be admitted by the Department of Veterans Affairs at any time upon satisfactory proof.

[13 FR 7089, Nov. 27, 1948. Redesignated at 61 FR 29024, June 7, 1996]

Premiums

§6.2 Premium rate.

Effective January 1, 1983, United States Government Life Insurance policies, and total disability income provisions, on a premium paying status are paid-up and no premiums are required to maintain such policies and provisions in force.

[48 FR 1960, Jan. 17, 1983. Redesignated and amended at 61 FR 29024, 29025, June 7, 1996]

POLICIES

§6.3 Incontestability of United States Government life insurance.

Discharge or release of an insured from military or naval service for the reason of fraudulent enlistment shall not invalidate United States Government life insurance issued on the basis

§6.3